

FP7-ICT-611140 CARRE

Project co-funded by the European Commission under the Information and Communication Technologies (ICT) 7^{th} Framework Programme



D.2.2. Functional Requirements & CARRE Information Model

DUTH, VULSK, OU

June 2014



CARRE Contacts

Project Coordinator:	Eleni Kaldoudi	kaldoudi@med.duth.gr	
Project Manager:	Koula Zigeridou	kzygerid@alex.duth.gr	
DUTH Democritus University	of Thrace	Eleni Kaldoudi	kaldoudi@med.duth.gr
OU The Open University		John Domingue	john.domingue@open.ac.uk
BED: Bedfordshire Universit	у	Enjie Liu	Enjie.Liu@beds.ac.uk
VULSK: Vilnius University Hos	pital Santariskių Kliniko	Domantas Stundys	Domantas.Stundys@santa.lt
KTU Kaunas University of T	Fechnology	Arunas Lukosevicius	arunas.lukosevicius@ktu.lt
PIAP Industrial Research I & Measurements	Institute for Automati	on Roman Szewczyk	rszewczyk@piap.pl

Disclaimer

This document contains description of the CARRE project findings, work and products. The authors of this document have taken any available measure in order for its content to be accurate, consistent and lawful. However, neither the project consortium as a whole nor the individual partners that implicitly or explicitly participated in the creation and publication of this document hold any sort of responsibility that might occur as a result of using its content.

In case you believe that this document harms in any way IPR held by you as a person or as a representative of an entity, please do notify us immediately.

The content of this publication is the sole responsibility of CARRE consortium and can in no way be taken to reflect the views of the European Union.

CARRE is a Specific Targeted Research Project partially funded by the European Union, under FP7-ICT-2013-10, Theme 5.1. "Personalized health, active ageing & independent living".





Document Control Page

Project

Contract No.:	611140
Acronym:	CARRE
Title:	Personalized Patient Empowerment and Shared Decision Support for Cardiorenal Disease and Comorbidities
Туре:	STREP
Start:	1 November 2013
End:	31 October 2016
Programme:	FP7-ICT-2013.5.1
Website:	http://www.carre-project.eu/

Deliverable

Deliverable No .:	D.2.2	
Deliverable Title:	Functional Requirements & CARRE information model	
Responsible Partner:	DUTH – Eleni Kaldoudi	
Authors:	E. Kaldoudi, A. Third, G. Gotsis, S. Roumeliotis, N. Karvelyte N., L. Rimsevicius, Pafili., D. Papazoglou, G Juozalenaite., E. Semertzidou, Z. Visockiene, K. Zigerio	
Input from:	All partners	
Peer Reviewers:	E. Liu (BED), D. Stundys (VULSK), J. Piwinski (PIAP), A. Third (OU)	
Task:	T.2.2. Functional Requirements & CARRE information model	
Task duration:	5 months: 1 Feb 2014 to 30 Jun 2014	
Work Package:	WP2: Domain analysis, requirements and design	
Work Package Leader:	DUTH – Eleni Kaldoudi	
Due Date:	30 June 2014	
Actual Delivery Date:	9 July 2014	
Dissemination Level:	PU	
Nature:	R & Web Demonstrator	
Files and format:	Deliverable report: 1 pdf file	
	Software: CARRE Risk Model Semantic Data Entry System <u>http://carre.kmi.open.ac.uk</u>	
Version:	04 – update #1 (31 Oct 2014) on the submitted version 03 (9 July 2014).	
Status:	Draft	
	Consortium reviewed	
	WP leader accepted	
	Coordinator accepted	
	EC accepted	



Document Revision History

Version	Date	Modifications	Contributors	
v01.1	07 May 2014	new content – outline	Eleni Semertzidou Eleni Kaldoudi	
v01.2	10 Jun 2014	Introduction Functional units Comorbidities conceptual model	Eleni Kaldoudi Eleni Semertzidou input from Technical meeting in London 6- 7 May 2014	
v02	24 Jun 1204	editing, figures Appendices	Eleni Kaldoudi Koula Zigeridou all authors	
v03	09 Jul 2014	revised version based on reviews	Eleni Kaldoudi	
v04	31 Oct 2014	Annex 2 updated	all DUTH and VULSK deliverable authors	



Table of Contents

1.	Int	roduction	.15
1	.1.	Functional Requirements and Conceptual Modelling	.15
1	.2.	Methodology	.16
2.	Pre	erequisites	.17
2	2.1.	CARRE Concept	.17
2	2.2.	CARRE Objectives	.17
2	2.3.	CARRE Predefined Framework	.18
3.	Pri	imary Functional Units	.20
4.	Co	onceptual Model of Comorbidities	.22
4	1.1.	Core Concepts and Concepts Relationships	.22
4	1.2.	Concept Attributes Tables	.23
4	1.3.	Class Diagram	.26
4	1.4.	Medical Controlled Vocabularies	.27
5.	Fu	nctional Requirements	.30
5	5.1.	Functional Requirements of System Functional Units	
	-	I.1. Patient Application	
	-	 I.2. Medical Expert Application I.3. Data Harvesting and Interlinking 	
		I.4. Comorbidities model visualization	
	5.1	I.5. Patient Empowerment and Decision Support Services	
5	5.2.	Consolidated Functional Requirements	
5	5.3.	CARRE Security Requirements	.34
An	nex	1 CARRE Risk Model Semantic Data Entry System	.35
An	nex	2 CARRE Risk Association Descriptions	.38
1.	Int	roduction	.39
n	р:		40
2.	кі: 2.1.	sk Associations Acute kidney injury \rightarrow Chronic kidney disease	
		Acute kidney injury \rightarrow Death	
	<i>2</i> . 2.3.	Acute kidney light $y \rightarrow Death$	
		Age \rightarrow Peripheral arterial disease	
	2.4. 2.5.	Age \rightarrow Periprieral arterial disease	
	2.6.	Anemia AND Acute myocardial infarction \rightarrow Death	
	2.7.	Anemia AND Heart Failure \rightarrow Death	
	2.8.	Atrial fibrillation \rightarrow Heart failure	
	2.9.	Chronic kidney disease \rightarrow Death	
2	2.10.	Chronic kidney disease \rightarrow Hospitalization	.51



2.11. Peripher	Chronic kidney disease \rightarrow Ischemic heart disease OR Heart failure OR Ischemic stroke OR ral arterial disease	53
2.12.	Chronic Kidney Disease $ ightarrow$ Peripheral arterial disease	.55
2.13.	Chronic kidney disease AND Heart failure \rightarrow Death	.56
2.14.	Chronic kidney disease AND (Hypertension OR Heart failure) \rightarrow Hyperkalemia	.57
2.15.	Chronic obstructive pulmonary disease \rightarrow Death: due to cardiovascular disease	.58
2.16.	Depression \rightarrow Ischemic stroke	.58
2.17.	Depression \rightarrow Ischemic heart disease	.59
2.18.	Diabetes \rightarrow Death: due to cardiovascular disease	.60
2.19.	Diabetes \rightarrow Heart failure	.60
2.20.	Diabetes \rightarrow Ischemic heart disease	.61
2.21.	Diabetes \rightarrow Ischemic heart disease OR Ischemic stroke	.62
2.22.	Diabetes \rightarrow Peripheral vascular disease	.63
2.23.	Diabetes: disease control \rightarrow Heart failure	.63
2.24.	Diabetes: disease control \rightarrow Ischemic heart disease	.65
2.25.	Diabetes: disease control \rightarrow Ischemic heart disease OR Ischemic stroke	.67
2.26.	Diabetic nephropathy \rightarrow Acute myocardial infarction OR Ischemic stroke	.70
2.27.	Drugs: β -blockers \rightarrow Diabetes	.80
2.28.	Drugs: contrast agents: coronary angiography \rightarrow Acute kidney injury	.80
2.29.	Drugs: diuretics \rightarrow Diabetes	.81
2.30.	Drugs: renin-angiotensin system dual blockade (any) \rightarrow Hyperkalemia	.82
2.31.	Drugs: renin-angiotensin system dual blockade (any) \rightarrow Hypotension	.82
2.32.	Drugs: renin-angiotensin system dual blockade (any) AND Heart failure \rightarrow Acute kidney injury.	.83
2.33.	Drugs: statins \rightarrow Diabetes	.84
2.34.	Drugs: statins AND Chronic kidney disease stage = 1 to $3 \rightarrow$ Chronic kidney disease = stage 5	585
2.35.	Drugs: statins AND Chronic kidney disease stage = 1 to $3 \rightarrow$ Death	.86
2.36.	Drugs: statins AND Chronic kidney disease \rightarrow Ischemic stroke	.87
2.37.	Drugs: Statins AND Chronic kidney disease stage 1 to $3 \rightarrow$ Myocardial Infraction	.88
2.38.	Dyslipidemia \rightarrow Heart Failure	.89
2.39.	Dyslipidemia \rightarrow Ischemic heart disease	.91
2.40.	Dyslipidemia \rightarrow Ischemic stroke	.92
2.41.	Dyslipidemia \rightarrow Peripheral arterial disease	.93
2.42.	Heart failure \rightarrow Ischemic stroke	.95
2.43.	Hyperkalemia AND Chronic kidney disease $ ightarrow$ Death	.96
2.44.	Hypertension \rightarrow Chronic kidney disease	.97
2.45.	Hypertension \rightarrow Death: cardiovascular	.98
2.46.	Hypertension \rightarrow Heart Failure	.99
2.47.	Hypertension \rightarrow Ischemic stroke	100



2.48.	Hypertension \rightarrow Peripheral arterial disease	. 101
2.49.	Hyperuricemia \rightarrow Heart failure	. 102
2.50.	$Hyperuricemia \rightarrow Hypertension$. 103
2.51.	Hyperuricemia \rightarrow Ischemic heart disease	. 103
2.52.	Hyperuricemia \rightarrow Ischemic stroke	.104
2.53.	Ischemic heart disease \rightarrow Death due to cardiovascular disease	. 105
2.54.	Ischemic heart disease \rightarrow Ischemic stroke	. 107
2.55.	Ischemic heart disease AND Chronic kidney disease \rightarrow Death	. 109
2.56.	Ischemic heart disease OR Ischemic stroke \rightarrow Peripheral vascular disease	.110
2.57.	Ischemic heart disease: family history \rightarrow Ischemic heart disease	.110
2.58.	Ischemic heart disease: family history \rightarrow Ischemic stroke	.113
2.59.	Ischemic heart disease: self history \rightarrow Heart failure	.116
2.60. OR Dea	Left ventricular hypertrophy \rightarrow Acute myocardial infarction OR Ischemic stroke OR Heart Failett: cardiovascular	
2.61.	Left ventricular hypertrophy \rightarrow Death: cardiovascular	.118
2.62.	Left ventricular hypertrophy \rightarrow Heart failure	.118
2.63.	Left ventricular hypertrophy \rightarrow Hypertension	.119
2.64.	Left ventricular hypertrophy \rightarrow Ischemic stroke	. 120
2.65.	$Obesity \rightarrow Asthma$. 121
2.66.	Obesity \rightarrow Atrial fibrillation	. 123
2.67.	Obesity \rightarrow Cancer: colorectal cancer	. 125
2.68.	Obesity \rightarrow Cancer: gastric cardiac cancer	. 125
2.69.	Obesity \rightarrow Cancer: pancreatic cancer	. 126
2.70.	Obesity \rightarrow Death: cardiovascular	. 127
2.71.	$Obesity \rightarrow Diabetes$. 128
2.72.	$Obesity \rightarrow Cholelithiasis$.130
2.73.	$\textit{Obesity} \rightarrow \textit{Heart Failure} \dots$.132
2.74.	Obesity \rightarrow Ischemic heart disease	.135
2.75.	Obesity \rightarrow Ischemic stroke	.138
2.76.	$Obesity \rightarrow Osteoarthritis$.139
2.77.	Obesity: central \rightarrow Acute myocardial infarction OR Old myocardial infarction	.140
2.78.	Obesity: central \rightarrow Diabetes	.142
2.79.	Obesity: central \rightarrow Dyslipidemia: HDL cholesterol serum concentration	.145
2.80.	Obesity: central \rightarrow Dyslipidemia: Triclycerides serum concentration	.149
2.81.	Obesity: central \rightarrow Hypertension	. 152
2.82.	Obstructive sleep apnoea \rightarrow Death: cardiovascular	.155
2.83.	Obstructive sleep apnoea \rightarrow Diabetes	. 156
2.84.	Obstructive sleep apnoea \rightarrow Heart failure	. 157



	2.85.	Obstructive sleep apnoea \rightarrow Hypertension	157
	2.86.	Obstructive sleep apnoea $ ightarrow$ Ischemic heart disease	159
	2.87.	Obstructive sleep apnoea $ ightarrow$ Ischemic stroke	160
	2.88.	Physical Activity \rightarrow Diabetes	161
	2.89.	Physical Activity $ ightarrow$ Ischemic heart disease	161
	2.90.	Physical activity \rightarrow Ischemic stroke	163
	2.91.	Physical activity AND Chronic kidney disease $ ightarrow$ Death	165
	2.92.	Smoking \rightarrow Death: cardiovascular	166
	2.93.	Smoking \rightarrow Albuminuria	168
	2.94.	Smoking \rightarrow Chronic Kidney Disease	169
	2.95.	Smoking \rightarrow Heart failure	169
	2.96.	Smoking $ ightarrow$ Ischemic heart disease	170
	2.97.	Smoking $ ightarrow$ Ischemic stroke	171
	2.98.	Smoking \rightarrow Peripheral Arterial Disease	172
3	. Risl	< Elements	173
	3.1.	Acute kidney injury	173
	3.2.	Acute myocardial infarction	174
	3.3.	Age	174
	3.4.	Albuminuria	174
	3.5.	Anemia	175
	3.6.	Asthma	175
	3.7.	Atrial fibrillation	176
	3.8.	Cholelithiasis	176
	3.9.	Chronic kidney disease	176
	3.10.	Chronic obstructive pulmonary disease (COPD)	. 177
	3.11.	Cancer: Colorectal	177
	3.12.	Cancer: Gastric cardiac cancer	178
	3.13.	Cancer: Pancreatic	178
	3.14.	Death	178
	3.15.	Death: due to cardiovascular disease	
	3.16.	Depression	
	3.17.	Diabetes	
	3.18.	Diabetes: disease control	
	3.19.	Diabetic nephropathy	
	3.20.	Drugs: β-blockers	
	3.21.	Drugs: Contrast agents	
	3.22.	Drugs: Diuretics	
	3.23.	Drugs: Renin-angiotensin system dual blockade (any)	182



	3.24.	Drugs: Statins	. 182
	3.25.	Dyslipidemia	. 182
	3.26.	Heart Failure	. 183
	3.27.	Hospitalization	. 183
	3.28.	Hyperkalemia	. 183
	3.29.	Hypertension	. 184
	3.30.	Hyperuricemia	. 184
	3.31.	Hypoglycaemia	. 185
	3.32.	Hypotension	. 185
	3.33.	Ischemic heart disease	. 185
	3.34.	Ischemic heart disease: Family history of	. 186
	3.35.	Ischemic heart disease: Self history	. 186
	3.36.	Ischemic stroke	. 186
	3.37.	Left ventricular hypertrophy	. 187
	3.38.	Obesity	. 187
	3.39.	Obesity: Central	. 188
	3.40.	Obstructive Sleep Apnoea	. 189
	3.41.	Osteoarthritis	. 189
	3.42.	Peripheral arterial disease	. 190
	3.43.	Peripheral vascular disease	. 190
	3.44.	Physical activity	. 190
	3.45.	Smoking	. 191
4	Obs	ervables	.191
		Acute kidney disease diagnosis	
		Acute myocardial infarction diagnosis	
		Age	
		AHI (Apnoea– hypopnoea index)	
		Atrial fibrillation diagnosis	
		β-blockers administration	
		Blood Glucose: 2h glucose after oral glucose tolerance test	
		Blood Glucose: fasting	
		Blood pressure	
	4.10.	BMI (Body Mass Index)	
	4.11.	Body Fat percentage	
	4.12.	Chronic kidney disease diagnosis	
	4.13.	Chronic obstructive pulmonary disease diagnosis	
	4.14.	Contrast agents: coronary angiography administration	
	4.15.	Depression diagnosis	
		-r	
	4.16.	Diabetes diagnosis	. 196



4.17.	Diuretics administration	
4.18.	eGFR	
4.19.	Fasting Plasma Glucose Levels	
4.20.	HbA1c	
4.21.	Haemoglobin (Hb)	
4.22.	HDL-C (High-density lipoprotein cholesterol)	
4.23.	Heart failure diagnosis	
4.24.	Hypertension Diagnosis	
4.25.	Ischemic heart disease diagnosis	
4.26.	Ischemic heart disease family history	
4.27.	Ischemic heart disease self history	
4.28.	Ischemic stroke diagnosis	
4.29.	LDL-C (Low-density lipoprotein cholesterol)	
4.30.	Left ventricular hypertrophy diagnosis	
4.31.	Non-HDL-C	
4.32.	Obstructive sleep apnea diagnosis	
4.33.	Physical activity	
4.34.	Renin-angiotensin system dual blockade administration	
4.35.	Serum creatinine level	
4.36.	Serum potassium	
4.37.	Sex	
4.38.	Smoking intensity	
4.39.	Smoking status	
4.40.	Statin administration	
4.41.	Time after myocardial infarction event	
4.42.	Total cholesterol	
4.43.	Triglycerides (TG)	
4.44.	Uric acid serum concentration	
4.45.	Waist circumference	
4.46.	Waist to height ratio	
4.47.	Waist to hip ratio	
5. Evi	idence Sources	
5.1.	PMID = 08025994	
5.2.	PMID = 09552903	
5.3.	PMID = 10069784	
5.4.	PMID = 10770144	
5.5.	PMID = 10972692	
5.6.	PMID = 11282794	
5.7.	PMID = 11352882	



5.8.	PMID = 11390335	207
5.9.	PMID = 11468199	207
5.10.	PMID = 12151467	208
5.11.	PMID = 12695299	208
5.12.	PMID = 12843775	208
5.13.	PMID = 14732743	208
5.14.	PMID = 15385656	209
5.15.	PMID = 15562125	209
5.16.	PMID = 16039877	209
5.17.	PMID = 16157837	209
5.18.	PMID = 16310551	209
5.19.	PMID = 16697315	210
5.20.	PMID = 16738019	210
5.21.	PMID = 17082208	210
5.22.	PMID = 17327354	210
5.23.	PMID = 17541263	211
5.24.	PMID = 18261929	211
5.25.	PMID = 18490538	211
5.26.	PMID = 1866765	211
5.27.	PMID = 18755344	212
5.28.	PMID = 19046219	212
5.29.	PMID = 19320986	212
5.30.	PMID = 19368979	212
5.31.	PMID = 19705980	213
5.32.	PMID = 19903920	213
5.33.	PMID = 19933936	213
5.34.	PMID = 20167359	213
5.35.	PMID = 20191515	214
5.36.	PMID = 20299666	214
5.37.	PMID = 20668832	214
5.38.	PMID = 20824805	214
5.39.	PMID = 21852664	214
5.40.	PMID = 22020036	215
5.41.	PMID = 22113526	215
5.42.	PMID = 22139711	215
5.43.	PMID = 22342847	215
5.44.	PMID = 22470299	216
5.45.	PMID = 22508734	216
5.46.	PMID = 22828826	216



5.47.	PMID = 22988888	216
5.48.	PMID = 23144362	217
5.49.	PMID = 23271790	217
5.50.	PMID = 23322741	217
5.51.	PMID = 23349764	217
5.52.	PMID = 23322741	218
5.53.	PMID = 23358488	218
5.54.	PMID = 23697611	218
5.55.	PMID = 23915883	218
5.56.	PMID = 23922053	219
5.57.	PMID = 23933579	219
5.58.	PMID = 24360912	219
5.59.	PMID = 24468137	219
5.60.	PMID = 24859435	219
5.61.	PMID = 24913219	220
5.62.	PMID = 2496858	

List of Figures

Figure 1. Process for deriving CARRE functional requirements	and conceptual model16
Figure 2. Overview of CARRE service environment as describe	ed in the DoW18
Figure 3. CARRE primary functional units.	20
Figure 4. CARRE basic concepts and their relationships	
Figure 5. Risk factor class diagram.	
Figure 6. Home page of Drupal-based semantic data entry sys	stem
Figure 7. Create a new Risk Association	
Figure 8. Create a new source Risk Element	

List of Tables

Table 2. Risk Association Evidence (RAE) Attributes.24Table 3. Risk Element (RE) Attributes24Table 4. Observable Attributes25Table 5. Evidence Source (ES) Attributes25Table 6. Related medical controlled vocabularies and ontologies27Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts28Table 8. Patient application functional requirements30Table 9. Medical expert application functional requirements31Table 10. Data harvesting & interlinking functional requirements32Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements33Table 13. Consolidated functional requirements33Table 14. Security requirements34	Table 1. Risk Association (RA) Attributes	23
Table 4. Observable Attributes25Table 5. Evidence Source (ES) Attributes25Table 6. Related medical controlled vocabularies and ontologies27Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts28Table 8. Patient application functional requirements30Table 9. Medical expert application functional requirements31Table 10. Data harvesting & interlinking functional requirements31Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements32Table 13. Consolidated functional requirements33	Table 2. Risk Association Evidence (RAE) Attributes	24
Table 5. Evidence Source (ES) Attributes25Table 6. Related medical controlled vocabularies and ontologies27Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts28Table 8. Patient application functional requirements30Table 9. Medical expert application functional requirements31Table 10. Data harvesting & interlinking functional requirements31Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements32Table 13. Consolidated functional requirements33	Table 3. Risk Element (RE) Attributes	24
Table 6. Related medical controlled vocabularies and ontologies27Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts28Table 8. Patient application functional requirements30Table 9. Medical expert application functional requirements31Table 10. Data harvesting & interlinking functional requirements31Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements32Table 13. Consolidated functional requirements33	Table 4. Observable Attributes	25
Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts28 Table 8. Patient application functional requirements	Table 5. Evidence Source (ES) Attributes	25
Table 8. Patient application functional requirements30Table 9. Medical expert application functional requirements31Table 10. Data harvesting & interlinking functional requirements31Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements32Table 13. Consolidated functional requirements33	Table 6. Related medical controlled vocabularies and ontologies	27
Table 9. Medical expert application functional requirements31Table 10. Data harvesting & interlinking functional requirements31Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements32Table 13. Consolidated functional requirements33	Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts .	28
Table 10. Data harvesting & interlinking functional requirements31Table 11. Comorbidities model functional requirements32Table 12. Patient empowerment & decision support services functional requirements32Table 13. Consolidated functional requirements33	Table 8. Patient application functional requirements	30
Table 11. Comorbidities model functional requirements 32 Table 12. Patient empowerment & decision support services functional requirements 32 Table 13. Consolidated functional requirements 33	Table 9. Medical expert application functional requirements	31
Table 12. Patient empowerment & decision support services functional requirements 32 Table 13. Consolidated functional requirements 33	Table 10. Data harvesting & interlinking functional requirements	31
Table 13. Consolidated functional requirements	Table 11. Comorbidities model functional requirements	32
	Table 12. Patient empowerment & decision support services functional requirements	32
Table 14. Security requirements	Table 13. Consolidated functional requirements	33
	Table 14. Security requirements	34



Executive Summary

The deliverable will contain a report on functional requirements and the corresponding CARRE information model. The deliverable also includes major risk factor associations and their descriptions, including descriptions on respective risk elements, observables, and evidence sources.

About CARRE

CARRE is an EU FP7-ICT funded project with the goal to provide innovative means for the management of comorbidities (multiple co-occurring medical conditions), especially in the case of chronic cardiac and renal disease patients or persons with increased risk of such conditions.

Sources of medical and other knowledge will be semantically linked with sensor outputs to provide clinical information personalised to the individual patient, so as to be able to track the progression and interactions of comorbid conditions. Visual analytics will be employed so that patients and clinicians will be able to visualise, understand and interact with this linked knowledge and also take advantage of personalised empowerment services supported by a dedicated decision support system.

The ultimate goal is to provide the means for patients with comorbidities to take an active role in care processes, including self-care and shared decision-making, and also to support medical professionals in understanding and treating comorbidities via an integrative approach.



Terms and Definitions

The following are definitions of terms, abbreviations and acronyms used in this document.

Term	Definition	
API	Application programming interface	
BMI	Body mass index	
DOI	Digital Object Identifier: a unique alphanumeric string assigned by a registration agency (the International DOI Foundation) to identify content and provide a persistent link to its location on the Internet.	
DoW	Description of Work	
HR	Hazard ratio	
ICD-10	International Statistical Classification of Diseases and Related Health Problems 10th Revision, <u>http://www.who.int/classifications/icd/en/</u>	
ID	Identification number	
ISO/IEC/IEEE 29148:2011	International Standard: Systems and software engineering – Life cycle processes – Requirements engineering. First edition, 01-12-2011 - contains provisions for the processes and products related to the engineering of requirements for systems and software products and services throughout the life cycle	
LOD	Linked Open Data cloud	
MedLinePlus	The National Institutes of Health's Web site for patients and their families and friends, http://medlineplus.gov	
MeSH	Medical Subject Headings, <u>http://www.ncbi.nlm.nih.gov/mesh</u>	
OCEBM	Oxford Centre for Evidence-Based Medicine, <u>http://www.cebm.net/ocebm-levels-of-evidence</u>	
OR	Odds ratio	
PMID	PubMed identification number	
PubMed	A service of the US National Library of Medicine that provides free access to MEDLINE, the NLM database of indexed citations and abstracts to medical, nursing, dental, veterinary, health care, and preclinical sciences journal articles. Accessible at http://www.ncbi.nlm.nih.gov/pubmed/	
RR	Relative ratio	
SNOMED CT	Systematized Nomenclature of Medicine Clinical Terms	
UMLS	Unified Medical Language System: a compilation of many controlled vocabularies in the biomedical sciences which integrates and distributes key terminology, classification and coding standards, and associated resources to promote creation of more effective and interoperable biomedical information systems and services, including electronic health records	
XML	Extensible Markup Language (XML) is a markup language that defines a set of rules for encoding documents in a format that is both human-readable and machine-readable.	



1. Introduction

This report presents the CARRE conceptual model for comorbidities and the functional requirements for the proposed environment.

1.1. Functional Requirements and Conceptual Modelling

A requirement is a statement that defines a function of a system or its component. A function is described as a set of inputs, the behaviour, and outputs. Generally, functional requirements are expressed in the form "system must/shall do <requirement>".

According to the ISO/IEC/IEEE 29148:2011(E) International Standard on Requirements Engineering¹, a well formed requirement is a statement that can be verified, has to be possessed by a system to solve a stakeholder problem, is qualified by measurable conditions, and defines the performance of a system (not the performance of a user). According to the same standard, major characteristics of individual requirements include the following:

- necessary: it defines an essential function;
- implementation free: it states what is required, not how this will be implemented;
- unambiguous: stated in a way so that it can be interpreted only in one way;
- consistent: it is free of conflict with other requirements;
- complete: it is measurable and sufficiently describes the functionality;
- singular: it includes only one requirement;
- feasible: it is technically achievable;
- traceable: it is directly connected to a documented stakeholder need;
- verifiable: it has the means to prove that the system satisfies it.

The formulations of the functional requirements have been carried out by trying to follow, as much as possible, to the above-mentioned characteristics. It must however be mentioned that this work is positioned within the scope of a research project. As such, while the scope of this work to set the project execution on a well-defined direction, it is also deemed appropriate to allow the necessary flexibility for research and innovation.

An information model is "a representation of concepts and the relationships, constraints, rules, and operations to specify data semantics for a chosen domain of discourse. Typically it specifies relations between kinds of things, but may also include relations with individual things. It can provide sharable, stable, and organized structure of information requirements or knowledge for the domain context."²

Information model is an abstract, formal representation of entity types that may include:

- entity properties
- relationships
- operations that can be performed on them

An information model provides formalism to the description of a problem domain without constraining how that description is mapped to an actual implementation.

¹ ISO/IEC/IEEE 29148:2011(E) International Standard: Systems and software engineering – Life cycle processes – Requirements engineering. First edition, 01-12-2011

² http://en.wikipedia.org/wiki/Information_model



1.2. Methodology

The procedure used for drafting up this deliverable is summarized in Figure 1. CARRE functional requirements and conceptual model are directly based on and derived from the following:

- contractual obligations as stated in DoW;
- medical domain analysis and patient empowerment literature survey as presented in deliverable D.2.1;
- CARRE use cases as described in Deliverable D.2.1.

At a first stage, each use case was used to identify major functional units of the system, presented in Section 3. Then, functional requirements of each functional unit are presented in Section 5.1, and these were consolidated to a set of CARRE functional requirements, presented in Section 5.2.

Medical domain analysis and use cases were also used to identify basic CARRE concepts and draft the CARRE conceptual model, described in Section 4. The consolidated functional requirements and the conceptual model will then drive the design of system architecture and the elicitation of non-functional requirements in the forthcoming Deliverable D.2.5.




Figure 1. Process for deriving CARRE functional requirements and conceptual model.

Section 2 of this document presents briefly the concept of the project. Section 3 identifies the main functional units of the system as mandated by the DoW prerequisites, the medical domain analysis and the use cases described in Deliverable D.2.1. Section 4 presents the CARRE conceptual model of risk associations in comorbidities. Section 5 gives a list of functional requirements for the main functional units of the system.

Annex 1 presents a web-based system developed for semantic data entry of the risk association descriptions. Annex 2 presents major risk factor associations and their description, together with the respective risk elements, observables and evidence sources. The list presented here is indicative and will be continually updated and amended; the up-to-date version at any time is available via the on-line system described in Annex 1.



2. Prerequisites

2.1. CARRE Concept

CARRE **goal** is to provide the means for patients with comorbidities to take an active role in care processes, including self-care and shared decision-making, and also to support medical professionals in understanding and treating comorbidities via an integrative approach.

One common case of comorbidities is chronic cardiorenal disease, which is the condition characterized by simultaneous kidney and heart disease while the primarily failing organ may be either the heart or the kidney. Very often the dysfunction occurs when the failing organ precipitates the failure of the other. The cardiorenal patient (or the person at risk of this condition) presents an interesting example for addressing and demonstrating novel patient empowerment services for personalized disease & comorbidities management and prevention for a number of reasons, as chronic cardiorenal disease has an increasing incidence and a number of serious (and of increasing incidence) comorbidities.

The current medical evidence on the comorbidities involved in cardiorenal syndrome (prior, during and as a result of) have been presented extensively in CARRE D.2.1. and are summarized in Figure 2 therein.

CARRE research aims to create technology in order to:

- foster understanding of the complex interdependent nature of the comorbid condition in general and as specialized for the specific patient,
- calculate informed estimations for disease progression and transition,
- compile a variety of personalized alerting, planning and educational services so that patients (and professionals) are empowered.

In particular, the CARRE project plans research and technological development that will lead to a technological infrastructure for visual and quantitative understanding of disease progression and transition pathways and comorbidities trajectories and their dynamics, enriched with up-to-date medical evidence and personalized for the individual patient. Based on this, CARRE will develop personalized shared decision support services for the patient and the medical professional.

2.2. CARRE Objectives

CARRE aims to innovate towards a service environment for providing personalized empowerment and shared decision support services for cardiorenal disease comorbidities.

The overall technological goal of CARRE is to show the potential of semantic interlinking of heterogeneous data to construct dynamic personalized models of complex comorbid medical conditions with disease progression pathways and comorbidity trajectories. Also, to show that visual analytics based on such models can support patient understanding of personal complex conditions (projected against ground knowledge and statistical views of similar patient population) and be the basis for shared decision support services for the management of comorbidities.

The project **objectives** include:

- provide visual and quantitative understanding of disease progression pathways and comorbidities trajectories, as enriched with up-to-date medical evidence and personalized for the individual patient;
- provide personalized risk calculations and analytics for comparison of personal state with the current medical evidence and the overall statistical views of 'similar' patients;
- use the personalized model of comorbidities for building shared decision support services targeting
 personalized education, complex risk calculation for disease progression and comorbidity trajectories,
 alerts for adverse events of multiple co-existing treatments and personalized planning for comorbidity
 monitoring and treatment.

Major expected technological breakthroughs include:



- an ontology and schema for the description of comorbidities management (in the case of cardiorenal disease and comorbidities);
- data aggregators for integration of heterogeneous sources of information, such as medical evidence, personal data (including dynamic sensor data), medical information and personal disposition & lifestyle;
- text analysis tools to semantically annotate and extract relevant metadata from unstructured sources (medical evidence, social media);
- generic aggregator technology to harvest semantic information from structured data sources as listed above (e.g. personal sensors, educational content items);
- Linked Data technologies for semantic data interlinking, and enrichment;
- tools and infrastructure for large scale processing of aggregated data for visual analytics mentioned above;
- data/model driven decision support systems to build shared decision support services for the patient and the medical professional based on the personalized comorbidities model of the patient.

2.3. CARRE Predefined Framework

An overview of the envisaged CARRE **service environment is described in the DoW** and is reproduced in Figure 2.




Figure 2. Overview of CARRE service environment as described in the DoW.



The overall environment includes six major components:

- 1. **Heterogeneous data resources** indicate all different kinds of data related to the personalised health care such as patient basic health caring environment, history record and social relationships/activities. These data should be the key factors for personalised care service selection and defining treatment plan. The data may be accessible from different types of resources with structured data formats (e.g. Web API outputs or database tables) or unstructured data formats (Web pages) and using heterogeneous presentation schema.
- 2. Semantic data extraction engine aims to enable crawling data harvested from heterogeneous data resources and extracting them with Linked Data principles into the Linked Data based repository (Data-centre). The extraction engine should follow the defined CARRE scheme to lift or transform all different crawled data into a unified data space.
- 3. Linked Data based Data-centre can efficiently integrate all different types of data, adding internal semantic links among them as well as external semantic links to Linked Open Data knowledge. In addition, the data centre will support the query endpoints for semantically retrieving the data.
- 4. **Data analytics and mining portal** supports the data analytics and mining tools and their accessing APIs to both patient self-caring applications at home and professional applications used in the health centres. The analytics and mining tools should enable the consumption of the Linked Data from the data centre for providing disease/treatment pattern recognition, prediction of patient health status and useful knowledge/information related to the particular patient.
- 5. **Personalised service for disease management** is a decision support services module that will suggest treatment guidance, alerts and education that are suitable to a particular patient's needs based on their personal data and supported by information from data analytics and mining. It can also provide personalised guidance for management of co-morbidities and integrated care to both the patient and professional organisation.
- 6. **Personalised prevention for disease progression and transition** is another decision support services module that will provide personalised information and life-style guidance to the patient in order to manage risks for comorbidities or progression of disease to more severe stages.



3. Primary Functional Units

Based on the above contractual commitments, on the medical domain analysis and use cases as presented in Deliverable D.2.1, we have identified the following major functional CARRE components (also shown in Figure 3):




Figure 3. CARRE primary functional units.

<u>Patient application</u>: This application integrates patient related personal information and forwards this to the CARRE personal repository. The main types of information this application will integrate are the following:

- monitoring data from personal monitoring devices
- health related data from a personal health record
- other personal information from social media

The patient application is also supports interaction with the CARRE system, including visualisation of and interaction with the generic and personalized comorbidity model, and access to the personalized patient empowerment and decision support services.

<u>Medical expert application</u>: This application allows the medical expert to insert, review, and update medical evidence based knowledge required for the development of the generic comorbidity model. It also supports interaction with the CARRE system, including visualization of and interaction with the generic and



personalized comorbidity model, and input, review and update of medical knowledge required for creation of medical alerts and planning.

Data harvesting and interlinking: This includes the CARRE repository, consisting of public medical evidence data and metadata and private personal health related data. Medical evidence data refers to evidence based medicine knowledge, is enriched via medical controlled vocabularies and is public. Personal health related data is also enriched via controlled vocabularies and related information on the web, but remains private and secured.

<u>Comorbidity model visualization:</u> This module creates and presents the generic comorbidity model as constructed based on public medical knowledge. Also, this functional unit creates personalized versions of the model using the private patient data. The generic model visualization is public, while the personalized model is private and secured.

Patient empowerment and decision support unit: This functional unit generates and delivers personalized services, including: education, alert, planning, and social support.



4. Conceptual Model of Comorbidities

The core of CARRE functionality revolves around the concept of comorbidity, and in particular comorbidities in the case of cardiorenal syndrome. From the overview of the medical domain presented in the CARRE Deliverable D.2.1, it is evident that cardiorenal disease and comorbidities is a complex domain. Related conditions do not have a single cause, but medical evidence suggests that there are multiple causal chains. In order to capture this, the CARRE conceptual model is presented as a complex network of risk factors, that is pairs of conditions related to one another via a (apparently) causal associations.

4.1. Core Concepts and Concepts Relationships

The core concept in the CARRE model is the risk association, directly related to the medical risk factor as this was described in CARRE Deliverable D.2.1, Section 2.4.1. Based on this description, primary concepts and their relationships are identified in the paragraphs below and shown schematically in Figure 4.




Figure 4. CARRE basic concepts and their relationships.

Risk Element: A risk association defines the (often causal) association of an agent (*source risk element*) to a health outcome (*target risk element*). This outcome is in most cases negative, but can also be positive (as shown in examples in Appendix 2). In cardiorenal disease and comorbidities, most often the (causal) agent is in itself a negative health outcome. In this sense, risk agents and their outcomes can be seen as instances of the same entity, called here '*risk element*'. Risk elements include all the disorders/diseases involved in the



comorbidity under discussion as well as any other risk causing agent, e.g. demographic (e.g. age, sex, race), genetic (gene polymorphisms), behavioural (e.g. smoking, physical exercise), environmental (e.g. air pollution, allergens) or even an intervention (e.g. pharmaceutical substances, contrast agents).

Risk Association: The association of one risk element as the risk source with another risk element which is the negative outcome under certain conditions is a '*risk association*'. This association is a rather complex one and is characterized by a number of other concepts:

- Association Type: The association can be of a certain 'association type'; most often, it is of type 'causes', but it can also be 'complicates', otherwise 'affects' or in the general case (and when there is no knowledge of a specific effect), 'is_an_issue_in'. There are also cases where an agent can have a positive effect, that is "reduces" the risk of a negative outcome. Generally, a number of other semantic relationships as described in UMLS could be encountered here.
- Risk Ratio: The association is always accompanied by the likelihood of the negative outcome to occur. This likelihood is expressed as a 'risk ratio', that is the ratio of the probability of the negative outcome when the person is exposed to the risk agent over the probability of the negative outcome when the person is not exposed to the risk agent.
- Observables Condition: For the association to occur, certain circumstances should exist. These prerequisite circumstances relate directly to the existence of the risk agent (source risk target) and/or its severity, and/or any other specific conditions. These are reported via certain 'observables', that is, physical variables that can be measured or otherwise ascertained (e.g. biomarkers, biometric variables, biological signals and other non-biological factors e.g. environmental). The circumstances thus are ascertained via an explicit logical expression that involves observables; this logical expression is termed 'observables condition'.
- Evidence Source: Risk associations in medicine are determined from clinical studies as reported in evidence based medical literature. Thus each association is directly related to an 'evidence source' which is a specific scientific publication.

Finally, a source risk element can be associated to a target risk element with more than one risk association.

4.2. Concept Attributes Tables

The basic concepts in modelling comorbidity are:

- risk factor;
- risk association;
- risk element;
- observable; and
- evidence source.

Based on the previous analysis, the draft description tables presented in CARRE Deliverable 2.1, Section 2.4.5 are revised and extended as in Table 1-Table 5.

Table 1. Risk Association (RA) Attributes			
Attribute Description		Multiplicity	Example
Risk Factor ID	Unique identifier of the particular risk factor	1	RF1
Risk Source	Risk agent	1 to N	obesity
Risk Target	Negative outcome	1	diabetes type 2
Risk Association ID	Risk association unique identifier (see Risk association attributes table)	1 to N	RA1



Table 2. Risk Association Evidence (RAE) Attributes				
Attribute Description		Multiplicity	Example	
RA ID:	Unique identifier of the particular association	1	RA1	
Observables:	Name of observables included in the logical condition that has to be satisfied for the reported risk ratio	1 to N	BMI (= Body Mass Index)	
Biomarker Condition:	What is the condition under which the following risk ratio is valid	1	23 < BMI < 34	
Ratio Type:	The type of statistical ratio, reflecting the statistical method used for its calculation; most common values include: – relative ratio (RR) – hazard ratio (HR) – odds ratio (OR)	1	relative ratio	
Ratio Value:	Value of risk ratio	1	1.61	
Confidence Interval	Interval of values corresponding to the 95% confidence interval of ratio value	0 to 1	1.40 – 1.84	
Adjusted for	Other parameters for which the ratio is statistically adjusted for	1 to N	sex, age	
Evidence Source ID	Unique identifier of the scientific publication reporting this evidence	1 to N	ESID 1	

Table 3. Risk Elen	Table 3. Risk Element (RE) Attributes			
Attribute	Description	Multiplicity	Example	
Risk Element ID	Unique identifier of the particular risk element	1	RE1	
Name	Name of the risk element	1	Diabetes	
Classifier	vocabularies; include vocabulary name414916001followed by classifier.MSH: D0097Major classification systems to be consideredMSH: D0097		SNOMEDCT: 414916001 MSH: D009765 MEDLINEPLUS:	
Description Full name and short description of the element.		0 to 1		
Туре	 Risk elements can be of the following types: biomedical (including condition, disorder and/or disease); demographic (e.g. age, sex, race, occupation, education); genetic (genetic polymorphism); behavioural (e.g. physical activity, diet, smoking); intervention (e.g. drugs); and 	1	biomedical	



	 environmental (e.g. air pollution, allergens). 		
Modifiable:	If the risk element can be modified by human intervention (yes or no). For example, age and diabetes are not modifiable, while weight and smoking are modifiable.		yes
Observables ID	Unique identifiers of the observables that can be used to determine the status of the specific risk element.	1 to N	O1, O2

Table 4. Observable Attributes			
Attribute	Description	Multiplicity	Example
Observable ID	Unique identifier of the particular observable	1	O1
Name	Name of the observable	1	BMI
Classifier	Classifier corresponding to this observable based on standardized medical controlled vocabularies; include vocabulary name followed by classifier. Major classification systems to be considered depend on the nature of the observable, a common on to a majority of health related observables being SNOMED CT.	0 to N	
Description	Full name and short description of the element.	0 to 1	Body mass index, defined as the ratio of the mass (Kg) over the square of the height (m)
Туре	Personal, clinical, other (e.g. third party measurement) – This reflects how this observable is measured, by the patient, the doctor or another party (e.g. air pollution as provided by certain bodies).	1 to N	
Data type	Type of the measurement, for example, real number, integer, value range, 2D signal, etc.	0 to 1	real
Unit	Unit of measurement	0 to 1	kg/m ²
Value ranges	Different expected value ranges of the observable and their classification if this exists as ground medical knowledge (i.e. normal, abnormal or other).	0 to N	BMI<18.5 underweight 25 <bmi<30 overweight<br="">30<bmi<40 obese<br="">BMI>40 morbid obese</bmi<40></bmi<30>

Table 5. Evidence Source (ES) Attributes			
Attribute	Description	Multiplicity	Example
Evidence Source ID	Unique identifier of the particular risk element	1	ES1
Classifier	Classifier corresponding to this evidence source based on a standardized scientific classification system. For CARRE purposes this identifier will the PubMed identification	0 to N	PMID: 23766260 doi: 10.1161/ATVBAHA.113. 301236



	number (PMID). However, other commonly used classifiers can also be included, e.g. DOI.		
Citation	Full citation. This may include a standardized publication XML format.	1	
Publication Type	Type of the study producing the evidence, e.g. systematic review with meta-analysis,	1	meta-analysis
OCEBM level	Level of evidence according to the OCEBM system	1	1

4.3. Class Diagram

An overview of a class diagram is given in

Figure 5.




Figure 5. Risk factor class diagram.



4.4. Medical Controlled Vocabularies

As presented above, the model incorporates standardised classifiers as attributes for the basic concepts. This is to facilitate semantic integration based on commonly used domain specific controlled vocabularies and ontologies.

A list of relevant controlled vocabularies and ontologies with a short description are given in Table 6.

	Table 6. Related medical controlled vocabularies and ontologies				
No	Ontology	Description of Ontology			
1	SNOMED CT	SNOMED CT is a systematically organized computer processable collection of medical terms providing codes, terms, synonyms and definitions used in clinical documentation and reporting. As a clinical terminology, SNOMED CT is inherently more suitable than other terminologies/classifications for clinical documentation in the EHR (electronic health record). http://www.ihtsdo.org/snomed-ct/			
2	ICD-10	The ICD-10 is designed as a health care classification system, providing a system of diagnostic codes for classifying diseases, including nuanced classifications of a wide variety of signs, symptoms, abnormal findings, complaints, social circumstances, and external causes of injury or disease. This system is designed to map health conditions to corresponding generic categories together with specific variations. Major categories are designed to include a set of similar diseases. http://www.who.int/classifications/icd/en/			
3	MeSH - Medical Subject Headings	The MeSH Browser is an online vocabulary look-up aid available for use with MeSH (Medical Subject Headings). It is designed to help quickly locate descriptors of possible interest and to show the hierarchy in which descriptors of interest appear. Virtually complete MeSH records are available, including the scope notes, annotations, entry vocabulary, history notes, allowable qualifiers, etc. Pubmed translates common terms to MeSH terms.			
4	MEDLINEPLUS - MedlinePlus Health Topics	MedlinePlus is the National Institutes of Health's Web site for patients and their families and friends. Produced by the National Library of Medicine, it brings information about diseases, conditions, and wellness issues in language that patient can understand. MedlinePlus offers reliable, up-to-date health information, anytime, anywhere for free. The MedLinePlus terminology contains terms meant for consumers. The topics are meant to cover a wide range of health interests, so topics may relate to more than one MeSH terms (956 MedLinePlus terms in 2013 as compared to more than 27,000 in MeSH) http://www.nlm.nih.gov/medlineplus/healthtopics.html			
5	Online Mendelian Inheritance in Man (OMIM)	OMIM is a database that catalogues all the known diseases with a genetic component. http://www.ncbi.nlm.nih.gov/omim/			
6	Environment Ontology	Ontology of environmental features and habitats produced by EnvO, community ontology for the concise, controlled description of environments. http://environmentontology.org/			
7	Quantity, Unit, Dimension and Type, QUDT	The QUDT, or 'Quantity, Unit, Dimension and Type' collection of ontologies define the base classes properties, and restrictions used for modelling physical quantities, units of measure, and their dimensions in various measurement systems. The goal of the QUDT ontology is to provide a unified model of, measurable quantities, units for measuring different kinds of quantities, the numerical values of quantities in different units of measure and the data structures and data types used to store and manipulate these objects in			



		software. This OWL schema is a foundation for a basic treatment of units. http://qudt.org/
8	Units of Measurement Ontology, UO	Metrical units for use in conjunction with PATO. http://code.google.com/p/unit-ontology/
9	ChEBI	Chemical Entities of Biological Interest (ChEBI) is a freely available dictionary of molecular entities focused on 'small' chemical compounds. The term 'molecular entity' refers to any constitutionally or isotopically distinct atom, molecule, ion, ion pair, radical, radical ion, complex, conformer, etc., identifiable as a separately distinguishable entity. The molecular entities in question are either products of nature or synthetic products used to intervene in the processes of living organisms. www.ebi.ac.uk/chebi/
10	ChEMBL	ChEMBL or ChEMBLdb is a manually curated chemical database of bioactive molecules with drug-like properties.[1] It is maintained by the European Bioinformatics Institute (EBI), of the European Molecular Biology Laboratory (EMBL), based on the Wellcome Trust Genome Campus, Hinxton, UK. https://www.ebi.ac.uk/chembldb/
11	RxNorm	RxNorm is a name of a US-specific terminology in medicine that contains all medications available on US market.[1] It can also be used in personal health records applications. It is part of UMLS terminology and is maintained by National Library of Medicine. http://www.nlm.nih.gov/research/umls/rxnorm/
11	UMLS	The Unified Medical Language System (UMLS) is a collection of many controlled vocabularies in the biomedical sciences. It provides a mapping structure among these vocabularies and thus allows one to translate among the various terminology systems. Each concept is assigned one or more semantic types (135 in total), which are linked with one another through semantic relationships (54 relationships in total). http://www.nlm.nih.gov/research/umls/

Based on the above suggested terminology classifiers for the CARRE concepts are listed in Table 7.

Table 7. Suggested controlled vocabularies as classifiers for CARRE primary and secondary concepts			
Primary Concepts	Primary Concepts		
Concept	oncept Controlled Vocabulary as Classifier		
Risk element	 of type biomedical: SNOMED, ICD-10, MeSH, Medlineplus of type demographic: SNOMED of type genetic: SNOMED, OMIM, MeSH, Medlineplus of type behavioural: SNOMED, MeSH, Medlineplus of type intervention: SNOMED, MeSH, Medlineplus, , ChEBI, ChEMBL, RxNorm of type environmental: SNOMED, Environmental Ontology, MeSH, Medlineplus 		
Observable	SNOMED		
Evidence source	PMID, DOI		



Secondary Concepts		
Concept	Controlled Vocabulary as Classifier	
Association type	UMLS	
Observable unit	SNOMED, QUDT, UO	
Observable value ranges	SNOMED, ICD-10	

5. Functional Requirements

The system shall have the functional components:

- 1) patient application
- 2) medical expert application
- 3) data harvesting and interlinking
- 4) comorbidity model visualization
- 5) decision support and patient empowerment services

5.1. Functional Requirements of System Functional Units

5.1.1. Patient Application

Table 8. Patient application functional requirements		
Requirement ID	Requirement Description	
FR_PA_01	The system must support user authentication.	
FR_PA_02	The user must be able to register new monitoring devices (from the list supported by the system) with the system.	
FR_PA_03	The system must retrieve monitoring data from personal monitoring devices.	
FR_PA_04	In the case of external devices that do not support wireless communication, the system must support cable connection.	
FR_PA_05	The system must accept manual observable data from end-users.	
FR_PA_06	The user must be able to register new personal health record systems.	
FR_PA_07	The system must retrieve health information from the personal health record system.	
FR_PA_08	The user must be able to register new on-line social media accounts.	
FR_PA_09	The system must retrieve personal information from the personal social media accounts.	
FR_PA_10	The user must be able to review recorded/retrieved data.	
FR_PA_11	The system must be able to transmit recorded/collected data to the data harvesting and interlinking module.	
FR_PA_12	The system must use data anonymization prior to data transmission.	
FR_PA_13	The system must be able to display the output of the model visualization module.	
FR_PA_14	The system must support user interaction (i.e. various views) with the model visualization.	
FR_PA_15	The system must be able to display the output of the patient empowerment and decision support services module.	
FR_PA_16	The system must support interaction with the output of the patient empowerment and decision support services module.	
FR_PA_17	Upon prompt for access to personal accounts, CARRE system must provide statement on privacy and legal issues.	
FR_PA_18	The system must provide online user manual.	



5.1.2. Medical Expert Application

Table 9. Medical expert application functional requirements		
Requirement ID	Requirement Definition	
FR_ME_01	The system must support user authentication.	
FR_ME_02	The system must allow the user to add descriptions of risk associations, risk elements, observables, and evidence based sources.	
FR_ME_03	The system must allow the user to view existing descriptions of risk associations, risk elements, observables, and evidence based sources.	
FR_ME_04	The system must allow the user to select and assign appropriate medical controlled vocabulary terms to descriptions of concepts.	
FR_ME_05	The system must give access to medical evidence based sources (PubMed) available on the web, and allow the automatic retrieval of their metadata	
FR_ME_06	The user must be able to select and assign appropriate medical controlled vocabulary terms to descriptions of concepts of risk associations, risk elements, observables, and evidence based sources.	
FR_ME_07	The user must be able to edit existing descriptions of risk associations, risk elements, observables, and evidence based sources.	
FR_ME_08	The system must search on-line medical literature to identify and suggest potential new risk associations.	
FR_ME_09	The user must be able to interact with suggested data (outcome of FR_ME_08) for final judgement of new evidence on risk association.	
FR_ME_10	The system must be able to display the output of data harvesting and interlinking.	
FR_ME_11	The user must be able to interact with data harvesting and interlinking for concept disambiguation.	
FR_ME_12	The system must be able to display the output of the model visualization module.	
FR_ME_13	The system must support user interaction with the output of the model visualization.	
FR_ME_14	The system must support user input to the patient empowerment and decision support services module.	
FR_ME_15	The system must support interaction with the output of the patient empowerment and decision support services module.	
FR_ME_16	The system must provide online user manual.	

5.1.3. Data Harvesting and Interlinking

Table 10. Data harvesting & interlinking functional requirements		
Requirement ID	Requirement Definition	
FR_DHI_01	The system must harvest data sent from the user (patient/physician) application.	
FR_DHI_02	The system must harvest data from medical evidence sources.	
FR_DHI_03	The system must harvest data from online patient education sources.	
FR_DHI_04	The system must harvest data from Linked Data Cloud and semantic web sources.	
FR_DHI_05	The system must harvest data only from authenticated user applications.	
FR_DHI_06	The system must store personal data on a private secure semantic repository.	
FR_DHI_07	The system must store public data on an open linked data repository.	



FR_DHI_08	The system must provide interfaces for secure access of personal data.
FR_DHI_09	The system must provide public interfaces for open access of public data.
FR_DHI_10	The system must access and analyse schemas and ontologies used for CARRE data representation.
FR_DHI_11	The system must access additional datasets, such as common vocabularies, to enrich harvested data.
FR_DHI_12	The system must semantically enrich harvested data.
FR_DHI_13	The system must allow users (medical experts) to assess the 'noise' of data enrichment.

5.1.4. Comorbidities model visualization

Table 11. Comorbidities model functional requirements		
Requirement ID	Requirement Definition	
FR_VIS_01	The system must display the generic comorbidities model constructed based on medical evidence.	
FR_VIS_02	The system must give individual views of risk factor associations, risk element, observables and evidence sources.	
FR_VIS_03	The system must allow user interaction with the generic risk association model.	
FR_VIS_04	The system must display comorbidities model personalized to specific patient.	
FR_VIS_05	The system must display personalized recorded data.	
FR_VIS_06	The system must display personal potential disease progression and transition.	
FR_VIS_07	The system must display actual personal disease progression and transition.	
FR_VIS_08	The system must display comparison of personal state with current medical evidence	
FR_VIS_09	The system must display comparison of personal state with overall statistical views of 'similar' patients.	
FR_VIS_10	The system must display simulated personalized views of virtual patients (for treatment planning and medical education)	
FR_VIS_11	The system must display overall statistical views of CARRE patients, in terms of health status, risk for progression, disease management	

5.1.5. Patient Empowerment and Decision Support Services

Table 12. Patient empowerment & decision support services functional requirements		
Requirement ID	Requirement Definition	
FR_DSS_01	The system must present educational material based on current state and risks	
FR_DSS_02	The system must present new medical evidence related to current state and risks	
FR_DSS_03	The system must support patients to create a personal plan for their diet.	
FR_DSS_04	The system must support patients to create a personal plan for their physical activities.	
FR_DSS_05	The system must allow comparison of plans with implied lifestyle, intentions, preferences (as deduced from social media).	
FR_DSS_06	The system must alert patients for medical check-ups.	
FR_DSS_07	The system must alert patients for monitoring.	



FR_DSS_08	The system must alert patients for increased risk of disease progression and transition.	
FR_DSS_09	The system must alert patients for increased risk of acute health episodes.	
FR_DSS_10	The system must alert patients for the need to change diet.	
FR_DSS_11	The system must alert patients for the need to change monitoring.	

5.2. Consolidated Functional Requirements

Table 13. Consolidated functional requirements		
Category	Requirement per Category	
Data	CARRE systems must accept data from: ✓ end users ✓ social media ✓ PUBMED ✓ monitor devices ✓ CARRE database	
Search	CARRE systems must search: ✓ PUBMED medical database ✓ CARRE database ✓ other medical databases	
Visualize	 CARRE systems must visualize: ✓ disease progression ✓ comparison between end-users health-status with similar patient ✓ comparison between end-users health-status with current medical evidence ✓ virtual patient ✓ pro & cons of different disease management 	
Export	CARRE system must export: ✓ data ✓ text ✓ visualization ✓ alert	
Create	CARRE system must create: ✓ diet plan ✓ physical activity plan ✓ comparison ✓ alert	
Alert	 CARRE system must create an alert for: ✓ medical check-ups ✓ monitoring ✓ increased risk of acute episodes ✓ increased risk of comorbidities ✓ need to change diet ✓ need to change monitoring ✓ overall changes of condition 	



5.3. CARRE Security Requirements

Table 14. Security requirements		
Requirement ID	Security Requirement	
FR_SEC_01	Secure computations in distributed programming frameworks	
FR_SEC_02	Secure best practice for non-relational data stores	
FR_SEC_03	Secure data storage and transactions logs.	
FR_SEC_04	End point input validation/filtering.	
FR_SEC_05	Real-time security/compliance monitoring.	
FR_SEC_06	Scalable and composable privacy-preserving data mining and analytics.	
FR_SEC_07	Granular access control.	
FR_SEC_08	Granular audits	
FR_SEC_09	Data provenance	



Annex 1 CARRE Risk Model Semantic Data Entry System



The model presented in this deliverable enables the clinical experts in the CARRE project to encode the risk associations between biological, demographic, lifestyle and environmental elements and clinical outcomes in accordance with evidence from the clinical literature. The CARRE system is based fundamentally on Linked Data principles³, and so in order to make the best use of these encoded associations, they must be available as Linked Data, making use of the vocabularies and ontologies discussed earlier; specifically, they must be encoded in the (standard) Resource Description Framework⁴ (RDF) format.

We have developed a web-based system for clinicians to use to enter this data. The Drupal content management system⁵ has been customised to reflect the structure of the model presented here, so that observables, evidence sources, risk elements and associations can be entered via web forms, and automatically translated to RDF. The system maintains referential integrity, so that if "diabetes" is entered as a risk element entity, then a risk association representing an observed link between diabetes and hypertension will refer to the existing diabetes risk element entity. Users are supported in the reuse of data already entered into the system by the user interface, which allows existing relevant entities to be selected via drop-down lists wherever possible.

In order to add evidence sources from the clinical literature, the system provides a search interface to PubMed⁶, enabling publications to be located and their unique PubMed identifiers to be inserted into the system easily and conveniently.

The system is available at <u>http://carre.kmi.open.ac.uk</u>.

carre.kmi.open.ac.uk		
Home Citations Risk Facto	rs Risk Evidence (Bio)markers	
Search PUBMED	Home Choose from the following options: • Add a new risk factor	
Navigation • SPARQL endpoint	 Add a new risk evidence Add a new risk element Add a new Observable Add a new citation (PUBMED) 	
User login Username *	• Add a new challon (FOBMED)	

Figure 6. Home page of Drupal-based semantic data entry system.

³ http://www.w3.org/DesignIssues/LinkedData.html

⁴ http://www.w3.org/RDF/


⁵ https://www.drupal.org/

⁶ http://www.ncbi.nlm.nih.gov/pubmed



Create RiskFactor

Sources *	
Point to one or more Risk Elements	
Add new Source Add existing Source	
Target *	
Point to one Risk Element	
Add new Target Add existing Target	
Association Type * - Select a value - 🔻	
Risk Evidence *	
Point to one or more Risk Evidence	
Add new Risk Evidence Add existing Risk Evidence	
Save Preview	



Add new Source	
Name *	
Type *	
- Select a value -	-
- Select a value - biomedical (including condition, disorder and/or disease) demographic (age, sex, race, occupation, NBI, education, etc) genetic (genetic polymorphism) behavioural (physical activity, diet, smoking, etc.) intervention (drugs, etc) environmental (air pollution, water contamination)	
Add new Observable Add existin	ng Observable
Modifiable	
Create Source Cancel	

Figure 8. Create a new source Risk Element



Annex 2 CARRE Risk Association Descriptions



1. Introduction

This Annex presents major risk factor associations and their description, together with the respective risk elements, observables and evidence sources.

This list is the updated list as on October 31, 2014.

The list presented here is indicative and will be continually updated and amended throughout the project. The list will be updated via manual medical expert entry and (semi)-automatically as a result of the work done in WP3, Task 3.4.

The up-to-date version at any time will be available via the on-line system described in Annex 1.

Section 2 of this Annex presents attributes tables for 98 different risk factors with their respective risk associations (total of 268). The involved risk elements (total of 45) attributes tables are presented in Section 3. Respective observables (total of 47) are given in Section 4. Finally, Section 5 presents the attributes tables for the sources of evidence mentioned in risk association descriptions (total of 62).



2. Risk Associations

2.1. Acute kidney injury \rightarrow Chronic kidney disease

Risk Association	
Risk Source:	Acute kidney injury (AKI)
Risk Target:	Chronic kidney disease
Association Type:	Is an issue in
RiskID:	REID1 – REID4
Author	Laurynas
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	Acute kidney disease diagnosis
Observable Condition:	Acute kidney disease diagnosis = diagnosed
Ratio Type:	HR
Ratio Value:	8.8
Confidence Interval:	3.1 – 25.5
Adjusted for:	-
Evidence source PMID	22113526
Author	Laurynas
Reviewed	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observable:	Acute kidney disease diagnosis
Observable Condition:	Acute kidney disease diagnosis = mild
Ratio Type:	HR
Ratio Value:	2.0
Confidence Interval:	1.4 – 2.8
Adjusted for:	-
Evidence source PMID	22113526
Author	Stefanos, Ploumis
Reviewed	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3



Observable:	Acute kidney disease diagnosis
Observable Condition:	Acute kidney disease diagnosis = moderate
Ratio Type:	HR
Ratio Value:	3.3
Confidence Interval:	1.7 – 6.2
Adjusted for:	-
Evidence source PMID	22113526
Author	Stefanos, Ploumis
Reviewed	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4
Observable:	Acute kidney disease diagnosis
Observable Condition:	Acute kidney disease diagnosis = severe
Ratio Type:	HR
Ratio Value:	28.2
Confidence Interval:	21.1- 37.5
Adjusted for:	-
Evidence source PMID	22113526
Author	Stefanos, Ploumis
Reviewed	Stefanos, Ploumis

2.2. Acute kidney injury \rightarrow Death

Risk Association	
Risk Source:	Acute kidney injury
Risk Target:	Death
Association Type:	Causes
RiskID:	REID1
Author	Laurynas
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	Acute kidney disease diagnosis
Observable Condition:	Acute kidney disease diagnosis = diagnosed
Ratio Type:	HR



Ratio Value:	2.0
Confidence Interval:	1.3 – 3.1
Adjusted for:	-
Evidence source PMID	22113526
Author	Laurynas
Reviewed	Stefanos, Ploumis

2.3. Age \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Age
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observables:	Age AND sex
Observable Condition:	$50 \le age \le 59$ AND sex=male
Ratio Type:	Risk ratio
Ratio Value:	5.18
Confidence Interval:	4.20 - 6.39
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observables:	Age Sex
Observable Condition:	$60 \le age \le 64$ AND sex = male



Ratio Type:	Risk ratio
Ratio Value:	9.08
Confidence Interval:	7.16 – 11.53
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observables:	Age AND sex
Observable Condition:	$54 \le age \le 59$ AND sex = female
Ratio Type:	Risk ratio
Ratio Value:	9.01
Confidence Interval:	5.62 – 14.44
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4
Observables:	Age AND Sex
Observable Condition:	$60 \le age \le 64$ AND sex = female
Ratio Type:	Risk ratio
Ratio Value:	24.12
Confidence Interval:	15.24 – 38.87
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis



Risk Association	
Risk Source:	Age
Risk Target:	Peripheral arterial disease
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Kalliopi, Dimitris
Reviewed	Kalliopi, Dimitris

2.4. Age \rightarrow Peripheral arterial disease

Risk Evidence ID1	
RiskID:	1
Observables:	age
Observable Condition:	55 < age ≤ 64
Ratio Type:	Odds ratio
Ratio Value:	1.8
Confidence Interval:	1.3 – 2.6
Adjusted for:	sex
Evidence source PMID	11282794
Author	Kalliopi, Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	age
Observable Condition:	65 ≤ age
Ratio Type:	Odds ratio
Ratio Value:	4.0
Confidence Interval:	2.8 – 5.9
Adjusted for:	sex
Evidence source PMID	11282794
Author	Kalliopi, Dimitris
Reviewed	Kalliopi, Dimitris

2.5. Atrial fibrillation \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Atrial fibrillation



Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed by	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Atrial fibrillation diagnosis AND Age
Observable Condition:	Atrial fibrillation diagnosis = diagnosed AND $50 \le age \le 59$
Ratio Type:	Relative Risk
Ratio Value:	4.0
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, Heart failure
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	Atrial fibrillation diagnosis AND Age
Observable Condition:	Atrial fibrillation diagnosis = diagnosed AND $60 \le age \le 69$
Ratio Type:	Relative Risk
Ratio Value:	2.6
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, Heart failure
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	Atrial fibrillation diagnosis



	AND Age
Observable Condition:	Atrial fibrillation diagnosis = diagnosed
	AND
	$70 \le age \le 79$
Ratio Type:	Relative Risk
Ratio Value:	3.3
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, Heart failure
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	Atrial fibrillation diagnosis AND Age
Observable Condition:	Atrial fibrillation diagnosis = diagnosed AND $50 \le age \le 59$
Ratio Type:	Relative Risk
Ratio Value:	4.5
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, Heart failure
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Dimitris

2.6. Anemia AND Acute myocardial infarction \rightarrow Death

Risk Association	
Risk Source:	Anemia
	AND Acute myocardial infarction
Risk Target:	Death
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Gintare
Reviewed	Stefanos, Ploumis

Risk Evidence ID1		



RiskID:	1
Observable:	Hemoglobin (Hb) level AND Acute myocardial infarction AND Time after Acute myocardial infarction event
Observable Condition:	Hb <12.5 g/dL AND Acute myocardial infarction diagnosis = diagnosed AND Time after Acute myocardial infarction event = 30 days
Ratio Type:	Hazard ratio
Ratio Value:	1.75
Confidence Interval:	1.02 - 3.01
Adjusted for:	Age, sex, history of type 2 diabetes mellitus, congestive heartfailure, revascularization, treatment with thrombolysis, Killip class on presentation, and renal function
Evidence source PMID	23351816
Author	Gintare
Reviewed	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observable:	Hemoglobin (Hb) level AND Acute myocardial infarction diagnosis AND Time after Acute myocardial infarction event
Observable Condition:	Hb < 12.5 g/dL AND Acute myocardial infarction diagnosis = diagnosed AND Time after Acute myocardial infarction event = 365 days
Ratio Type:	Hazard ratio
Ratio Value:	1.63
Confidence Interval:	1.10 – 2.40
Adjusted for:	Age, sex, history of type 2 diabetes mellitus, congestive heartfailure, revascularization, treatment with thrombolysis, Killip class on presentation, and renal function
Evidence source PMID	23351816
Author	Gintare
Reviewed	Stefanos, Ploumis



2.7. Anemia AND Heart Failure \rightarrow Death

Risk Association	
Risk Source:	Anemia
	AND Heart Failure
Risk Target:	Death
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	

Risk Evidence ID1	
RiskID:	1
Observable:	Hemoglobin (Hb) level AND Heart Failure diagnosis
Observable Condition:	Hb <12.5 g/dL AND Heart failure diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.46
Confidence Interval:	1.26 – 1.69
Adjusted for:	Age, Gender, Renal Function, Severity of Heart Failure, Medical History, Medication
Evidence source PMID	18755344
Author	Dimitris
Reviewed	Dimitris

2.8. Atrial fibrillation \rightarrow Heart failure

Risk Association	
Risk Source:	Atrial fibrillation
Risk Target:	Heart failure
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1



Observables:	Atrial fibrillation diagnosis
Observable Condition:	Atrial fibrillation diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.89
Confidence Interval:	1.42 – 2.51
Adjusted for:	sex, hypertension, BMI, ischemic heart disease, diabetes mellitus, smoking, valvular heart disease, lower high-density lipoprotein cholesterol, atrial fibrillation, and the presence of LV hypertrophy or left bundle-branch block
Evidence source PMID	23271790
Author	Dimitris
Reviewed	Dimitris

2.9. Chronic kidney disease \rightarrow Death

Risk Association	
Risk Source:	Chronic kidney disease
Risk Target:	Death
Association Type:	causes
RiskID:	REID1 – REID4
Author:	Stefanos
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	Chronic kidney disease diagnosis = stage 3A OR $45 \le eGFR \le 59$
Ratio Type:	HR
Ratio Value:	1.2
Confidence Interval:	1.1 – 1.2
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis



Risk Evidence ID2	
RiskID:	2
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	Chronic kidney disease diagnosis = stage 3 B OR $30 \le eGFR \le 44$
Ratio Type:	HR
Ratio Value:	1.8
Confidence Interval:	1.7 – 1.9
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	Chronic kidney disease diagnosis = stage 4 OR $15 \le eGFR \le 29$
Ratio Type:	HR
Ratio Value:	3.2
Confidence Interval:	3.1 – 3.4
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4



Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	Chronic kidney disease diagnosis = stage 5 OR eGFR < 15
Ratio Type:	HR
Ratio Value:	5.9
Confidence Interval:	5.4 - 6.5
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

2.10. Chronic kidney disease \rightarrow Hospitalization

Risk Association	
Risk Source:	Chronic Kidney Disease (CKD)
Risk Target:	Hospitalization
Association Type:	causes
RiskID:	REID1 – REID4
Author:	Stefanos
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	$45 \le eGFR \le 59$ OR Chronic kidney disease diagnosis = stage 3A
Ratio Type:	HR
Ratio Value:	1.1
Confidence Interval:	1.1-1.1
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior Ischemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or



	less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	$30 \le eGFR \le 44$ OR Chronic kidney disease diagnosis = stage 3 B
Ratio Type:	HR
Ratio Value:	1.5
Confidence Interval:	1.5-1.5
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior Ischemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observable:	Chronic kidney disease diagnosis
	OR eGFR
Observable Condition:	15≤eGFR≤29
	OR
	Chronic kidney disease diagnosis = stage 4
Ratio Type:	HR
Ratio Value:	2.1
Confidence Interval:	2.0-2.2
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656



Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	eGFR < 15 OR Chronic kidney disease diagnosis = stage 5
Ratio Type:	HR
Ratio Value:	3.1
Confidence Interval:	3.0-3.3
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

2.11. Chronic kidney disease \rightarrow Ischemic heart disease OR Heart failure OR Ischemic stroke OR Peripheral arterial disease

Risk Association	
Risk Source:	Chronic Kidney Disease (CKD)
Risk Target:	Ischemic disease OR heart failure OR Ischemic stroke, OR peripheral arterial disease
Association Type:	causes
RiskID:	REID1 – REID4
Author:	Stefanos
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	$45 \le eGFR \le 59$ OR



	Chronic kidney disease diagnosis = stage 3A
Ratio Type:	HR
Ratio Value:	1.4
Confidence Interval:	1.4 – 1.5
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	$30 \le eGFR \le 44$ OR Chronic kidney disease diagnosis = stage 3B
Ratio Type:	HR
Ratio Value:	2.0
Confidence Interval:	1.9 – 2.1
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observable:	Chronic kidney disease diagnosis
	OR eGFR
Observable Condition:	$15 \le eGFR \le 29$
	OR
	Chronic kidney disease diagnosis = stage 4
Ratio Type:	HR
Ratio Value:	2.8



Confidence Interval:	2.6 – 2.9
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4
Observable:	Chronic kidney disease diagnosis
	OR eGFR
Observable Condition:	eGFR < 15
	OR
	Chronic kidney disease diagnosis = stage 5
Ratio Type:	HR
Ratio Value:	3.4
Confidence Interval:	3.1 – 3.8
Adjusted for:	age, sex, income, education, use or nonuse of dialysis, the presence or absence of prior lschemic heart disease, prior chronic heart failure, prior ischemic stroke or transient ischemic attack, prior peripheral arterial disease, diabetes mellitus, hypertension, dyslipidemia, cancer, a serum albumin level of 3.5 g per deciliter or less, dementia, cirrhosis or chronic liver disease, chronic lung disease, documented proteinuria, and prior hospitalizations.
Evidence source PMID	15385656
Author:	Stefanos
Reviewed:	Stefanos, Ploumis

2.12. Chronic Kidney Disease \rightarrow Peripheral arterial disease

Risk Association	
Risk Source:	Chronic kidney disease
Risk Target:	Peripheral Arterial Disease
Association Type:	causes
RiskID:	REID1
Author:	Stefanos
Reviewed	Dimitris, Kalliopi

Risk Evidence ID1



RiskID:	1
Observable:	Chronic kidney disease diagnosis OR eGFR
Observable Condition:	eGFR < 60 ml/min OR [Chronic kidney disease diagnosis = stage 3 OR Chronic kidney disease diagnosis = stage 4
	OR Chronic kidney disease diagnosis = stage 5]
Ratio Type:	OR
Ratio Value:	2.5
Confidence Interval:	1.2-5.1
Adjusted for:	age, diabetes, hypertension, ischemic heart disease, stroke history, and hypercholesterolemia
Evidence source PMID	14732743
Author:	Stefanos
Reviewed:	Kalliopi, Dimitris

2.13. Chronic kidney disease AND Heart failure \rightarrow Death

Risk Association	
Risk Source:	Chronic kidney disease AND Heart Failure
Risk Target:	Death
Association Type:	Issue in
RiskID:	REID1
Author	Dimitris
Reviewed	

Risk Evidence ID1	
RiskID:	1
Observable:	[Chronic kidney disease diagnosis OR eGFR] AND Heart failure diagnosis
Observable Condition:	[eGFR < 90 ml/min/1.73m ² OR Chronic kidney disease diagnosis = stage 2 OR Chronic kidney disease diagnosis = stage 3 OR Chronic kidney disease diagnosis = stage 4



	OR
	Chronic kidney disease diagnosis = stage 5]
	AND
	Heart failure diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.56
Confidence Interval:	1.53 - 1.60
Adjusted for:	age, gender, race, comorbidities, medications, physical exam and symptoms, ejection fraction, electrocardiogram findings, laboratory values, and neurohormonal measures
Evidence source PMID	16697315
Author	Dimitris
Reviewed	

2.14. Chronic kidney disease AND (Hypertension OR Heart failure) \rightarrow Hyperkalemia

Risk Association	
Risk Source:	Chronic kidney disease AND (Hypertension OR Heart failure)
Risk Target:	Hyperkalemia
Association Type:	Issue in
RiskID:	REID1
Author	Neringa
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	(Chronic kidney disease diagnosis OR eGFR) AND (hypertension OR heart failure)
Observable Condition:	(eGFR < 60 ml/min/1.73m ² OR Chronic kidney disease diagnosis = stage 3 OR Chronic kidney disease diagnosis = stage 4 OR Chronic kidney disease diagnosis = stage 5) AND (Hypertension diagnosis = diagnosed OR Heart failure diagnosis = diagnosed)
Ratio Type:	Odds ratio
Ratio Value:	2.14
Confidence Interval:	2.02-2.28



Adjusted for:	-
Evidence source PMID	22342847
Author	Neringa
Reviewed	Stefanos, Ploumis

2.15. Chronic obstructive pulmonary disease \rightarrow Death: due to cardiovascular disease

Risk Association	
Risk Source:	Chronic obstructive pulmonary disease
Risk Target:	Death: Cardiovascular
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Chronic obstructive pulmonary disease diagnosis
Observable Condition:	Chronic obstructive pulmonary disease diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.28
Confidence Interval:	1.01–1.57
Adjusted for:	Age, gender, BMI, emergency procedure, prior myocardial infarction, congestive heart failure, stroke, peripheral artery disease, chronic atrial fibrillation, malignancy, hypertension, diabetes without insulin therapy, diabetes with insulin therapy, dialysis, chronic renal disease, anemia, current smoking status, left ventricular dysfunction, chronic total occlusion of the coronary artery, proximal left anterior descending ischemic heart disease, left main Ischemic heart disease, and triple vessel disease
Evidence source PMID	19368979
Author	Gintare
Reviewed	Gintare, Kalliopi, Dimitris

2.16. Depression \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Depression
Risk Target:	Ischemic stroke
Association Type:	is an issue in



RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Depression diagnosis
Observable Condition:	Depression diagnosis = diagnosed
Ratio Type:	Relative risk
Ratio Value:	1.34
Confidence Interval:	1.17–1.54
Adjusted for:	Age, sex, body mass index, smoking, educational level, hypertension, diabetes, and history of cardiac disease
Evidence source PMID	22020036
Author	Gintare
Reviewed	Gintare, Kalliopi, Dimitris

2.17. Depression \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Depression
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk evidence ID1	
RiskID:	1
Observable	Depression diagnosis
Observable Condition:	Depression diagnosis = diagnosed
Ratio Type:	Relative risk
Ratio Value:	1.90
Confidence Interval:	1.49–2.42
Adjusted for:	age, sex, marital status, smoking, alcohol, physical activity, cholesterol, blood pressure, BMI, diabetes, CHD severity—previous history, number of affected vessels, dyspnoea, left ventricular (LV) function
Evidence source PMID	17082208



CARRE	D.2.2: Functional Requirements & CARRE Information Model
Author	Gintare
Reviewed	Gintare, Kalliopi, Dimitris

2.18. Diabetes \rightarrow Death: due to cardiovascular disease

Risk Association	
Risk Source:	Diabetes
Risk Target:	Death: due to cardiovascular disease
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Diabetes diagnosis AND Sex
Observable Condition:	Diabetes diagnosis = diagnosed AND Sex = female
Ratio Type:	Relative Risk
Ratio Value:	2.93
Confidence Interval:	2.13 – 4.04
Adjusted for:	age, menopausal status, postmenopausal hormone use, and prior report of Ischemic heart disease. Hypertension, smoking, hypercholesterolemia, parental history of myocardial infarction, BMI
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.19. Diabetes \rightarrow Heart failure

Risk Association	
Risk Source:	Diabetes
Risk Target:	Heart failure
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris



Risk Evidence ID1	
RiskID:	REID1
Observable:	Diabetes diagnosis
Observable Condition:	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	2.50
Confidence Interval:	2.03–3.08
Adjusted for:	age, sex, hypertension, BMI, heart rate, CHD, valvular heart disease, lower high- density lipoprotein cholesterol, atrial fibrillation, presence of LV hypertrophy or left bundle-branch block
Evidence source PMID	23271790
Author	Dimitris
Reviewed	Dimitris

2.20. Diabetes \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Diabetes
Risk Target:	Ischemic heart disease
Association Type:	causes
RiskID:	REID1, REID2
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID1:	1
Observables:	Diabetes diagnosis AND Sex
Observable Condition:	Diabetes diagnosis = diagnosed AND Sex = female
Ratio Type:	RR
Ratio Value:	2.82
Confidence Interval:	2.35 – 3.38
Adjusted for:	
Evidence source PMID	24859435
Author	Kalliopi
Reviewed	Kalliopi, Dimitris



Risk Evidence ID2	
RiskID:	2
Observables:	Diabetes diagnosis
	AND Sex
Observable Condition:	Diabetes diagnosis = diagnosed
	AND
	Sex = male
Ratio Type:	RR
Ratio Value:	2.16
Confidence Interval:	1.82 – 2.56
Adjusted for:	
Evidence source PMID	24859435
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

2.21. Diabetes \rightarrow Ischemic heart disease OR Ischemic stroke

Risk Association	
Risk Source:	Diabetes
Risk Target:	Ischemic heart disease OR Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable	Diabetes diagnosis
Observable Condition:	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.96
Confidence Interval:	1.44-2.66
Adjusted for:	age, sex, systolic blood pressure, hypertension treatment, current smoking, total cholesterol and body mass index
Evidence source PMID	15562129
Author	Kalliopi
Reviewed	Kalliopi, Dimitris



Risk Association	
Risk Source:	Diabetes
Risk Target:	Peripheral vascular disease
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.22. Diabetes \rightarrow Peripheral vascular disease

Risk Evidence ID1	
RiskID:	1
Observable:	Diabetes diagnosis
Observable Condition:	Diabetes diagnosis = diagnosed
Ratio Type:	Odds ratio
Ratio Value:	1.68
Confidence Interval:	1.53–1.84
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.23. Diabetes: disease control \rightarrow Heart failure

Risk Association	
Risk Source:	Diabetes: disease control
Risk Target:	Heart failure
Association Type:	issue in
RiskID:	REID1 – REID4
Author	Zydrune
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND $7.0 \le HbA1c < 8.0$



Ratio Type:	Hazard ratio
Ratio Value:	1.15
Confidence Interval:	0.93–1.43
Adjusted for:	Age. sex, BP, lipid, smoking, BMI or WC, DM medication, DM duration
Evidence source PMID	11390335
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND 8.0% ≤ HbA1c < 9.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.10
Confidence Interval:	0.88–1.38
Adjusted for:	Age, sex, BP, lipid, smoking, BMI or WC, DM medication, DM duration
Evidence source PMID	11390335
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Diabetes diagnosis
	AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed
	AND
	9.0% ≤ HbA1c < 10.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.39
Confidence Interval:	1.11–1.74
Adjusted for:	Age,sex, BP, lipid, smoking, BMI or WC, DM medication, DM duration
Evidence source PMID	11390335
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4



RiskID:	4
Observable:	Diabetes diagnosis
	AND HbA1c
Observable Condition:	Diabetes diagnosis= diagnosed
	AND
	HbA1c ≥ 10.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.56
Confidence Interval:	1.26–1.93
Adjusted for:	Age, sex, BP, lipid, smoking, BMI or WC, DM medication, DM duration
Evidence source PMID	11390335
Author	Zydrune
Reviewed	Kalliopi, Dimitris

2.24. Diabetes: disease control \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Diabetes: disease control
Risk Target:	Ischemic Heart Disease
Association Type:	issue in
RiskID:	REID1 – REID5
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND HbA1c < 5.2%
Ratio Type:	Hazard ratio
Ratio Value:	1
Confidence Interval:	-
Adjusted for:	Age, Sex, BP, Lipids, Smoking, BMI
Evidence source PMID	16157837
Author	Dimitris
Reviewed	Kalliopi, Dimitris



Risk Evidence ID2	
RiskID:	2
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND 5.2% ≤ HbA1c < 5.7%
Ratio Type:	Hazard ratio
Ratio Value:	1.24
Confidence Interval:	0.77 – 1.98
Adjusted for:	Age, Sex, BP, Lipids, Smoking, BMI
Evidence source PMID	16157837
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Diabetes diagnosis
	AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed
	AND
	5.7% ≤ HbA1c < 6.5%
Ratio Type:	Hazard ratio
Ratio Value:	1.57
Confidence Interval:	0.98 – 2.52
Adjusted for:	Age, Sex, BP, Lipids, Smoking, BMI
Evidence source PMID	16157837
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis =diagnosed AND 6.5% ≤ HbA1c < 8.2%
Ratio Type:	Hazard ratio
Ratio Value:	2.04



Confidence Interval:	1.30 – 3.19
Adjusted for:	Age, Sex, BP, Lipids, Smoking, BMI
Evidence source PMID	16157837
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND HbA1c ≥ 8.2%
Ratio Type:	Hazard ratio
Ratio Value:	2.37
Confidence Interval:	1.50 - 3.72
Adjusted for:	Age, Sex, BP, Lipids, Smoking, BMI
Evidence source PMID	16157837
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.25. Diabetes: disease control \rightarrow Ischemic heart disease OR Ischemic stroke

Risk Association	
Risk Source:	Diabetes: disease control
Risk Target:	Ischemic heart disease OR Ischemic stroke
Association Type:	issue in
RiskID:	REID1 – REID6
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Diabetes diagnosis = diagnosed AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND HbA1c < 6.0%



Ratio Type:	Hazard ratio
Ratio Value:	1
Confidence Interval:	-
Adjusted for:	age at diagnosis, duration of diabetes, gender, ethnicity, socio-economic status, smoking status, systolic blood pressure, serum total cholesterol : HDL ratio, body mass index and urine albumin : creatinine ratio
Evidence source PMID	19046219
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND 6.0% ≤ HbA1c < 7.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.08
Confidence Interval:	0.97 – 1.19
Adjusted for:	age at diagnosis, duration of diabetes, gender, ethnicity, socio-economic status, smoking status, systolic blood pressure, serum total cholesterol : HDL ratio, body mass index and urine albumin : creatinine ratio
Evidence source PMID	19046219
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND 7.0% ≤ HbA1c < 8.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.13
Confidence Interval:	1.02 – 1.25
Adjusted for:	age at diagnosis, duration of diabetes, gender, ethnicity, socio-economic status, smoking status, systolic blood pressure, serum total cholesterol : HDL ratio, body mass index and urine albumin : creatinine ratio
Evidence source PMID	19046219



Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Diabetes diagnosis AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed AND $8.0\% \le HbA1c < 9.0\%$
Ratio Type:	Hazard ratio
Ratio Value:	1.26
Confidence Interval:	1.12 – 1.41
Adjusted for:	age at diagnosis, duration of diabetes, gender, ethnicity, socio-economic status, smoking status, systolic blood pressure, serum total cholesterol : HDL ratio, body mass index and urine albumin : creatinine ratio
Evidence source PMID	19046219
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observable:	Diabetes diagnosis
	AND HbA1c
Observable Condition:	Diabetes diagnosis = diagnosed
	AND
	9.0% ≤ HbA1c < 10.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.31
Confidence Interval:	1.15 – 1.50
Adjusted for:	age at diagnosis, duration of diabetes, gender, ethnicity, socio-economic status, smoking status, systolic blood pressure, serum total cholesterol : HDL ratio, body mass index and urine albumin : creatinine ratio
Evidence source PMID	19046219
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	
RiskID:	6
Observable:	Diabetes diagnosis AND HbA1c



Observable Condition:	Diabetes diagnosis = diagnosed AND HbA1c ≥ 10.0%
Ratio Type:	Hazard ratio
Ratio Value:	1.53
Confidence Interval:	1.34 – 1.73
Adjusted for:	age at diagnosis, duration of diabetes, gender, ethnicity, socio-economic status, smoking status, systolic blood pressure, serum total cholesterol : HDL ratio, body mass index and urine albumin : creatinine ratio
Evidence source PMID	19046219
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.26. Diabetic nephropathy \rightarrow Acute myocardial infarction OR Ischemic stroke

Risk Association	
Risk Source:	Diabetic nephropathy
Risk Target:	Acute myocardial infarction OR Ischemic stroke
Association Type:	issue in
RiskID:	REID1 – REID18
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	eGFR
	AND Diabetes diagnosis
Observable Condition:	60 ≤ eGFR ≤89
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.14
Confidence Interval:	1.01–1.29
Adjusted for:	age, sex, duration of diabetes, smoking status, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, diabetic retinopathy, treatment with ACE inhibitors or angiotensin-receptor blockers, treatment group and log of the UACR (as a continuous covariate)
Evidence source PMID	20668832
Author	Zydrune
Reviewed	Kalliopi, Dimitris



Risk Evidence ID2	
RiskID:	2
Observable:	eGFR
	AND Diabetes diagnosis
Observable Condition:	30≤ eGFR ≤69
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.59
Confidence Interval:	1.28–1.98
Adjusted for:	age, sex, duration of diabetes, smoking status, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, diabetic retinopathy, treatment with ACE inhibitors or angiotensin-receptor blockers, treatment group and log of the UACR (as a continuous covariate)
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3		
RiskID:	3	
Observable:	eGFR AND Uric acid serum concentration AND Sex AND Diabetes diagnosis	
Observable Condition:	$60 \le eGFR \le 89$ AND Uric acid serum concentration < 2.5 mg/mmol AND Sex = male AND Diabetes diagnosis = diagnosed	
Ratio Type:	Hazard ratio	
Ratio Value:	1.11	
Confidence Interval:	0.95–1.29	
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group	
Evidence source PMID	16310551	
Author	Zydrune	
Reviewed	Kalliopi, Dimitris	



Risk Evidence ID4	
RiskID:	4
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	$60 \le eGFR \le 89$
	AND
	Uric acid serum concentration < 3.5 mg/mmol
	AND
	Sex = female
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.11
Confidence Interval:	0.95–1.29
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	$30 \le eGFR \le 59$
	AND
	Uric acid serum concentration < 2.5 mg/mmol
	AND
	Sex = male
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.63
Confidence Interval:	1.20–2.20
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group



Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	
RiskID:	6
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes
Observable Condition:	$30 \le eGFR \le 59$
	AND
	Uric acid serum concentration < 3.5 mg/mmol
	AND
	Sex = female
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.63
Confidence Interval:	1.20–2.20
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID7	
RiskID:	7
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	eGFR > 90
	AND
	Uric acid serum concentration > 2.5 mg/mmol
	AND
	Sex = male
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.25



Confidence Interval:	1.01–1.54
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID8	
RiskID:	8
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	eGFR > 90
	AND
	Uric acid serum concentration > 3.5 mg/mmol
	AND
	Sex = female
	AND
	Diabetes = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.25
Confidence Interval:	1.01–1.54
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID9	
RiskID:	9
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	$60 \le eGFR \le 89$
	AND
	Uric acid serum concentration > 2.5 mg/mmol
	AND
	Sex = male



	AND Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.43
Confidence Interval:	1.18–1.72
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID10	
RiskID:	10
Observable:	eGFR AND Uric acid serum concentration AND Sex AND Diabetes
Observable Condition:	$60 \le eGFR \le 89$ AND Uric acid serum concentration > 3.5 mg/mmol AND Sex = female AND Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.43
Confidence Interval:	1.18–1.72
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID11	
RiskID:	11
Observable:	eGFR AND Uric acid serum concentration AND Sex AND Diabetes
Observable Condition:	$30 \le eGFR \le 59$



	AND
	Uric acid serum concentration > 2.5 mg/mmol
	AND
	Sex = male
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.94
Confidence Interval:	1.37–2.73
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin-angiotensin- aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID12	
RiskID:	12
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes
Observable Condition:	$30 \le eGFR \le 59$
	AND
	Uric acid serum concentration > 3.5 mg/mmol
	AND
	Sex = female
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.94
Confidence Interval:	1.37–2.73
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID13	
RiskID:	13
Observable:	eGFR



	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	eGFR > 90
	AND
	Uric acid serum concentration > 25 mg/mmol
	AND
	Sex = male
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.19
Confidence Interval:	0.76–1.85
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID14	
RiskID:	14
Observable:	eGFR AND Uric acid serum concentration AND Sex AND Diabetes diagnosis
Observable Condition:	eGFR > 90 AND Uric acid serum concentration > 35 mg/mmol AND Sex = female AND Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.19
Confidence Interval:	0.76–1.85
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris



Risk Evidence ID15	
RiskID:	15
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	$60 \le eGFR \le 89$
	AND
	Uric acid serum concentration > 25 mg/mmol
	AND
	Sex = male
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.77
Confidence Interval:	1.33–2.36
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID16	
RiskID:	16
Observable:	eGFR AND Uric acid serum concentration AND Sex
	AND Diabetes diagnosis
Observable Condition:	$60 \le eGFR \le 89$ AND Uric acid serum concentration > 35 mg/mmol AND Sex = female AND Diabetes diagnosed = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.77
Confidence Interval:	1.33–2.36
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551



Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID17	
RiskID:	17
Observable:	eGFR
	AND Uric acid serum concentration
	AND Sex
	AND Diabetes diagnosis
Observable Condition:	$30 \le eGFR \le 59$
	AND
	Uric acid serum concentration >25 mg/mmol
	AND
	Sex = male
	AND
	Diabetes diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	2.30
Confidence Interval:	1.48–3.55
Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

Risk Evidence ID18	
RiskID:	18
Observable:	eGFR AND Uric acid serum concentration AND Sex AND Diabetes
Observable Condition:	$30 \le eGFR \le 59$ AND Uric acid serum concentration > 35 mg/mmol AND Sex = female AND Diabetes = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	2.30
Confidence Interval:	1.48–3.55



Adjusted for:	age, sex, duration of diabetes, smoking, BMI, systolic BP, HbA1c, HDL- cholesterol, LDL-cholesterol, triacylglycerol, retinopathy, renin–angiotensin– aldosterone inhibition and treatment group
Evidence source PMID	16310551
Author	Zydrune
Reviewed	Kalliopi, Dimitris

2.27. Drugs: β -blockers \rightarrow Diabetes

Risk Association	
Risk Source:	Drugs: β-blockers
Risk Target:	Diabetes
Association Type:	issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	β-blockers administration
Observable Condition:	β -blockers administration = yes
Ratio Type:	Relative risk
Ratio Value:	1.32
Confidence Interval:	1.16 –1.49
Adjusted for:	-
Evidence source PMID	18490538
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.28. Drugs: contrast agents: coronary angiography \rightarrow Acute kidney injury

Risk Association	
Risk Source:	Contrast agents: coronary angiography
Risk Target:	Acute kidney injury
Association Type:	causes
RiskID:	REID1
Author:	Dimitris
Reviewed	Stefanos, Ploumis



Risk Evidence ID1	
RiskID:	1
Observable:	coronary angiography contrast agents administration
Observable Condition:	coronary angiography contrast agents administration = yes
Ratio Type:	RR
Ratio Value:	2.39
Confidence Interval:	1.98 – 2.90
Adjusted for:	baseline severity of illness variables
Evidence source PMID	23322741
Author:	Dimitris
Reviewed	Stefanos, Ploumis

2.29. Drugs: diuretics \rightarrow Diabetes

Risk Association	
Risk Source:	Drugs: diuretics
Risk Target:	Diabetes
Association Type:	issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Diuretics administration
Observable Condition:	Diuretics administration = yes
Ratio Type:	Relative risk
Ratio Value:	1.32
Confidence Interval:	0.18 –1.49
Adjusted for:	-
Evidence source PMID	18490538
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Association		
Risk Source:	Dual blockade of the renin-angiotensin system (any)	
Risk Target:	Hyperkalemia	
Association Type:	Causes	
RiskID:	REID1	
Author	Laurynas	
Reviewed	Dimitris	

2.30. Drugs: renin-angiotensin system dual blockade (any) \rightarrow Hyperkalemia

Risk Evidence ID1	
RiskID:	REID1
Observable:	Drug therapy
Observable Condition:	[Use of ACEI AND use of ATII inhibitors] OR [Use of ACE AND use of Renin inhibitors] OR [Use of ATII inhibitors AND use of Renin inhibitors]
Ratio Type:	RR
Ratio Value:	1.55
Confidence Interval:	1.32-1.82
Adjusted for:	-
Evidence source PMID	23358488
Author	Laurynas
Reviewed	Dimitris

2.31. Drugs: renin-angiotensin system dual blockade (any) \rightarrow Hypotension

Risk Association		
Risk Source:	Dual blockade of the renin-angiotensin system (any)	
Risk Target:	Hypotension	
Association Type:	Causes	
RiskID:	REID1	
Author	Laurynas	
Reviewed	Dimitris	

Risk Evidence ID1	
RiskID:	1
Observable:	Renin-angiotensin system dual blockade administration
Observable Condition:	[Use of ACEI AND use of ATII inhibitors] OR [Use of ACE AND use of Renin inhibitors] OR



	[Use of ATII inhibitors AND use of Renin inhibitors]
Ratio Type:	RR
Ratio Value:	1.66
Confidence Interval:	1.38 - 1.98
Adjusted for:	-
Evidence source PMID	23358488
Author	Laurynas
Reviewed	Dimitris

2.32. Drugs: renin-angiotensin system dual blockade (any) AND Heart failure \rightarrow Acute kidney injury

Risk Association	
Risk Source:	Dual blockade of the renin-angiotensin system (any)
	AND Heart failure
Risk Target:	Acute kidney injury
Association Type:	Causes
RiskID:	REID1
Author	Laurynas
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Heart failure
	AND
	Renin-angiotensin system dual blockade administration
Observable Condition:	Heart failure
	AND
	{[Use of ACEI AND use of ATII inhibitors] OR
	[Use of ACE AND use of Renin inhibitors] OR
	[Use of ATII inhibitors AND use of Renin inhibitors] }
Ratio Type:	RR
Ratio Value:	2.19
Confidence Interval:	1.82 - 2.65
Adjusted for:	-
Evidence source PMID	23358488
Author	Laurynas
Reviewed	Dimitris



2.33. Dru	gs: statins	$s \rightarrow \text{Diabetes}$
-----------	-------------	---------------------------------

Risk Association	
Risk Source:	Drug therapy: statins
Risk Target:	Diabetes
Association Type:	issue in
RiskID:	REID1 – REID5
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Statin administration
Observable Condition:	Statin administration = Atorvastatin
Ratio Type:	Relative risk
Ratio Value:	1.14
Confidence Interval:	0.89 –1.46
Adjusted for:	-
Evidence source PMID	20167359
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Statin administration
Observable Condition:	Statin administration = Simvastatin
Ratio Type:	Relative risk
Ratio Value:	1.11
Confidence Interval:	0.97 –1.26
Adjusted for:	-
Evidence source PMID	20167359
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Statin administration
Observable Condition:	Statin administration = Rosuvastatin



Ratio Type:	Relative risk
Ratio Value:	1.18
Confidence Interval:	1.04 –1.33
Adjusted for:	-
Evidence source PMID	20167359
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Statin administration
Observable Condition:	Statin administration = Pravastatin
Ratio Type:	Relative risk
Ratio Value:	1.03
Confidence Interval:	0.90 –1.19
Adjusted for:	-
Evidence source PMID	20167359
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observable:	Statin administration
Observable Condition:	Statin administration = Lovastatin
Ratio Type:	Relative risk
Ratio Value:	0.98
Confidence Interval:	0.70 –1.38
Adjusted for:	-
Evidence source PMID	20167359
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.34. Drugs: statins AND Chronic kidney disease stage = 1 to 3 \rightarrow Chronic kidney disease = stage 5

Risk Association	
Risk Source:	Drugs: Statins AND Chronic kidney disease diagnosis = stage 1 to 3



Risk Target:	Chronic kidney disease = stage 5
Association Type:	Is an issue in
RiskID:	REID1
Author	Stefanos
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	REID1
Observable:	(Chronic kidney disease diagnosis OR eGFR) AND Statins administration
Observable Condition:	Statins administration = yes AND (Chronic kidney disease diagnosis = stage 1 OR Chronic kidney disease diagnosis = stage 2 OR Chronic kidney disease diagnosis = stage 3 OR $90 \le eGFR \le 30$)
Ratio Type:	RR
Ratio Value:	0.98
Confidence Interval:	0.62-1.56
Adjusted for:	
Evidence source PMID	22508734
Author	Stefanos
Reviewed	Dimitris

2.35. Drugs: statins AND Chronic kidney disease stage = 1 to $3 \rightarrow$ Death

Risk Association	
Risk Source:	Use of statins in Chronic kidney disease stage 1-3
Risk Target:	Death
Association Type:	Is an issue in
RiskID:	REID1
Author	Stefanos
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1



Observable:	Statin administration AND Chronic kidney disease diagnosis
Observable Condition:	Chronic kidney disease diagnosis = stage 1ORChronic kidney disease diagnosis = stage 2ORChronic kidney disease diagnosis = stage 3OR $90 \le eGFR \le 30)$ ANDStatin administration = yes
Ratio Type:	RR
Ratio Value:	0.81
Confidence Interval:	0.71-0.94
Adjusted for:	
Evidence source PMID	22508734
Author	Stefanos
Reviewed	Dimitris

2.36. Drugs: statins AND Chronic kidney disease \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Use of statins in CKD 1-3
Risk Target:	Ischemic stroke
Association Type:	Is an issue in
RiskID:	REID1
Author	Stefanos
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Statin administration AND Chronic kidney disease diagnosis
Observable Condition:	(Chronic kidney disease diagnosis = stage 1 OR Chronic kidney disease diagnosis = stage 2 OR Chronic kidney disease diagnosis = stage 3 OR



	$90 \le eGFR \le 30)$
	AND
	Statin administration = yes
Ratio Type:	RR
Ratio Value:	0.61
Confidence Interval:	0.41-0.91
Adjusted for:	
Evidence source PMID	22508734
Author	Stefanos
Reviewed	Dimitris

2.37. Drugs: Statins AND Chronic kidney disease stage 1 to 3 \rightarrow Myocardial Infraction

Risk Association	
Risk Source:	Use of statins in Chronic kidney disease stage 1-3
Risk Target:	Myocardial infarction
Association Type:	Is an issue in
RiskID:	REID1
Author	Stefanos
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Statin administration
	AND
	Chronic kidney disease diagnosis
Observable Condition:	(Chronic kidney disease diagnosis = stage 1
	OR
	Chronic kidney disease diagnosis = stage 2
	OR
	Chronic kidney disease diagnosis = stage 3
	OR
	$90 \le \text{eGFR} \le 30$)
	AND
	Statin administration = yes
Ratio Type:	RR
Ratio Value:	0.73
Confidence Interval:	0.54-0.98
Adjusted for:	



Evidence source PMID	22508734
Author	Stefanos
Reviewed	Dimitris

2.38. Dyslipidemia \rightarrow Heart Failure

Risk Association	
Risk Source:	Dyslipidemia
Risk Target:	Heart failure
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Gintare
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	HDL-C (High-density lipoprotein cholesterol) AND Sex
Observable Condition:	$40 \le HDL-C \le 54 \text{ (mg/dL)}$ AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	0.77
Confidence Interval:	0.65 – 0.91
Adjusted for:	Age, sex, body mass index, systolic blood pressure, hypertension treatment, diabetes mellitus, and smoking
Evidence source PMID	19933936
Author	Gintare
Reviewed	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observable:	High-density lipoprotein cholesterol (HDL-C) AND Sex
Observable Condition:	$50 \le HDL-C \le 64mg/dL$ AND Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	0.77



Confidence Interval:	0.65 – 0.91
Adjusted for:	Age, sex, body mass index, systolic blood pressure, hypertension treatment, diabetes mellitus, and smoking
Evidence source PMID	19933936
Author	Gintare
Reviewed	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observable:	High-density lipoprotein cholesterol (HDL-C) AND Sex
Observable Condition:	HDL-C \ge 55 mg/dL AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	0.60
Confidence Interval:	0.48 - 0.74
Adjusted for:	Age, sex, body mass index, systolic blood pressure, hypertension treatment, diabetes mellitus, and smoking
Evidence source PMID	19933936
Author	Gintare
Reviewed	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4
Observable:	High-density lipoprotein cholesterol (HDL-C) AND Sex
Observable Condition:	HDL-C \geq 65 mg/dL AND Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	0.60
Confidence Interval:	0.48 - 0.74
Adjusted for:	Age, sex, body mass index, systolic blood pressure, hypertension treatment, diabetes mellitus, and smoking
Evidence source PMID	19933936
Author	Gintare
Reviewed	Stefanos, Ploumis



Risk Association	
Risk Source:	Dyslipidemia
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1 – REID3
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.39. Dyslipidemia \rightarrow Ischemic heart disease

Risk Evidence ID1	
RiskID:	1
Observable:	Non-HDL cholesterol serum concentration
Observable Condition:	Non-HDL ≥ 169 mg%
Ratio Type:	Hazard ratio
Ratio Value:	1.56
Confidence Interval:	1.47-1.66
Adjusted for:	nonlipid risk factors
Evidence source PMID	19903920
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	HDL cholesterol serum concentration
Observable Condition:	HDL ≤ 50 mg%
Ratio Type:	Hazard ratio
Ratio Value:	0.71
Confidence Interval:	0.68-0.75
Adjusted for:	nonlipid risk factors
Evidence source PMID	19903920
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Tryglicerides serum concentration
Observable Condition:	Tryglicerides ≥ 150mg%



Ratio Type:	Hazard ratio
Ratio Value:	1.37
Confidence Interval:	1.31-1.42
Adjusted for:	nonlipid risk factors
Evidence source PMID	19903920
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.40. Dyslipidemia \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Dyslipidemia
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1 – REID3
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Non-HDL cholesterol serum concentration
Observable Condition:	Non-HDL cholesterol ≥ 169 mg%
Ratio Type:	Hazard ratio
Ratio Value:	1.12
Confidence Interval:	1.04-1.20
Adjusted for:	nonlipid risk factors
Evidence source PMID	19903920
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	HDL cholesterol serum concentration
Observable Condition:	HDL cholesterol \leq 50 mg%
Ratio Type:	Hazard ratio
Ratio Value:	0.93
Confidence Interval:	0.84-1.02



Adjusted for:	nonlipid risk factors
Evidence source PMID	19903920
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Tryglicerides serum concentration
Observable Condition:	Tryglicerides ≥ 150mg%
Ratio Type:	Hazard ratio
Ratio Value:	1.02
Confidence Interval:	0.94-1.11
Adjusted for:	nonlipid risk factors
Evidence source PMID	19903920
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.41. Dyslipidemia \rightarrow Peripheral arterial disease

Risk Association	
Risk Source:	Dyslipidemia
Risk Target:	Peripheral arterial disease
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Gintare
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Total cholesterol (TC) serum concentration
Observable Condition:	Total cholesterol > 200 mg/dL
Ratio Type:	Odds ratio
Ratio Value:	1.16
Confidence Interval:	1.08–1.25
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare



Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	LDL-C
Observable Condition:	LDL-C > 130 mg/dL
Ratio Type:	Odds ratio
Ratio Value:	1.03
Confidence Interval:	0.94–1.13
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare
Reviewed	Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	HDL-C
Observable Condition:	HDL-C < 40 mg/dL
Ratio Type:	Odds ratio
Ratio Value:	0.92
Confidence Interval:	0.83–1.01
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare
Reviewed	Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Triglycerides (TG) serum concentration
Observable Condition:	Triglycerides >150 mg/dL
Ratio Type:	Odds ratio
Ratio Value:	1.22
Confidence Interval:	1.10–1.35
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare
Reviewed	Dimitris



Risk Association	
Risk Source:	Heart failure
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed by	Kalliopi, Dimitris

2.42. Heart failure \rightarrow Ischemic stroke

Risk Evidence ID1	
RiskID:	1
Observables:	Heart failure diagnosis AND Age
Observable Condition:	Heart failure diagnosis = diagnosed AND $50 \le age \le 59$
Ratio Type:	Relative Risk
Ratio Value:	3.9
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	Heart failure diagnosis
	AND Age
Observable Condition:	Heart failure diagnosis= diagnosed
	AND
	$60 \le age \le 69$
Ratio Type:	Relative Risk
Ratio Value:	2.4
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Kalliopi, Dimitris



Risk Evidence ID3	
RiskID:	3
Observables:	Heart failure diagnosis
	AND Age
Observable Condition:	Heart failure diagnosis= diagnosed
	AND
	$70 \le age \le 79$
Ratio Type:	Relative Risk
Ratio Value:	2.2
Confidence Interval:	
Adjusted for:	Hypertension, Ischemic heart disease, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi
Reviewed by	Kalliopi, Dimitris

Risk Evidence ID4	Risk Evidence ID4	
RiskID:	4	
Observables:	Heart failure diagnosis AND Age	
Observable Condition:	Heart failure diagnosis = diagnosed AND $80 \le age \le 89$	
Ratio Type:	Relative Risk	
Ratio Value:	1.7	
Confidence Interval:		
Adjusted for:	Hypertension, Ischemic heart disease, atrial fibrillation	
Evidence source PMID	1866765	
Author	Kalliopi	
Reviewed by	Kalliopi, Dimitris	

2.43. Hyperkalemia AND Chronic kidney disease \rightarrow Death

Risk Association	
Risk Source:	Hyperkalemia AND Chronic kidney disease
Risk Target:	death
Association Type:	cause
RiskID:	REID1
Author	Neringa



Reviewed	Stefanos, Ploumis
----------	-------------------

Risk Evidence ID1	
RiskID:	1
Observable:	serum potassium AND (Chronic kidney disease diagnosis OR eGFR)
Observable Condition:	Serum potassium > 5.0 mEq/L AND (Chronic kidney disease diagnosis = stage 3 OR Chronic kidney disease diagnosis = stage 4 OR Chronic kidney disease diagnosis = stage 5 OR eGFR ≤ 44)
Ratio Type:	Odds ratio
Ratio Value:	1.63
Confidence Interval:	1.04-2.55
Adjusted for:	-
Evidence source PMID	22342847
Author	Neringa
Reviewed	Stefanos, Ploumis

2.44. Hypertension \rightarrow Chronic kidney disease

Risk Association	
Risk Source:	Hypertension
Risk Target:	Chronic kidney disease (CKD)
Association Type:	Causes
RiskID:	REID1
Author	Laurynas
Reviewed	Dimitiris

Risk Evidence ID1	
RiskID:	1
Observable:	Blood pressure OR Hypertension diagnosis
Observable Condition:	Hypertension diagnosis = diagnosed OR



	systolic blood pressure ≥ 140 mmHg AND/OR
	diastolic blood pressure \geq 90 mmHg
Ratio Type:	Odds ratio
Ratio Value:	2.0
Confidence Interval:	1.8 - 2.2
Adjusted for:	age, sex, smoking status and GFR
Evidence source PMID	21852664
Author	Dimitris
Reviewed	kalliopi, Dimitris

2.45. Hypertension \rightarrow Death: cardiovascular

Risk Association	
Risk Source:	Hypertension
Risk Target:	Death: due to cardiovascular disease
Association Type:	Is an issue
RiskID:	REID1, REID 2
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Blood pressure
Observable Condition:	120mmHg ≤ Systolic blood pressure ≤ 139mmHg, AND/OR 80mmHg ≤ Diastolic blood pressure ≤ 89mmHg
Ratio Type:	Relative Risk
Ratio Value:	1.23
Confidence Interval:	0.85 - 1.79
Adjusted for:	age, gender, race/ethnicity, smoking status, leisure time physical activity, hypercholesterolemia, obesity, diabetes, chronic kidney disease, history of heart attack, congestive heart failure and stroke.
Evidence source PMID	18261929
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2



Observable:	Blood pressure
Observable Condition:	Systolic blood pressure ≥ 140mmHg, AND/OR Diastolic blood pressure ≥ 90mmHg
Ratio Type:	Relative Risk
Ratio Value:	1.64
Confidence Interval:	1.11 - 2.41
Adjusted for:	age, gender, race/ethnicity, smoking status, leisure time physical activity, hypercholesterolemia, obesity, diabetes, chronic kidney disease, history of heart attack, congestive heart failure and stroke.
Evidence source PMID	18261929
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.46. Hypertension \rightarrow Heart Failure

Risk Association	
Risk Source:	Hypertension
Risk Target:	Heart failure
Association Type:	Causes
RiskID:	REID1
Author	Gintare
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Blood pressure
	OR Hypertension diagnosis
Observable Condition:	Hypertension diagnosis = diagnosed
	OR
	systolic blood pressure \geq 140 mmHg
	AND/OR
	diastolic blood pressure \geq 90 mmHg
	AND/OR
	antihypertensive drug administration = yes
Ratio Type:	Hazard ratio
Ratio Value:	1.58
Confidence Interval:	1.26–1.9
Adjusted for:	Multivariable-Adjusted
Evidence source PMID	23271790
Author	Gintare



Reviewed

Dimitris

2.47. Hypertension \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Hypertension
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi, Dimitris
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observables:	Hypertension diagnosis AND Age
Observable Condition:	Hypertension diagnosis = diagnosed AND $50 \le age \le 59$
Ratio Type:	Relative Risk
Ratio Value:	3.5
Confidence Interval:	
Adjusted for:	Ischemic heart disease, heart failure, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi, Dimitris
Reviewed	Stefanos, Ploumis

Risk Evidence ID2	
RiskID:	2
Observables:	Hypertension diagnosis AND Age
Observable Condition:	Hypertension diagnosis = diagnosed AND $60 \le age \le 69$
Ratio Type:	Relative Risk
Ratio Value:	3.2
Confidence Interval:	
Adjusted for:	Ischemic heart disease, heart failure, atrial fibrillation
Evidence source PMID	1866765



Author	Kalliopi, Dimitris
Reviewed	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observables:	Hypertension diagnosis AND Age
Observable Condition:	Hypertension diagnosis = diagnosed AND $70 \le age \le 79$
Ratio Type:	Relative Risk
Ratio Value:	2.5
Confidence Interval:	
Adjusted for:	Ischemic heart disease, heart failure, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi, Dimitris
Reviewed	Stefanos, Ploumis

Risk Evidence ID4	
RiskID:	4
Observables:	Hypertension diagnosis AND Age
Observable Condition:	Hypertension diagnosis = diagnosed AND $79 \le age \le 89$
Ratio Type:	Relative Risk
Ratio Value:	1.7
Confidence Interval:	
Adjusted for:	Ischemic heart disease, heart failure, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi, Dimitris
Reviewed	Stefanos, Ploumis

2.48. Hypertension \rightarrow Peripheral arterial disease

Risk Association	
Risk Source:	Hypertension
Risk Target:	Peripheral arterial disease
Association Type:	is an issue in



RiskID:	REID1
Author	Gintare
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Blood pressure OR Hypertension diagnosis
Observable Condition:	Hypertension diagnosis = diagnosed OR systolic blood pressure ≥ 140 mmHg AND/OR diastolic blood pressure ≥ 90 mmHg
Ratio Type:	Odds ratio
Ratio Value:	1.47
Confidence Interval:	1.37–1.57
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare
Reviewed	Dimitris

2.49. Hyperuricemia \rightarrow Heart failure

Risk Association	
Risk Source:	Hyperuricemia
Risk Target:	Heart failure
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Uric acid serum concentration
Observable Condition:	Uric acid serum concentration > 6.8 mg%
Ratio Type:	Hazard ratio
Ratio Value:	1.65
Confidence Interval:	1.41 – 1.94



Adjusted for:	-
Evidence source PMID	23933579
Author	Dimitris
Reviewed	Dimitris

2.50. Hyperuricemia \rightarrow Hypertension

Risk Association	
Risk Source:	Hyperuricemia
Risk Target:	Hypertension
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Uric acid serum concentration
Observable Condition:	Uric acid serum concentration > 6.8 mg%
Ratio Type:	RR
Ratio Value:	1.41
Confidence Interval:	1.23 – 1.58
Adjusted for:	Multivariable adjusted
Evidence source PMID	20824805
Author	Dimitris
Reviewed	Dimitris

2.51. Hyperuricemia \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Hyperuricemia
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris, Kalliopi



Risk Evidence ID1	
RiskID:	1
Observables:	Uric acid serum concentration
Observable Condition:	Uric acid serum concentration > 6.8 mg%
Ratio Type:	RR
Ratio Value:	1.09
Confidence Interval:	1.03 – 1.16
Adjusted for:	age, gender, hypertension, hypercholesterolemia and blodd glucose
Evidence source PMID	20191515
Author	Dimitris
Reviewed	Dimitris, Kalliopi

2.52. Hyperuricemia \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Hyperuricemia
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Larynas
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Uric acid serum concentration AND Sex
Observable Condition:	Uric acid serum concentration > 6.8 mg% AND Sex = male
Ratio Type:	RR
Ratio Value:	1.08
Confidence Interval:	0.85 – 1.38
Adjusted for:	Multivariable adjusted to established cardiovascular risk factors
Evidence source PMID	24468137
Author	Larynas
Reviewed	Dimitris

Risk Evidence ID2



RiskID:	2
Observables:	Uric acid serum concentration AND Sex
Observable Condition:	Uric acid serum concentration > 6.8 mg% AND Sex = female
Ratio Type:	RR
Ratio Value:	1.25
Confidence Interval:	1.04–1.46
Adjusted for:	Multivariable adjusted to established cardiovascular risk factors
Evidence source PMID	24468137
Author	Larynas
Reviewed	Dimitris

2.53. Ischemic heart disease \rightarrow Death due to cardiovascular disease

Risk Association	
Risk Source:	Ischemic heart disease
Risk Target:	Death due to cardiovascular disease
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observables:	Ischemic heart disease diagnosis
	AND age
	AND sex
Observable Condition:	Ischemic heart disease diagnosis = diagnosed
	AND
	$50 \le age \le 59$
	AND
	sex = male
Ratio Type:	Risk ratio
Ratio Value:	6.79
Confidence Interval:	4.81 – 9.59
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784



Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk EvidenceID2	
RiskID:	2
Observables:	Ischemic heart disease diagnosis
	AND age
	AND sex
Observable Condition:	Ischemic heart disease diagnosis = diagnosed
	AND
	$60 \le age \le 64$
	AND
	sex = male
Ratio Type:	Risk ratio
Ratio Value:	12.93
Confidence Interval:	8.91 – 18.77
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID3	
RiskID:	3
Observables:	Ischemic heart disease diagnosis
	AND age
	AND sex
Observable Condition:	Ischemic heart disease diagnosis = diagnosed
	AND
	54 ≤ age ≤ 59
	AND
	sex = female
Ratio Type:	Risk ratio
Ratio Value:	7.84
Confidence Interval:	2.87 – 21.40
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis

Risk Evidence ID4



RiskID:	4
Observables:	Ischemic heart disease diagnosis AND age AND sex
Observable Condition:	Ischemic heart disease diagnosis = diagnosed AND $60 \le age \le 64$ AND sex = female
Ratio Type:	Risk ratio
Ratio Value:	40.38
Confidence Interval:	15.38 – 102.01
Adjusted for:	Smoking, HDL cholesterol ratio, systolic blood pressure, BMI, diabetes
Evidence source PMID	10069784
Author	Kalliopi
Reviewed	Stefanos, Ploumis

2.54. Ischemic heart disease \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Ischemic heart disease
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi, Dimitris
Reviewed by	

Risk Evidence ID1	
RiskID:	1
Observables:	Ischemic heart disease diagnosis AND Age
Observable Condition:	Ischemic heart disease diagnosis = diagnosed AND $50 \le age \le 59$
Ratio Type:	Relative Risk
Ratio Value:	2.9
Confidence Interval:	
Adjusted for:	Hypertension, heart failure, atrial fibrillation
Evidence source PMID	1866765



Author	Kalliopi, Dimitris
Reviewed by	

Risk Evidence ID2	
RiskID:	2
Observables:	Ischemic heart disease diagnosis AND Age
Observable Condition:	Ischemic heart disease diagnosis = diagnosed AND $60 \le age \le 69$
Ratio Type:	Relative Risk
Ratio Value:	2.0
Confidence Interval:	
Adjusted for:	Hypertension, heart failure, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi, Dimitris
Reviewed by	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	Ischemic heart disease diagnosis AND Age
Observable Condition:	Ischemic heart disease diagnosis = diagnosed AND $70 \le age \le 79$
Ratio Type:	Relative Risk
Ratio Value:	1.7
Confidence Interval:	
Adjusted for:	Hypertension, heart failure, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi, Dimitris
Reviewed by	

Risk Evidence ID4	
RiskID:	4
Observables:	Ischemic heart disease diagnosis AND Age
Observable Condition:	Ischemic heart disease diagnosis = diagnosed AND



	$80 \le age \le 89$
Ratio Type:	Relative Risk
Ratio Value:	0.7
Confidence Interval:	
Adjusted for:	Hypertension, heart failure, atrial fibrillation
Evidence source PMID	1866765
Author	Kalliopi, Dimitris
Reviewed by	

2.55. Ischemic heart disease AND Chronic kidney disease \rightarrow Death

Risk Association	
Risk Source:	Ischemic heart disease AND Chronic kidney disease
Risk Target:	Death
Association Type:	cause
RiskID:	REID1
Author	Neringa
Reviewed	Stefanos, Ploumis

Risk Evidence ID1	
RiskID:	1
Observable:	Ischemic heart disease diagnosis AND (Chronic kidney disease diagnosis OR eGFR)
Observable Condition:	Ischemic heart disease diagnosis = diagnosed AND (Chronic kidney disease diagnosis = stage 3 OR Chronic kidney disease diagnosis = stage 4 OR Chronic kidney disease diagnosis = stage 5 OR $eGFR \le 44$)
Ratio Type:	Odds ratio
Ratio Value:	1.66
Confidence Interval:	1.05 – 2.63
Adjusted for:	-
Evidence source PMID	22342847
Author	Neringa



Reviewed	Stefanos, Ploumis
----------	-------------------

2.56. Ischemic heart disease OR Ischemic stroke \rightarrow Peripheral vascular disease

Risk Association	
Risk Source:	Cardiovascular disease
Risk Target:	Peripheral vascular disease
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Ischemic heart disease diagnosis OR Ischemic stroke diagnosis
Observable Condition:	Ischemic heart disease diagnosis = diagnosed OR Ischemic stroke diagnosis = diagnosed
Ratio Type:	Odds ratio
Ratio Value:	2.27
Confidence Interval:	1.98–2.59
Adjusted for:	
Evidence source PMID	23915883
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.57. Ischemic heart disease: family history \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Ischemic heart disease: family history
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1 – REID6
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1



RiskID:	1
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease history = maternal AND Sex = male
Ratio Type:	Relative risk
Ratio Value	2.14
Confidence Interval:	1.64–2.79
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease history = maternal AND Sex = female
Ratio Type:	Relative risk
Ratio Value	1.76
Confidence Interval:	1.09–2.87
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease history = paternal AND Sex = male



Ratio Type:	Relative risk
Ratio Value	1.58
Confidence Interval:	1.33–1.89
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease history = paternal AND Sex = female
Ratio Type:	Relative risk
Ratio Value	0.93
Confidence Interval:	0.60–1.45
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease history = paternal & maternal AND Sex = male
Ratio Type:	Relative risk
Ratio Value	1.98
Confidence Interval:	1.41–2.78
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and



	postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	
RiskID:	6
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease history = paternal & maternal AND Sex = female
Ratio Type:	Relative risk
Ratio Value	2.49
Confidence Interval:	1.46–4.24
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.58. Ischemic heart disease: family history \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Ischemic heart disease: family history
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1 – REID6
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease family history = maternal AND Sex = male



Ratio Type:	Relative risk
Ratio Value	1.26
Confidence Interval:	0.92–1.72
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease family history = maternal AND Sex = female
Ratio Type:	Relative risk
Ratio Value	1.14
Confidence Interval:	0.69–1.90
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease family history = paternal AND Sex = male
Ratio Type:	Relative risk
Ratio Value	1.05
Confidence Interval:	0.87–1.27
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and



	postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease family history = paternal AND Sex = female
Ratio Type:	Relative risk
Ratio Value	1.15
Confidence Interval:	0.81–1.63
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease family history = paternal & maternal AND Sex = male
Ratio Type:	Relative risk
Ratio Value	1.03
Confidence Interval:	0.67–1.60
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris



Risk Evidence ID6	
RiskID:	6
Observable:	Ischemic heart disease family history AND Sex
Observable Condition:	Ischemic heart disease family history = paternal & maternal AND Sex = female
Ratio Type:	Relative risk
Ratio Value	1.45
Confidence Interval:	0.80–2.62
Adjusted for:	age, BMI, smoking status, exercise, and alcohol intake. Additional covariates in models for men included randomized aspirin and beta-carotene treatment; for women, randomized aspirin and vitamin E treatment, postmenopausal status, and postmenopausal hormone use
Evidence source PMID	11468199
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.59. Ischemic heart disease: self history \rightarrow Heart failure

Risk Association	
Risk Source:	Ischemic heart disease: self history
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Ischemic heart disease self history
Observable Condition:	Ischemic heart disease self history = yes
Ratio Type:	Hazard ratio
Ratio Value	1.70
Confidence Interval:	1.37–2.12
Adjusted for:	age, sex, hypertension, BMI, heart rate, CHD, diabetes mellitus, valvular heart disease, lower high-density lipoprotein cholesterol, atrial fibrillation, presence of LV hypertrophy or left bundle-branch block
Evidence source PMID	23271790
Author	Dimitris



Reviewed	
I CONCOCO	

Dimitris

2.60. Left ventricular hypertrophy \rightarrow Acute myocardial infarction OR Ischemic stroke OR Heart Failure OR Death: cardiovascular

Risk Association	
Risk Source:	Left ventricular hypertrophy
Risk Target:	Acute myocardial infarction
	OR Ischemic stroke
	OR Heart Failure OR Death: cardiovascular
Association Type:	issue in
RiskID:	REID1, REID2
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk EvidenceID1	
RiskID:	1
Observables:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	1.39
Confidence Interval:	1.12 – 1.73
Adjusted for:	adjusted for age, race, SBP, diabetes, total cholesterol, smoking and QRS duration
Evidence source PMID	22139711
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk EvidenceID2	
RiskID:	2
Observable:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	1.37



Confidence Interval:	1.06 – 1.76
Adjusted for:	adjusted for age, race, SBP, diabetes, total cholesterol, smoking and QRS duration
Evidence source PMID	22139711
Author	Neringa
Reviewed	Kalliopi, Dimitris

2.61. Left ventricular hypertrophy \rightarrow Death: cardiovascular

Risk Association	
Risk Source:	Left ventricular hypertrophy
Risk Target:	Death: cardiovascular
Association Type:	issue in
RiskID:	REID1
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	REID1
Observable:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	2.37
Confidence Interval:	1.52 – 3.71
Adjusted for:	ECG-LVH, Insulin sensitivity index, proinsulin, LDL cholesterol, HDL cholesterol, Triglycerides, waist circumference, hypertension, smoking, previous ischemic heart disease
Evidence source PMID	11352882
Author	Neringa
Reviewed	Kalliopi, Dimitris

2.62. Left ventricular hypertrophy \rightarrow Heart failure

Risk Association	
Risk Source:	Left ventricular hypertrophy
Risk Target:	Heart failure



Association Type:	Issue in
RiskID:	REID1, REID2
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = male
Ratio Type:	relative Hazard ratio
Ratio Value:	1.96
Confidence Interval:	1.36-2.83
Adjusted for:	-
Evidence source PMID	22139711
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = female
Ratio Type:	relative Hazard ratio
Ratio Value:	2.75
Confidence Interval:	1.94-3.91
Adjusted for:	-
Evidence source PMID	22139711
Author	Neringa
Reviewed	Kalliopi, Dimitris

2.63. Left ventricular hypertrophy \rightarrow Hypertension

Risk Association	
Risk Source:	Left ventricular hypertrophy



Risk Target:	Hypertension
Association Type:	Issue in
RiskID:	REID1
Author	Neringa
Reviewed	Dimitris, Kalliopi

Risk Evidence ID1	
RiskID:	REID1
Observable:	Left ventricular hypertrophy diagnosis
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed
Ratio Type:	Odds ratio
Ratio Value:	1.2
Confidence Interval:	1.04 – 1.39
Adjusted for:	sex, baseline age, systolic and diastolic blood pressures, body mass index, alcohol consumption, and systolic blood pressure from 8 years before the index examination.
Evidence source PMID	08025994
Author	Neringa
Reviewed	Dimitris, Kalliopi

2.64. Left ventricular hypertrophy \rightarrow Ischemic stroke

Risk Assocation	
Risk Source:	Left ventricular hypertrophy
Risk Target:	Ischemic stroke
Association Type:	Issue in
RiskID:	REID1, REID2
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	REID1
Observable:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = male
Ratio Type:	relative Hazard ratio
Ratio Value:	1.7



Confidence Interval:	1.01-1.84
Adjusted for:	-
Evidence source PMID	22139711
Author	Neringa
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	REID2
Observable:	Left ventricular hypertrophy diagnosis AND Sex
Observable Condition:	Left ventricular hypertrophy diagnosis = diagnosed AND Sex = female
Ratio Type:	relative Hazard ratio
Ratio Value:	2.77
Confidence Interval:	1.70 – 4.52
Adjusted for:	-
Evidence source PMID	22139711
Author	Neringa
Reviewed	Kalliopi, Dimitris

2.65. Obesity \rightarrow Asthma

Risk Association	
Risk Source:	Obesity
Risk Target:	asthma
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed	Dimitris

Risk EvidenceID1	
RiskID1:	1
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = male
Ratio Type:	Relative Risk



Ratio Value:	1.20
Confidence Interval:	1.08 – 1.33
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID2:	2
Observables:	BMI
	AND sex
Observable Condition:	BMI > 30
	AND
	Sex = male
Ratio Type:	Relative Risk
Ratio Value:	1.43
Confidence Interval:	1.14 – 1.79
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID3	
RiskID3:	3
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = female
Ratio Type:	Relative Risk
Ratio Value:	1.25
Confidence Interval:	1.05 – 1.49
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID4	
RiskID4:	4



Observables:	ВМІ
	AND Sex
Observable Condition:	BMI > 30
	AND
	Sex = female
Ratio Type:	Relative Risk
Ratio Value:	1.78
Confidence Interval:	1.36 – 2.32
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

2.66. Obesity \rightarrow Atrial fibrillation

Risk Association	
Risk Source:	Obesity
Risk Target:	Atrial fibrillation
Association Type:	Is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI
	AND Sex
Observable Condition:	$25 \le BMI \le 30$
	AND
	Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	1.10
Confidence Interval:	0.84 – 1.46
Adjusted for:	age, systolic blood pressure, use of antihypertensive therapy, diabetes mellitus, electrocardiographic left ventricular hypertrophy, prior myocardial infarction or congestive heart failure, regular use of cigarettes in the prior year, significant murmur, interim media thickness
Evidence source PMID	15562125
Author	Kalliopi
Reviewed	Dimitris



Risk Evidence ID2	
RiskID2:	2
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	1.13
Confidence Interval:	0.84 – 1.52
Evidence source PMID	15562125
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	BMI AND Sex
Observable Condition:	BMI >30 AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	1.52
Confidence Interval:	1.09 – 2.13
Adjusted for:	age, systolic blood pressure, use of antihypertensive therapy, diabetes mellitus, electrocardiographic left ventricular hypertrophy, prior myocardial infarction or congestive heart failure, regular use of cigarettes in the prior year, significant murmur, interim media thickness
Evidence source PMID	15562125
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	BMI
	AND Sex
Observable Condition:	BMI >30
	AND
	Sex = female
Ratio Type:	Hazard ratio



Ratio Value:	1.46
Confidence Interval:	1.03 – 2.07
Evidence source PMID	15562125
Author	Kalliopi
Reviewed	Dimitris

2.67. Obesity \rightarrow Cancer: colorectal cancer

Risk Association	
Risk Source:	Obesity
Risk Target:	Cancer: colorectal cancer
Association Type:	is an issue in
RiskID:	REID1
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI
Observable Condition:	BMI > 30
Ratio Type:	Relative Risk
Ratio Value:	1.33
Confidence Interval:	1.25 – 1.42
Adjusted for:	-
Evidence source PMID	23349764
Author	Kalliopi
Reviewed	Dimitris

2.68. Obesity \rightarrow Cancer: gastric cardiac cancer

Risk Association	
Risk Source:	Obesity
Risk Target:	Cancer: gastric cardiac cancer
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Kalliopi
Reviewed	Dimitris



Risk Evidence ID1	
RiskID3:	1
Observables:	BMI
Observable Condition:	$25 \leq BMI \leq 30$
Ratio Type:	Relative Risk
Ratio Value:	1.21
Confidence Interval:	
Adjusted for:	-
Evidence source PMID	23697611
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	BMI
Observable Condition:	BMI > 30
Ratio Type:	Relative Risk
Ratio Value:	1.82
Confidence Interval:	
Adjusted for:	-
Evidence source PMID	23697611
Author	Kalliopi
Reviewed	Dimitris

2.69. Obesity \rightarrow Cancer: pancreatic cancer

Risk Association	
Risk Source:	Obesity
Risk Target:	Cancer: pancreatic cancer
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI



Observable Condition:	$25 \le BMI \le 30$
Ratio Type:	Relative Risk
Ratio Value:	1.28
Confidence Interval:	0.94 – 1.75
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk EvidenceID2	
RiskID:	2
Observables:	BMI
Observable Condition:	BMI > 30
Ratio Type:	Relative Risk
Ratio Value:	2.29
Confidence Interval:	1.65 – 3.19
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

2.70. Obesity \rightarrow Death: cardiovascular

Risk Association	
Risk Source:	Obesity
Risk Target:	Sudden cardiac death
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 29.9$ AND Sex = female



Ratio Type:	Relative Risk
Ratio Value:	1.06
Confidence Interval:	0.72-1.56
Adjusted for:	age, menopausal status, postmenopausal hormone use, and prior report of Ischemic heart disease, parental history myocardial infarction, Hypercholesterolemia, smoking, hypertension, diabetes
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	BMI
Observable Condition:	BMI ≥ 30
Ratio Type:	Relative Risk
Ratio Value:	1.63
Confidence Interval:	1.10-2.43
Adjusted for:	age, menopausal status, postmenopausal hormone use, and prior report of Ischemic heart disease, parental history myocardial infarction, Hypercholesterolemia, smoking, hypertension, diabetes
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.71. Obesity \rightarrow Diabetes

Risk Association	
Risk Source:	Obesity
Risk Target:	Diabetes
Association Type:	causes
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Waist to height ratio
Observable Condition:	0.49 < waist to height ratio < 0.65
Ratio Type:	RR



Ratio Value:	1.61
Confidence Interval:	1.41 – 1.84
Adjusted for:	
Evidence source PMID	23144362
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	BMI
Observable Condition:	$23 \le BMI \le 34$
Ratio Type:	RR
Ratio Value:	1.61
Confidence Interval:	1.40 – 1.84
Adjusted for:	
Evidence source PMID	23144362
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Waist circumference
Observable Condition:	79.3 < WC < 107.5
Ratio Type:	RR
Ratio Value:	1.65
Confidence Interval:	1.42 – 1.91
Adjusted for:	
Evidence source PMID	23144362
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Waist to hip ratio
Observable Condition:	0.81 < waist to hip ratio < 0.93
Ratio Type:	RR
Ratio Value:	1.61
Confidence Interval:	1.35 – 1.93



Adjusted for:	
Evidence source PMID	23144362
Author	Kalliopi
Reviewed	Dimitris

2.72. Obesity \rightarrow Cholelithiasis

Risk Association	
Risk Source:	Obesity
Risk Target:	Cholelithiasis
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = male
Ratio Type:	Relative Risk
Ratio Value:	1.09
Confidence Interval:	0.87 – 1.37
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	BMI
	AND Sex
Observable Condition:	BMI > 30
	AND
	Sex = male
Ratio Type:	Relative Risk
Ratio Value:	1.43



Confidence Interval:	1.04 – 1.96
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = female
Ratio Type:	Relative Risk
Ratio Value:	1.44
Confidence Interval:	1.05 – 1.98)
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	ВМІ
	AND sex
Observable Condition:	BMI >30
	AND
	Sex = female
Ratio Type:	Relative Risk
Ratio Value:	2.32
Confidence Interval:	1.17 – 4.57
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris



2.73. Obesity \rightarrow Heart Failure

Risk Association	
Risk Source:	Obesity
Risk Target:	Heart failure
Association Type:	Is an issue in
RiskID:	REID1 – REID7
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI
	AND Sex
Observable Condition:	$25 \le BMI \le 30$
	AND
	Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	1.5
Confidence Interval:	
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	BMI
	AND Sex
Observable Condition:	$30 \le BMI \le 35$
	AND
	Sex = female
Ratio Type:	hazard ratio
Ratio Value:	1.6
Confidence Interval:	
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial



	infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	BMI AND Sex
Observable Condition:	$35 \le BMI \le 40$ AND Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	3.4
Confidence Interval:	
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	BMI
	AND sex
Observable Condition:	BMI > 40
	AND
	Sex = female
Ratio Type:	Hazard ratio
Ratio Value:	5.6
Confidence Interval:	
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris



Risk Evidence ID5	
RiskID5:	5
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	1.2
Confidence Interval:	95%
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID6	
RiskID:	6
Observables:	BMI AND Sex
Observable Condition:	$30 \le BMI \le 35$ AND Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	1.8
Confidence Interval:	
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID7	
RiskID:	7
Observables:	BMI
	AND Sex
Observable Condition:	$35 \leq BMI \leq 40$



	AND
	Sex = male
Ratio Type:	Hazard ratio
Ratio Value:	2.8
Confidence Interval:	
Adjusted for:	age, total serum cholesterol level, cigarette smoking, alcohol consumption, and presence or absence of valve disease, hypertension, diabetes mellitus, electrocardiographic evidence of left ventricular hypertrophy, and myocardial infarction at base line
Evidence source PMID	12151467
Author	Kalliopi
Reviewed	Dimitris

2.74. Obesity \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Obesity
Risk Target:	Ischemic heart disease
Association Type:	Is an issue in
RiskID:	REID1 – REID8
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = male
Ratio Type:	risk ratio
Ratio Value:	1.29
Confidence Interval:	1.18 – 1.41
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2



RiskID:	2
Observables:	BMI
	AND Sex
Observable Condition:	BMI >30
	AND
	Sex = male
Ratio Type:	risk ratio
Ratio Value:	1.72
Confidence Interval:	1.51 – 1.96
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$94 \le WC \le 102$ AND Sex = male
Ratio Type:	risk ratio
Ratio Value:	1.41
Confidence Interval:	1.16 – 1.72
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC >102 AND Sex = male
Ratio Type:	risk ratio
Ratio Value:	1.81
Confidence Interval:	1.45 – 2.25



Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID5	
RiskID:	5
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$80 \le WC \le 88$ AND Sex = female
Ratio Type:	risk ratio
Ratio Value:	1.82
Confidence Interval:	1.41 – 2.36
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID6	
RiskID:	6
Observables:	Waist circumference (WC)
	AND Sex
Observable Condition:	WC > 88
	AND
	Sex = female
Ratio Type:	Risk ratio
Ratio Value:	2.69
Confidence Interval:	2.05 - 3.53
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID7	
RiskID:	7
Observables:	BMI



	AND Sex
Observable Condition:	$25 \le BMI \le 30$ AND Sex = female
Ratio Type:	risk ratio
Ratio Value:	1.80
Confidence Interval:	1.64 – 1.98
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID8	
RiskID8:	8
Observables:	BMI
	AND Sex
Observable Condition:	BMI >30
	AND
	Sex = female
Ratio Type:	risk ratio
Ratio Value:	3.10
Confidence Interval:	2.81 – 3.43
Adjusted for:	-
Evidence source PMID	19320986
Author	Kalliopi
Reviewed	Dimitris

2.75. Obesity \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Obesity
Risk Target:	Ischemic stroke
Association Type:	Is an issue in
RiskID:	REID1, REID2
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	



RiskID:	1
Observables:	BMI
Observable Condition:	$25 \le BMI \le 30$
Ratio Type:	Risk ratio
Ratio Value:	1.22
Confidence Interval:	1.05 – 1.41
Adjusted for:	-
Evidence source PMID	20299666
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	BMI
Observable Condition:	BMI >30
Ratio Type:	Risk ratio
Ratio Value:	1.64
Confidence Interval:	1.36 – 1.99
Adjusted for:	-
Evidence source PMID	20299666
Author	Kalliopi
Reviewed	Dimitris

2.76. Obesity \rightarrow Osteoarthritis

Risk Association	
Risk Source:	Obesity
Risk Target:	Osteoarthritis
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	BMI
Observable Condition:	$25 \le BMI \le 30$



Ratio Type:	Relative Risk
Ratio Value:	1.80
Confidence Interval:	1.75 – 1.85
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	BMI
Observable Condition:	BMI > 30
Ratio Type:	Relative Risk
Ratio Value:	1.96
Confidence Interval:	1.88 – 2.04
Adjusted for:	-
Evidence source PMID	24360912
Author	Kalliopi
Reviewed	Dimitris

2.77. Obesity: central \rightarrow Acute myocardial infarction OR Old myocardial infarction

Risk Association	
Risk Source:	Obesity: central
Risk Target:	Acute myocardial infarction OR Old myocardial infarction
Association Type:	is an issue in
RiskID:	REID – REID 4
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Waist circumference (WC) AND sex
Observable Condition:	94 ≤ WC ≤102 AND sex = male
Ratio Type:	Odds ratio



Ratio Value:	1
Confidence Interval:	0.5 - 4.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	Waist circumference (WC)
	AND Sex
Observable Condition:	WC >102
	AND
	Sex = male
Ratio Type:	Odds ratio
Ratio Value:	2.75
Confidence Interval:	1.08- 7.03
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	Risk Evidence ID3	
RiskID:	3	
Observables:	Waist circumference (WC) AND Sex	
Observable Condition:	$80 \le WC \le 88$ AND Sex = female	
Ratio Type:	Odds ratio	
Ratio Value:	1.5	
Confidence Interval:	0.1-7.5	
Adjusted for:	age and smoking status	
Evidence source PMID	19705980	
Author	Kalliopi	
Reviewed	Kalliopi, Dimitris	

Risk Evidence ID4	
RiskID:	4



Observables:	Waist circumference (WC) AND sex
Observable Condition:	WC > 88 AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	1.43
Confidence Interval	0.37- 5.50
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

2.78. Obesity: central \rightarrow Diabetes

Risk Association	
Risk Source:	Obesity: central
Risk Target:	Diabetes
Association Type:	Causes
RiskID:	REID1 – REID8
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$88.2 \le WC \le 94.2$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3.9
Confidence Interval:	1.0 - 8.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2



RiskID:	2
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$94.3 \le WC \le 99.3$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3.9
Confidence Interval:	1.0 - 8.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$99.4 \le WC \le 106.2$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	7.8
Confidence Interval:	2.0 -14.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	Waist circumference (WC)
	AND Sex
Observable Condition:	WC > 106.2
	AND
	Sex = male
Ratio Type:	Odds ratio
Ratio Value:	8
Confidence Interval:	4.0 - 18.0



Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$73.7 \le WC \le 80.3$ AND sex = female
Ratio Type:	Odds ratio
Ratio Value:	2
Confidence Interval:	0,5 -4.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	
RiskID:	6
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$80.4 \le WC \le 87.0$ AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	1
Confidence Interval:	0.3 - 2.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID7	
RiskID:	7
Observables:	Waist circumference (WC) AND Sex



Observable Condition:	$87.1 \le WC \le 96.2$
	AND
	Sex = female
Ratio Type:	Odds ratio
Ratio Value:	4
Confidence Interval:	2.0 - 8.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID8	
RiskID:	8
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 96.2 AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	6
Confidence Interval:	4.0 – 10.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

2.79. Obesity: central \rightarrow Dyslipidemia: HDL cholesterol serum concentration

Risk Association	
Risk Source:	Obesity: central
Risk Target:	Dyslipidemia: HDL cholesterol serum concentration
Association Type:	Is an issue in
RiskID:	REID1 – REID8
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Waist circumference (WC)



	AND Sex
Observable Condition:	$88.2 \le WC \le 94.2$
	AND
	Sex = male
Ratio Type:	Odds ratio
Ratio Value:	2
Confidence Interval:	1.5 -4.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	Waist circumference (WC) AND sex
Observable Condition:	94.3 ≤ WC ≤ 99.3 AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3
Confidence Interval:	1.7 – 4.2
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$99.4 \le WC \le 106.2$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	4
Confidence Interval:	2.0 - 8.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980



Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID	4
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 106.2 AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3
Confidence Interval:	1.7- 4.2
Adjusted for:	age and smoking status
Evidence source PMID	1970598
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$73.7 \le WC \le 80.2$ AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	1.5
Confidence Interval:	1.0 - 3.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	
RiskID:	6
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$\begin{array}{l} 80.4 \leq WC \leq 87 \\ \text{AND} \end{array}$



	Sex = female
Ratio Type:	Odds ratio
Ratio Value:	3
Confidence Interval:	1.5- 3.9
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID7	Risk Evidence ID7	
RiskID:	7	
Observables:	Waist circumference (WC) AND Sex	
Observable Condition:	$87.1 \le WC \le 96.2$ AND Sex = female	
Ratio Type:	Odds ratio	
Ratio Value:	3.9	
Confidence Interval:	2.5 - 6.0	
Adjusted for:	age and smoking status	
Evidence source PMID	19705980	
Author	Kalliopi	
Reviewed	Kalliopi, Dimitris	

Risk Evidence ID8	
RiskID:	8
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 96.2 AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	3.5
Confidence Interval:	1.5- 4.3
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris



Risk Association	
Risk Source:	Obesity: central
Risk Target:	Dyslipidemia: Triclycerides serum concentratiion
Association Type:	Is an issue in
RiskID:	REID1 – REID8
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

2.80. Obesity: central \rightarrow Dyslipidemia: Triclycerides serum concentration

Risk Evidence ID1	
RiskID:	1
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	88.2 ≤ WC ≤94.2 AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	2
Confidence Interval:	1.0 - 3.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$94.3 \le WC \le 99.3$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3.5
Confidence Interval:	2.0 - 4.2
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris



Risk Evidence ID3	
RiskID:	3
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$99.4 \le WC \le 106.2$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3
Confidence Interval:	1.6- 3.9
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 106.2 AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	2.5
Confidence Interval:	1.3-3.8
Confidence Interval:	95%
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$73.7 \le WC \le 80.3$ AND Sex = female
Ratio Type:	Odds ratio



Ratio Value:	3
Confidence Interval:	1.2- 4.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	Risk Evidence ID6	
RiskID:	6	
Observables:	Waist circumference (WC) AND Sex	
Observable Condition:	$80.4 \le WC \le 87$ AND Sex = female	
Ratio Type:	Odds ratio	
Ratio Value:	5	
Confidence Interval:	3.9- 8.0	
Adjusted for:	age and smoking status	
Evidence source PMID	19705980	
Author	Kalliopi	
Reviewed	Kalliopi, Dimitris	

Risk Evidence ID7	Risk Evidence ID7	
RiskID:	7	
Observables:	Waist circumference (WC) AND Sex	
Observable Condition:	$87.1 \le WC \le 96.2$ AND Sex = female	
Ratio Type:	Odds ratio	
Ratio Value:	7	
Confidence Interval:	5.0 – 12.0	
Adjusted for:	age and smoking status	
Evidence source PMID	19705980	
Author	Kalliopi	
Reviewed	Kalliopi, Dimitris	

Risk Evidence ID8	
RiskID:	8



Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 96.2 AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	8
Confidence Interval:	7.0 – 14.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

2.81. Obesity: central \rightarrow Hypertension

Risk Association	
Risk Source:	Central obesity
Risk Target:	Hypertension
Association Type:	causes
RiskID:	REID1 – REID8

Risk Evidence ID1	
RiskID:	1
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$88.2 \le WC \le 94.2$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	1.5
Confidence Interval:	1.0 - 3.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observables:	Waist circumference (WC)



	AND Sex
Observable Condition:	$94.3 \leq WC \leq 99.3$
	AND
	Sex = male
Ratio Type:	Odds ratio
Ratio Value:	1.7
Confidence Interval:	1.0 – 3.5
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$99.4 \le WC \le 106.2$ AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	2.5
Confidence Interval:	1.5 – 4.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 106.2 AND Sex = male
Ratio Type:	Odds ratio
Ratio Value:	3.5
Confidence Interval:	2.0 - 5.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980



Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID5	
RiskID:	5
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$73.7 \le WC \le 80.3$ AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	1
Confidence Interval:	0.5 -1.5
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID6	
RiskID:	6
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$80.4 \le WC \le 87$ AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	2
Confidence Interval:	1.0 - 3.0
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID7	
RiskID:	7
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	$\begin{array}{l} 87.1 \leq WC \leq 96.2 \\ AND \end{array}$



	Sex = female
Ratio Type:	Odds ratio
Ratio Value:	3
Confidence Interval:	1.5 – 3.9
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

Risk Evidence ID8	
RiskID:	8
Observables:	Waist circumference (WC) AND Sex
Observable Condition:	WC > 96.2 AND Sex = female
Ratio Type:	Odds ratio
Ratio Value:	5
Confidence Interval:	3.5 -7.5
Adjusted for:	age and smoking status
Evidence source PMID	19705980
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

2.82. Obstructive sleep apnoea \rightarrow Death: cardiovascular

Risk Association	
Risk Source:	Obstructive sleep apnea (OSA)
Risk Target:	Death due to Cardiovascular disease
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Gintare

Risk Evidence ID1	
RiskID:	1
Observable:	AHI
Observable Condition:	AHI > 30



Ratio Type:	Hazard ratio
Ratio Value:	2.09
Confidence Interval:	1.20–3.65
Adjusted for:	Age, gender, race, BMI, smoking, alcohol consumption, glucose, lipid levels, lipid disorders, lipid-lowering medications, diabetes mellitus, blood pressure, use of antihypertensives, CV disease, CV drugs, left ventricular function, lschemic intervention, lung disease, atrial fibrillation.
Evidence source PMID	22828826
Author	Gintare
Reviewed	Gintare

2.83. Obstructive sleep apnoea \rightarrow Diabetes

Risk Association	
Risk Source:	Obstructive sleep apnea (OSA)
Risk Target:	Diabetes
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	AHI
	OR Obstructive sleep apnea diagnosis
Observable Condition:	5 ≤ AHI <15
	OR
	Obstructive sleep apnea diagnosis = mild
Ratio Type:	Hazard ratio
Ratio Value:	1.22
Confidence Interval:	0.91–1.6
Adjusted for:	multivariate
Evidence source PMID	22988888
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	AHI



	OR Obstructive sleep apnea diagnosis
Observable Condition:	AHI ≥ 15
	OR
	Obstructive sleep apnea diagnosis = moderate
	OR Obstructive sleep apnea diagnosis = severe
Ratio Type:	Hazard ratio
Ratio Value:	1.63
Confidence Interval:	1.09–2.45
Adjusted for:	multivariate
Evidence source PMID	22988888
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.84. Obstructive sleep apnoea \rightarrow Heart failure

Risk Association	
Risk Source:	Obstructive sleep apnea (OSA)
Risk Target:	Heart failure
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	

Risk Evidence ID1	
RiskID:	1
Observable:	Obstructive sleep apnea diagnosis
Observable Condition:	Obstructive sleep apnea diagnosis = diagnosed
Ratio Type:	Odds ratio
Ratio Value:	3.84
Confidence Interval:	3.56–4.14
Adjusted for:	history of cardiovascular events, diabetes, hypertension, hypercholesterolemia
Evidence source PMID	16039877
Author	Dimitris
Reviewed	Dimitris

2.85. Obstructive sleep apnoea \rightarrow Hypertension

Risk Association



Risk Source:	Obstructive sleep apnea (OSA)
Risk Target:	Hypertension
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	AHI
Observable Condition:	1.5 ≤ AHI < 4.9
Ratio Type:	Odds ratio
Ratio Value:	1.07
Confidence Interval:	0.91-1.26
Adjusted for:	Adjusted for demographics, BMI, neck, wait-to-hip ratio, alcohol use, smoking
Evidence source PMID	10770144
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	AHI
	OR \ Obstructive sleep apnea diagnosis
Observable Condition:	5 ≤ AHI < 14.9
	OR
	Obstructive sleep apnea diagnosis = mild
Ratio Type:	Odds ratio
Ratio Value:	1.20
Confidence Interval:	1.01-1.42
Adjusted for:	Adjusted for demographics, BMI, neck, wait-to-hip ratio, alcohol use, smoking
Evidence source PMID	10770144
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	AHI
	OR Obstructive sleep apnea diagnosis



Observable Condition:	15 ≤ AHI < 29.9 OR
	Obstructive sleep apnea diagnosis = moderate
Ratio Type:	Odds ratio
Ratio Value:	1.25
Confidence Interval:	1.00-1.56
Adjusted for:	Adjusted for demographics, BMI, neck, wait-to-hip ratio, alcohol use, smoking
Evidence source PMID	10770144
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	AHI OR Obstructive sleep apnea diagnosis
Observable Condition:	AHI ≥ 30 OR Obstructive sleep apnea diagnosis = severe
Ratio Type:	Odds ratio
Ratio Value:	1.37
Confidence Interval:	1.03-1.83
Adjusted for:	Adjusted for demographics, BMI, neck, wait-to-hip ratio, alcohol use, smoking
Evidence source PMID	10770144
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.86. Obstructive sleep apnoea \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Obstructive sleep apnea (OSA)
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1



Observable:	Obstructive sleep apnea diagnosis
Observable Condition:	Obstructive sleep apnea diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	1.92
Confidence Interval:	1.06–3.48
Adjusted for:	Age, gender, race, BMI, smoking, alcohol consumption, glucose, lipid levels, lipid disorders, lipid-lowering medications, diabetes mellitus, blood pressure, use of antihypertensives, CV disease, CV drugs, left ventricular function, coronary intervention, lung disease, atrial fibrillation.
Evidence source PMID	22828826
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.87. Obstructive sleep apnoea \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Obstructive sleep apnea (OSA)
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Obstructive sleep apnea diagnosis
Observable Condition:	Obstructive sleep apnea diagnosis = diagnosed
Ratio Type:	Hazard ratio
Ratio Value:	2.24
Confidence Interval:	1.57–3.19
Adjusted for:	Age, gender, race, BMI, smoking, alcohol consumption, glucose, lipid levels, lipid disorders, lipid-lowering medications, diabetes mellitus, blood pressure, use of antihypertensives, CV disease, CV drugs, left ventricular function, coronary intervention, lung disease, atrial fibrillation.
Evidence source PMID	22828826
Author	Gintare
Reviewed	Kalliopi, Dimitris



Risk Association	
Risk Source:	Physical activity
Risk Target:	Diabetes type 2
Association Type:	is an issue in
RiskID:	1
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.88. Physical Activity \rightarrow Diabetes

Risk Evidence ID1	
RiskID:	1
Observable:	Physical activity
Observable Condition:	Physical activity = moderate
Ratio Type:	RR
Ratio Value:	0.83
Confidence Interval:	0.75–0.91
Adjusted for:	BMI
Evidence source PMID	17327354
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.89. Physical Activity \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Physical activity
Risk Target:	Ischemic heart disease
Association Type:	Is an issue in
RiskID:	REID1 – REID4
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Physical activity AND Sex
Observable Condition:	Physical activity = moderate AND Sex = male



Ratio Type:	RR
Ratio Value:	0.85
Confidence Interval:	0.77-0.93
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Physical activity AND Sex
Observable Condition:	Physical activity = moderate AND Sex = female
Ratio Type:	RR
Ratio Value:	0.78
Confidence Interval:	0.72-0.85
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Physical activity
	AND Sex
Observable Condition:	Physical activity = high
	AND
	Sex = male
Ratio Type:	RR
Ratio Value:	0.79
Confidence Interval:	0.73-0.85
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4



RiskID:	4
Observable:	Physical activity
	AND sex
Observable Condition:	Physical activity = high
	AND
	Sex = female
Ratio Type:	RR
Ratio Value:	0.71
Confidence Interval:	0.65-0.77
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.90. Physical activity \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Physical activity
Risk Target:	Ischemic stroke
Association Type:	Is an issue in
RiskID:	REID1 – REID4
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Physical activity AND Sex
Observable Condition:	Physical activity = moderate AND Sex = male
Ratio Type:	RR
Ratio Value:	0.73
Confidence Interval:	0.62-0.85
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris



Risk Evidence ID2	
RiskID:	2
Observable:	Physical activity AND Sex
Observable Condition:	Physical activity = moderate AND Sex = female
Ratio Type:	RR
Ratio Value:	0.89
Confidence Interval:	0.79-1.00
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Physical activity AND Sex
Observable Condition:	Physical activity = high AND Sex = male
Ratio Type:	RR
Ratio Value:	0.71
Confidence Interval:	0.60-0.84
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Physical activity AND Sex
Observable Condition:	Physical activity = high AND Sex = female
Ratio Type:	RR
Ratio Value:	0.78



Confidence Interval:	0.66-0.92
Adjusted for:	Age, smoking
Evidence source PMID	22470299
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.91. Physical activity AND Chronic kidney disease \rightarrow Death

Risk Association	
Risk Source:	Physical activity AND Chronic kidney disease
Risk Target:	Death
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Laurynas
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Physical activity
	AND Chronic kidney disease diagnosis
Observable Condition:	Physical activity = moderate
	AND
	Chronic kidney disease diagnosis = stage 5
Ratio Type:	Relative risk
Ratio Value:	1.2
Confidence Interval:	0.7–1.8
Adjusted for:	age, sex, race, body-mass index
Evidence source PMID	12843775
Author	Laurynas
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Physical activity AND Chronic kidney disease diagnosis
Observable Condition:	Physical activity = high AND Chronic kidney disease diagnosis = stage 5
Ratio Type:	Relative risk



Ratio Value:	2.2
Confidence Interval:	1.3–3.8
Adjusted for:	age, sex, race, body-mass index
Evidence source PMID	12843775
Author	Laurynas
Reviewed	Kalliopi, Dimitris

2.92. Smoking \rightarrow Death: cardiovascular

Risk Factor	
Risk Source:	Smoking status
Risk Target:	Death: cardiovascular
Association Type:	is an issue in
RiskID:	REID1 – REID4
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	REID1
Observable:	Smoking status AND Sex
Observable Condition:	Smoking status = ex-smoker AND Sex = female
Ratio Type:	Relative Risk
Ratio Value:	1.49
Confidence Interval:	1.08-2.06
Adjusted for:	Multivariate-adjusted
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Smoking status AND smoking intensity AND sex
Observable Condition:	status = Current AND 1 ≤smoking intensity ≤ 14 cigarettes/day



	AND
	sex = female
Ratio Type:	Relative Risk
Ratio Value:	2.83
Confidence Interval:	1.80-4.45
Adjusted for:	Multivariate-adjusted
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID3	
RiskID:	3
Observable:	Smoking status AND Smoking intensity AND Sex
Observable Condition:	Smoking status = Current AND $15 \le$ Smoking intensity ≤ 24 cigarettes/day AND Sex = female
Ratio Type:	Relative Risk
Ratio Value:	2.40
Confidence Interval:	1.55-3.72
Adjusted for:	Multivariate-adjusted
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

Risk Evidence ID4	
RiskID:	4
Observable:	Smoking status AND Smoking intensity AND Sex
Observable Condition:	Smoking status = Current AND Smoking intensity ≥ 25 cigarettes/day AND Sex=female
Ratio Type:	Relative Risk
Ratio Value:	4.13



Confidence Interval:	2.69- 6.33
Adjusted for:	Multivariate-adjusted
Evidence source PMID	12695299
Author	Gintare
Reviewed	Kalliopi, Dimitris

2.93. Smoking \rightarrow Albuminuria

Risk Association	
Risk Source:	Smoking
Risk Target:	Albuminuria
Association Type:	Causes
RiskID:	REID1, REID2
Author:	Stefanos
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Smoking status
Observable Condition:	Smoking status = Current Smoker
Ratio Type:	Relative Risk
Ratio Value:	3.26
Confidence Interval:	1.66 - 6.80
Adjusted for:	
Evidence source PMID	10972692
Author:	Stefanos
Reviewed:	Dimitris

Risk Evidence ID2	
RiskID:	2
Observable:	Smoking status
Observable Condition:	Smoking status = Ex-smoker
Ratio Type:	Relative Risk
Ratio Value:	2.69
Confidence Interval:	1.24 – 5.99
Adjusted for:	
Evidence source PMID	10972692



Author:	Stefanos
Reviewed:	Dimitris

2.94. Smoking \rightarrow Chronic Kidney Disease

Risk Association	
Risk Source:	Smoking
Risk Target:	Chronic kidney disease
Association Type:	Is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Dimitris

Risk Evidence ID1	
RiskID:	1
Observables:	Smoking status AND Sex
Observables Condition:	Smoking status = current AND Sex = male
Ratio Type:	Relative risk
Ratio Value:	2.4
Confidence Interval:	1.2-4.5
Adjusted for:	-
Evidence source PMID	17541263
Author	Dimitris
Reviewed	Dimitris

2.95. Smoking \rightarrow Heart failure

Risk Association	
Risk Source:	Smoking
Risk Target:	Heart failure
Association Type:	is an issue in
RiskID:	REID1
Author	Dimitris
Reviewed	Kalliopi



Risk Evidence ID1	
RiskID:	1
Observable:	Smoking status
Observable Condition:	Smoking status = Current
Ratio Type:	Hazard ratio
Ratio Value:	1.64
Confidence Interval:	1.28 – 2.01
Adjusted for:	age, sex, hypertension, BMI, heart rate, CHD, diabetes mellitus, valvular heart disease, lower high-density lipoprotein cholesterol, atrial fibrillation, presence of LV hypertrophy or left bundle-branch block
Evidence source PMID	23271790
Author	Dimitris
Reviewed	Dimitris

2.96. Smoking \rightarrow Ischemic heart disease

Risk Association	
Risk Source:	Smoking
Risk Target:	Ischemic heart disease
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Smoking status AND Sex
Observable Condition:	Smoking status = Current AND Sex = male
Ratio Type:	Relative risk
Ratio Value:	1.43
Confidence Interval:	1.26-1.62
Adjusted for:	arterial blood pressure, total and high density lipoprotein cholesterol concentrations, triglyceride concentrations, diabetes, body mass index, height, alcohol intake, physical activity, and level of education
Evidence source PMID	09552903
Author	Dimitris



Reviewed	Kalliopi, Dimitris
----------	--------------------

Risk Evidence ID2	
RiskID:	2
Observable:	Smoking status AND Sex
Observable Condition:	Smoking status = Current AND Sex = female
Ratio Type:	Relative risk
Ratio Value:	2.24
Confidence Interval:	1.85-2.71
Adjusted for:	arterial blood pressure, total and high density lipoprotein cholesterol concentrations, triglyceride concentrations, diabetes, body mass index, height, alcohol intake, physical activity, and level of education
Evidence source PMID	09552903
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.97. Smoking \rightarrow Ischemic stroke

Risk Association	
Risk Source:	Smoking
Risk Target:	Ischemic stroke
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Smoking status
Observable Condition:	Smoking status = Current
Ratio Type:	Relative risk
Ratio Value:	1.5
Confidence Interval:	1.4 – 1.6
Adjusted for:	-
Evidence source PMID	2496858
Author	Dimitris



Reviewed	Kalliopi, Dimitris
----------	--------------------

Risk Evidence ID2	
RiskID:	2
Observable:	Smoking status
Observable Condition:	Smoking status = Ex-smoker
Ratio Type:	Relative risk
Ratio Value:	1.17
Confidence Interval:	1.05 - 1.30
Adjusted for:	-
Evidence source PMID	2496858
Author	Dimitris
Reviewed	Kalliopi, Dimitris

2.98. Smoking \rightarrow Peripheral Arterial Disease

Risk Association	
Risk Source:	Smoking
Risk Target:	Peripheral arterial disease
Association Type:	is an issue in
RiskID:	REID1, REID2
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID1	
RiskID:	1
Observable:	Smoking status
Observable Condition:	Smoking status = Current smoker
Ratio Type:	Relative risk
Ratio Value:	2.71
Confidence Interval:	2.28 - 3.21
Adjusted for:	-
Evidence source PMID	23922053
Author	Dimitris
Reviewed	Kalliopi, Dimitris

Risk Evidence ID2



RiskID:	2
Observable:	Smoking status
Observable Condition:	Smoking status = Ex-smoker
Ratio Type:	Relative risk
Ratio Value:	1.67
Confidence Interval:	1.54 - 1.81
Adjusted for:	-
Evidence source PMID	23922053
Author	Dimitris
Reviewed	Kalliopi, Dimitris

3. Risk Elements

3.1. Acute kidney injury

Risk Element	
Name	Acute Kidney Injury http://purl.bioontology.org/ontology/ICD9CM/584 C0022660
Туре	biomedical
Modifiable	yes
Observables	serum creatinine urine output diagnosis
Diagnosis Condition	[(serum creatine +0.3 of baseline OR serum creatine +150-200% of baseline) AND <0.5 ml/kg/h urine output for more than 6 hours] OR acute kidney injury diagnosis = mild [serum creatine +200-300% of baseline AND <0.5 ml/kg/h urine output for more than 12 hours] OR acute kidney injury diagnosis = moderate [(serum creatine +>300% of baseline OR serum creatine >0.4mg/dl)



	AND
	(urine output <0.3 ml/kg/h for more than 24 hours
	OR
	urine output < 100 ml/24 hours for 12 hours)]
	OR
	acute kidney injury diagnosis = severe
Author	Stefanos
Reviewed	Stefanos, Ploumis, Kalliopi

3.2. Acute myocardial infarction

Risk Element	
Name	Acute myocardial infarction http://purl.bioontology.org/ontology/ICD9CM/410 C0155626
Туре	Biomedical
Modifiable	No
Observables	Acute myocardial infarction
Diagnosis Condition	Acute myocardial infarction = diagnosed
Author	Kalliopi, Dimitris
Reviewed	Kalliopi, Dimitris

3.3. Age

Risk Element	
Name	Age http://purl.bioontology.org/ontology/SNOMEDCT/71395006 C0001783
Туре	demographic
Modifiable	no
Observables	age
Diagnosis condition	N/A
Author	Kalliopi
Reviewed	Kalliopi

3.4. Albuminuria

Risk Element	
Name	Albuminuria



	http://purl.bioontology.org/ontology/SNOMEDCT/274769005 C0001925
Туре	biomedical
Modifiable	yes
Observables	albuminuria
Diagnosis condition	Albuminuria ≥ 30 mg/24h
Author	Stefanos
Reviewed	Kalliopi, Dimitris

3.5. Anemia

Risk Element	
Name	Anemia
	http://purl.bioontology.org/ontology/SNOMEDCT/271737000
	C0002871
	C1510654
Туре	Biomedical
Modifiable	Yes
Observables	Hemoglobin level
Diagnosis condition	$Hb \leq 12.5 \text{ g/dL}$
Author	Gintare
Reviewed	Kalliopi, Dimitris

3.6. Asthma

Risk Element	
Name	Asthma
	http://purl.bioontology.org/ontology/ICD9CM/493
	C0004096
Туре	Biomedical
Modifiable	yes
Observables	Asthma
Diagnosis condition	Asthma = diagnosed
Author	Kalliopi
Reviewed	Kalliopi, Dimitris



3.7. Atrial fibrillation

Risk Element	
Name	Atrial fibrillation http://purl.bioontology.org/ontology/ICD9CM/427.31
	C0004238
Туре	biomedical
Modifiable	yes
Observables	Atrial fibrillation
Diagnosis condition	Atrial fibrillation = diagnosed
Author	Neringa
Reviewed	Kalliopi, Dimitris

3.8. Cholelithiasis

Risk Element	
Name	Cholelithiasis
	http://purl.bioontology.org/ontology/ICD9CM/574
	C0008350
Туре	Biomedical
Modifiable	yes
Observables	Cholelithiasis
Diagnosis condition	Cholelithiasis = diagnosed
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

3.9. Chronic kidney disease

Risk Element	
Name	Chronic kidney disease http://purl.bioontology.org/ontology/ICD9CM/585 C1561643
Туре	Biomedical
Modifiable	Yes
Observables	glomerular filtration rate (eGFR)
Diagnosis condition	[Chronic kidney disease = stage 1 OR eGFR \ge 90] OR [Chronic kidney disease = stage 2 OR



Reviewed	Kalliopi, Dimitris
Author	Stefanos
	eGFR < 15]
	OR
	[Chronic kidney disease = stage 5
	OR
	$15 \le eGFR \le 29$]
	OR
	[Chronic kidney disease = stage 4
	OR
	$30 \le eGFR \le 44$]
	OR
	[Chronic kidney disease = stage 3B
	OR
	45 ≤ eGFR ≤ 59]
	OR
	[Chronic kidney disease = stage 3A
	OR
	60 ≤ eGFR ≤ 89]

3.10. Chronic obstructive pulmonary disease (COPD)

Risk Element	
Name	Chronic obstructive pulmonary disease (COPD)
	http://purl.bioontology.org/ontology/ICD9CM/490-496.99
	C0178278
Туре	Biomedical
Modifiable	Yes
Observables	Chronic obstructive pulmonary disease diagnosis
Diagnosis condition	Chronic obstructive pulmonary disease diagnosis = diagnosed
Author	Gintare
Reviewed	Kalliopi, Dimitris

3.11. Cancer: Colorectal

Risk Element	
Name	Colorectal Cancer http://purl.bioontology.org/ontology/ICD9CM/153
	C0007102
Туре	Biomedical, genetic, environmental
Modifiable	no



Observables	Colorectal Cancer
Diagnosis condition	Colorectal Cancer = diagnosed
Author	Kalliopi
Reviewed	kalliopi, Dimitris

3.12. Cancer: Gastric cardiac cancer

Risk Element	
Name	Gastric cardiac Cancer http://purl.bioontology.org/ontology/ICD9CM/151.0
	C0153417
Туре	Biomedical, genetic, environmental
Modifiable	no
Observables	Colorectal Cancer
Diagnosis condition	Colorectal Cancer = diagnosed
Author	Kalliopi
Reviewed	kalliopi, Dimitris

3.13. Cancer: Pancreatic

Risk Element	
Name	Pancreatic Cancer http://purl.bioontology.org/ontology/ICD9CM/157 C0346647
Туре	Biomedical, genetic, environmental
Modifiable	no
Observables	Colorectal Cancer
Diagnosis condition	Colorectal Cancer = diagnosed
Author	Kalliopi
Reviewed	kalliopi, Dimitris

3.14. Death

Risk Element	
Name	Death http://purl.bioontology.org/ontology/ICD9CM/798 C0520806
Туре	biomedical
Modifiable	no



Observables	Death
Diagnosis condition	Death = diagnosed
Author	Gintare
Reviewed	Kalliopi, Dimitris

3.15. Death: due to cardiovascular disease

Risk Element	
Name	Death: cardiovascular
	http://purl.bioontology.org/ontology/SNOMEDCT/95281009
	C0085298
Туре	biomedical
Modifiable	no
Observables	Death: cardiovascular
Diagnosis condition	Death: cardiovascular = diagnosed
Author	Gintare
Reviewed	Kalliopi, Dimitris

3.16. Depression

Risk Element	
Name	Depression <u>http://purl.bioontology.org/ontology/ICD9CM/311</u> C0868892
Туре	Biomedical
Modifiable	Yes
Observables	Depression Antidepressant medication
	Depression = diagnosed OR Antidepressant medication administration = yes
Author	Gintare
Reviewed	Gintare

3.17. Diabetes

Risk Element	
Name	Diabetes



	http://purl.bioontology.org/ontology/ICD9CM/250
	C0011849
Туре	biomedical
Modifiable	yes
Observables	Fasting plasma glucose levels HbA1c random plasma glucose levels glucose at two hours after oral glucose tolerance test antidiabetic medication administration diabetes
Diagnosis condition	Fasting plasma glucose levels \geq 126 mg% OR HbA1c \geq 6.5% OR random plasma glucose levels \geq 200 mg% OR glucose at two hours after oral glucose tolerance test \geq 200 mg% OR antidiabetic medication administration = yes OR diabetes = diagnosed
Author	Zydrune, Gintare, Kalliopi
Reviewed	Gintare, Kalliopi, Dimitris

3.18. Diabetes: disease control

Risk Element	
Name	see 2.28—2.30
Туре	clinical
Modifiable	yes
Observables	Diabetes AND HbA1c
Diagnosis condition	Diabetes = diagnosed AND HbA1c > 5.7
Author	Kalliopi
Reviewed	Kalliopi, Dimitris



3.19. Diabetic nephropathy

Risk Element	
Name	Diabetic nephropathy http://purl.bioontology.org/ontology/ICD9CM/250.4 C0011881
Туре	biomedical
Modifiable	no
Observables	Diabetic nephropathy
Diagnosis condition	Diabetic nephropathy = diagnosed
Author	Zydrune
Reviewed	Kalliopi, Dimitris

3.20. Drugs: β-blockers

Risk Element	
Name	Drugs: β-blockers
Туре	Intervention
Modifiable	yes
Observables	drug administration
Diagnosis condition	drug administration = yes
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

3.21. Drugs: Contrast agents

Risk Element	
Name	Contrast agents
Туре	intervention
Modifiable	yes
Observables	contrast agents administration
Diagnosis condition	contrast agents administration = yes
Author	Dimitris
Reviewed	Kalliopi, Dimitris

3.22. Drugs: Diuretics

Risk Element



Name	Drugs: diuretics
Туре	intervention
Modifiable	yes
Observables	contrast agents administration
Diagnosis condition	contrast agents administration = yes
Author	Dimitris
Reviewed	Kalliopi, Dimitris

3.23. Drugs: Renin-angiotensin system dual blockade (any)

Risk Element	
Name	Drugs: Renin-angiotensin system dual blockade (any)
Туре	intervention
Modifiable	yes
Observables	Drugs: Renin-angiotensin system dual blockade (any) administration
Diagnosis condition	Drugs: Renin-angiotensin system dual blockade (any) administration = yes
Author	Dimitris
Reviewed	Kalliopi, Dimitris

3.24. Drugs: Statins

Risk Element	
Name	Drugs: Statins
Туре	intervention
Modifiable	yes
Observables	Drugs: Statins administration
Diagnosis condition	Drugs: Statins administration = yes
Author	Dimitris
Reviewed	Kalliopi, Dimitris

3.25. Dyslipidemia

Risk Element	
Name	Dyslipidemia http://purl.bioontology.org/ontology/ICD9CM/272 C0154251
Туре	Biomedical
Modifiable	Yes



Observables	Total cholesterol (TC) low-density lipoprotein cholesterol (LDL-C) high-density lipoprotein cholesterol (HDL-C) triglycerides (TG)
Diagnosis condition	dislipidemia = diagnosed
Author	Gintare
Reviewed	Kalliopi, Dimitris

3.26. Heart Failure

Risk Element	
Name	Heart failure
	http://purl.bioontology.org/ontology/ICD9CM/428
	C0018801
Туре	Biomedical
Modifiable	yes
Observables	Heart failure
Diagnosis condition	Heart failure = diagnosed
Author	Gintare, Zydrune
Reviewed	Kalliopi, Dimitris

3.27. Hospitalization

Risk Element	
Name	http://purl.bioontology.org/ontology/SNOMEDCT/281685003
	C0150124
Туре	clinical
Modifiable	yes
Observables	diagnosis
Diagnosis condition	hospitalization = yes
Author	Dimitris
Reviewed	Dimitris

3.28. Hyperkalemia

Risk Element	
Name	Hyperkalemia http://purl.bioontology.org/ontology/ICD9CM/276.7 C0020461



Туре	biomedical
Modifiable	yes
Observables	Serum potassium
Diagnosis condition	Serum potassium > 5 mEq/l
Author	Neringa
Reviewed	Kalliopi, Dimitris

3.29. Hypertension

Risk Element		
Name	Hypertension <u>http://purl.bioontology.org/ontology/ICD9CM/401-405.99</u> C0020538	
Туре	biomedical	
Modifiable	yes	
Observables	Systolic blood pressure (SBP)	
	Diastolic blood pressure (DBP)	
Diagnosis condition	SBP ≥140 mmHg and/or DBP ≥ 90 mmHg	
	OR	
	[Grade 1 hypertension: 140–159 mmHg SBP and/or 90–99 mmHg DBP Grade 2 hypertension: 160–179 mmHg SBP and/or 100–109 mmHg DBP Grade 3 hypertension: ≥180 mmHg SBP and/or ≥110 mmHg DBP] OR	
	antihypertensive medication administration = yes	
Author	Neringa, Gintare, Zydrune	
Reviewed	Neringa, Kalliopi, Dimitris	

3.30. Hyperuricemia

Risk Element		
Name	Hyperuricemia http://purl.bioontology.org/ontology/SNOMEDCT/35885006 C0740394	
Туре	biomedical	
Modifiable	yes	
Observables	Uric acid serum concentration	
Diagnosis condition	Uric acid serum concentration > 7 mg%	
Author	Laurynas	
Reviewed	Kalliopi, Dimitris	



3.31. Hypoglycaemia

Risk Element		
Name	Hypoglycaemia http://purl.bioontology.org/ontology/ICD9CM/251.2	
	C0020615	
Туре	clinical	
Modifiable	yes	
Observables	Fasting Plasma Glucose	
Diagnosis condition	Fasting Plasma Glucose < 50 mg%	
Author	Stefanos	
Reviewed	Kalliopi, Dimitris	

3.32. Hypotension

Risk Element	
Name	Hypotension http://purl.bioontology.org/ontology/SNOMEDCT/67763001 C0520541
Туре	clinical
Modifiable	yes
Observables	blood pressure
Diagnosis condition	
Author	Dimitris
Reviewed	Kalliopi, Dimitris

3.33. Ischemic heart disease

Risk Element	
Name	Ischemic heart disease
	http://purl.bioontology.org/ontology/ICD9CM/410-414.99
	C0151744
Туре	Biomedical
Modifiable	No
Observables	Acute myocardial infarction
	Angina pectoris
	Old myocardial infarction



Diagnosis Condition	Acute myocardial infarction = diagnosed	
	OR	
	Angina pectoris = diagnosed	
	OR	
	Old myocardial infarction = diagnosed	
Author	Kalliopi, Dimitris	
Reviewed	Kalliopi, Dimitris	

3.34. Ischemic heart disease: Family history of

Risk Element		
Name	Family history of Ischemic heart disease	
	http://purl.bioontology.org/ontology/ICD9CM/V17.3	
	C0260520	
Туре	Genetic	
Modifiable	No	
Observables	Family history of Ischemic heart disease	
Diagnosis condition	Family history of Ischemic heart disease = yes	
Author	Gintare	
Reviewed	Kalliopi, Dimitris	

3.35. Ischemic heart disease: Self history

Risk Element		
Name	Ischemic heart disease: self history http://purl.bioontology.org/ontology/ICD9CM/412	
	C0155668	
Туре	Biomedical	
Modifiable	No	
Observables	Old myocardial infarction	
Diagnosis Condition	Old myocardial infarction = diagnosed	
Author	Kalliopi, Dimitris	
Reviewed	Kalliopi, Dimitris	

3.36. Ischemic stroke

Risk Element	
Name	Ischemic stroke
	http://purl.bioontology.org/ontology/ICD9CM/434



	C0028790	
Туре	biomedical	
Modifiable	no	
Observables	Ischemic stroke	
Diagnosis condition	Ischemic stroke = diagnosed	
Author	Dimitris, Stefanos, Gintare	
Reviewed	Kalliopi, Dimitris	

3.37. Left ventricular hypertrophy

Risk Element		
Name	Left ventricular hypertrophy http://purl.bioontology.org/ontology/SNOMEDCT/55827005	
	C0149721	
Туре	biomedical	
Modifiable	yes	
Observables	Left ventricular hypertrophy	
Diagnosis condition	Left ventricular hypertrophy = diagnosed	
Author	Neringa	
Reviewed	Kalliopi, Dimitris	

3.38. Obesity

Risk Element		
Name	Obesity http://purl.bioontology.org/ontology/ICD9CM/278.00 C0028754	
Туре	behavioral	
Modifiable	yes	
Observables	BMI, body fat percentage	
Diagnosis Condition	BMI range – kg/m ²	Category
	less than 15	Very severely underweight
	from 15.0 to 16.0	Severely underweight
	from 16.0 to 18.5	Underweight
	from 18.5 to 25	Normal (healthy weight)
	from 25 to 30	Overweight
	from 30 to 35	Obese Class I (Moderately obese)



	from 35 to 40	Ob	ese Class II (Severely obese)
	over 40	Ob	ese Class III (Very severely obese)
	OR		
	Description	Women	Men
	Essential fat	10–13%	2–5%
	Athletes	14–20%	6–13%
	Fitness	21–24%	14–17%
	Average	25–31%	18–24%
	Obese	32%+	25%+
Author	Kalliopi		
Reviewed	Kalliopi, Dimitris		

3.39. Obesity: Central

Risk Element	
Name	Central obesity http://purl.bioontology.org/ontology/SNOMEDCT/248311001 C0311277
Туре	behavioural
Modifiable	yes
Observables	waist circumference waist to hip ratio waist to height ratio
	[Men Normal: < 94 in men decent: 80 to 88 too high: >88 women normal: <80 decent: 94 to 102 too high: >102] OR [Normal: 0.30- 0.49 Abnormal: <0.30 or >0.50] OR [Normal: <0.30 or >0.50]



	Abnormal:
	male: >0.96
	female: >0.81]
Author	Kalliopi
Reviewed	Kalliopi, Dimitris

3.40. Obstructive Sleep Apnoea

Risk Element	
Name	Obstructive sleep apnea (OSA) http://purl.bioontology.org/ontology/ICD9CM/327.23 C0520679
Туре	Biomedical
Modifiable	Yes
Observables	Apnoea–hypopnoea index (AHI)
Diagnosis condition	$ \begin{bmatrix} 5 \le AHI < 15 \\ OR \\ OSA = mild \end{bmatrix} $ $ OR \\ \begin{bmatrix} 15 \le AHI < 29.9 \\ OR \\ OSA = moderate \end{bmatrix} $ $ OR \\ \begin{bmatrix} AHI \ge 30 \\ OR \\ OSA = severe \end{bmatrix} $
Author	Gintare
Reviewed	Kalliopi, Dimitris

3.41. Osteoarthritis

Risk Element		
Name	Osteoarthritis http://purl.bioontology.org/ontology/ICD9CM/715.0	
	C1384584	
Туре	Biomedical	
Modifiable	no	
Observables	Osteoarthritis	
Diagnosis condition	Osteoarthritis = diagnosed	
Author	Kalliopi	
Reviewed	Kalliopi, Dimitris	



3.42. Peripheral arterial disease

Risk Element	
Name	Peripheral arterial disease http://purl.bioontology.org/ontology/ICD9CM/440.2 C3495604
Туре	Biomedical, behavioural
Modifiable	yes
Observables	ankle-branchial index
Author	Dimitris, Kalliopi
Reviewed	Dimitris, Kalliopi

3.43. Peripheral vascular disease

Risk Element		
Name	Peripheral vascular disease	
	http://purl.bioontology.org/ontology/ICD10CM/I73.9	
	C0085096	
Туре	Biomedical, behavioural	
Modifiable	yes	
Observables		
Author	Dimitris, Kalliopi	
Reviewed	Dimitris, Kalliopi	

3.44. Physical activity

Risk Element		
Name	Physical activity http://purl.bioontology.org/ontology/SNOMEDCT/61686008 C0015259	
Туре	behavioural, intervention	
Modifiable	yes	
Observables	physical activity	
Diagnosis condition	[physical activity = moderate OR physical activity < 2.5 h per week of aerobic activity] OR [physical activity = high OR physical activity ≥ 2.5 h per week of aerobic activity]	



Author	Stefanos, Dimitris
Reviewed	Kalliopi, Dimitris

3.45. Smoking

Risk Element	
Name	Smoking http://purl.bioontology.org/ontology/SNOMEDCT/365981007
	C0453996
Туре	behavioral
Modifiable	yes
Observables	smoking status
Diagnosis condition	smoking status = ex-smoker OR smoking status = current OR smoking status = never
Author	Dimitris
Reviewed	Kalliopi, Dimitris

4. Observables

4.1. Acute kidney disease diagnosis

Observable	
Name	Acute kidney disease diagnosis
Туре	personal
Data type	text
Unit	
Values/range	diagnosed mild moderate severe not diagnosed



4.2. Acute myocardial infarction diagnosis

Observable	
Name	Acute myocardial infarction diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.3. Age

Observable	
Name	Age
Туре	personal
Data type	integer
Unit	years, months, days
Values/range	

4.4. AHI (Apnoea– hypopnoea index)

Observable		
Name	Apnoea– hypopnoea index (AHI)	
Туре	clinical	
Data type	integer	
Unit	the number of apnoeas or hypopnoeas per hour of sleep	
Values/range	Normal: < 5 per hour Mild OSA: AHI \ge 5, but < 15 per hour Moderate OSA: AHI \ge 15, but < 30 per hour Severe OSA: AHI \ge 30 per hour	

4.5. Atrial fibrillation diagnosis

Observable	
Name	Atrial fibrillation diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed



not diagnosed

4.6. β-blockers administration

Observable		
Name	β-blockers administration	
Туре	clinical	
Data type	text	
Unit		
Values/range	yes	
	no	

4.7. Blood Glucose: 2h glucose after oral glucose tolerance test

Observable		
Name	2h glucose after oral glucose tolerance test	
Туре	clinical	
Data type	integer	
Unit	mg/dl	
Values/range	Normal: <140 Prediabetes: 140-199 Diabetes: ≥200	

4.8. Blood Glucose: fasting

Observable		
Name	Plasma glucose	
Туре	clinical	
Data type	integer	
Unit	mmol/l	
Values/range	Normal: Fasting plasma glucose 3.3 – 6.1 mmol/l Abnormal: Fasting plasma glucose ≥7.0mmol/l	

4.9. Blood pressure

Observable	
Name	Blood pressure (BP)
Туре	clinical



Data type	real	
Unit	mmHg	
Values/range	Normal values: systolic pressure ≤140 mmHg and/or diastolic pressure ≤90 mmHg high normal BP: SBP 130-139 mmHg and/or DBP 85-89 mmHg. normal BP: SBP 120-129 mmHg and/or DBP 80-84 mmHg; Optimal: SBP<120 mmHg and DBP<80 mmHg;	
	abnormal values: Grade 1 hypertension: 140–159 mmHg SBP and/or 90–99 mmHg DBP Grade 2 hypertension: 160–179 mmHg SBP and/or 100–109 mmHg DBP Grade 3 hypertension: ≥180 mmHg SBP and/or ≥110 mmHg DBP Isolated systolic hypertension ≥140 SBP mmHg and <90 mmHg DBP	

4.10. BMI (Body Mass Index)

Observable				
Name	BMI	BMI		
Туре	personal			
Data type	integer			
Unit	kg/m ²			
Values/range	BMI range – kg/m ²	Category		
	less than 15	Very severely underweight		
	from 15.0 to 16.0	Severely underweight		
	from 16.0 to 18.5	Underweight		
	from 18.5 to 25	Normal (healthy weight)		
	from 25 to 30	Overweight		
	from 30 to 35	Obese Class I (Moderately obese)		
	from 35 to 40	Obese Class II (Severely obese)		
	over 40	Obese Class III (Very severely obese)		

4.11. Body Fat percentage

Observable	
Name	body fat percentage
Туре	personal and clinical
Data type	real
Unit	%



Values/range	Description	Women	Men
	Essential fat	10–13%	2–5%
	Athletes	14–20%	6–13%
	Fitness	21–24%	14–17%
	Average	25–31%	18–24%
	Obese	32%+	25%+

4.12. Chronic kidney disease diagnosis

Observable	
Name	Chronic kidney disease diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed
	stage 1
	stage 2
	stage 3A
	stage 3B
	stage 4
	stage 5
	not diagnosed

4.13. Chronic obstructive pulmonary disease diagnosis

Observable	
Name	Chronic obstructive pulmonary disease diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.14. Contrast agents: coronary angiography administration

Observable	
Name	Contrast agents: coronary angiography administration



Туре	clinical
Data type	text
Unit	
Values/range	yes
	no

4.15. Depression diagnosis

Observable	
Name	Depression diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.16. Diabetes diagnosis

Observable	
Name	Diabetes diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.17. Diuretics administration

Observable	
Name	Diuretics administration
Туре	clinical
Data type	text
Unit	
Values/range	yes
	no



4.18. eGFR

Observable	
Name	eGFR
Туре	clinical
Data type	real
Unit	ml/min/1.73 m ²
Values/range	Normal: >90 Stage 1: Mildly decreased: 60–89 Stage 2: Mildly to moderately decreased: 45–59 Stage 3: Moderately to severely decreased: 30–44 Stage 4:Severely decreased: 15–29 Stage 5: Kidney failure:<15

4.19. Fasting Plasma Glucose Levels

Observable	
Name	Fasting Plasma Glucose levels
Туре	clinical, personal
Data type	integer
Unit	mg/dl
Values/range	Normal: <100 Prediabetes: 100 to 126 Diabetes: \geq 126
Author	Kalliopi
Reviewed	

4.20. HbA1c

Observable	
Name	HbA1c
Туре	clinical
Data type	real
Unit	%
Values/range	Normal: <5.7
	Prediabetes: 5.7 to 6.4
	Diabetes: ≥6.5



4.21. Haemoglobin (Hb)

Observable	
Name	Haemoglobin (Hb)
Туре	biomedical
Data type	integer
Unit	g/dL
Values/range	IF Sex = male, Normal: >13 IF Sex = female, Normal >12g/dL
	IF Sex = male, Abnormal <13 g/dL IF Sex = female, Abnormal <12g/dL

4.22. HDL-C (High-density lipoprotein cholesterol)

Observable	
Name	HDL-C (High-density lipoprotein cholesterol)
Туре	Clinical
Data type	Real
Unit	mmol/L or mg/dL
Values/range	Normal: >1.0 mmol/L (~40 mg/dL) in men; >1.2 mmol/L (~45 mg/dL) in women Abnormal: <1.0 mmol/L (~40 mg/dL) in men; <1.2 mmol/L (~45 mg/dL) in women

4.23. Heart failure diagnosis

Observable	
Name	Heart failure diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.24. Hypertension Diagnosis

Observable	
Name	Hypertension diagnosis



Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.25. Ischemic heart disease diagnosis

Observable	
Name	Ischemic heart disease diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.26. Ischemic heart disease family history

Observable	
Name	Ischemic heart disease family history
Туре	clinical
Data type	text
Unit	
Values/range	yes maternal paternal maternal & paternal no

4.27. Ischemic heart disease self history

Observable	
Name	Ischemic heart disease self history
Туре	clinical
Data type	text
Unit	
Values/range	yes
	no



Observable	
Name	Stroke diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed not diagnosed

4.28. Ischemic stroke diagnosis

4.29. LDL-C (Low-density lipoprotein cholesterol)

Observable	
Name	LDL-C (Low-density lipoprotein cholesterol)
Туре	Clinical
Data type	Real
Unit	mmol/L or mg/dL
Values/range	Normal <3 mmol/L (less than ~115 mg/dL) for subjects at low or moderate risk; <2.5 mmol/L (less than ~100 mg/dL) for subjects at high risk Abnormal >3 mmol/L (more than ~115 mg/dL) for subjects at low or moderate risk ; >2.5 mmol/L (more than ~100 mg/dL) for subjects at high risk

4.30. Left ventricular hypertrophy diagnosis

Observable	
Name	Left ventricular hypertrophy diagnosis
Туре	Clinical
Data type	text
Unit	
Values/range	diagnosed
	not diagnosed

4.31. Non-HDL-C

Observable	
Name	Non-HDL-C cholesterol serum concentration
Туре	Clinical



Data type	Real
Unit	mmol/L or mg/dL
Values/range	

4.32. Obstructive sleep apnea diagnosis

Observable	
Name	Obstructive sleep apnea diagnosis
Туре	clinical
Data type	text
Unit	
Values/range	diagnosed
	mild
	moderate
	severe
	not diagnosed

4.33. Physical activity

Observable	
Name	physical exercise
Туре	personal
Data type	text
Unit	
Values/range	no moderate high

4.34. Renin-angiotensin system dual blockade administration

Observable		
Name	Renin-angiotensin system dual blockade administration	
Туре	clinical	
Data type	text	
Unit		
Values/range	yes	
	no	



4.35. Serum creatinine level

Observable	
Name	serum creatinine level
Туре	biomedical
Data type	integer
Unit	µmol per liter or mg per deciliter
Values/range	Normal men = $0,7 - 1,4 \text{ mg/dL} (71 - 115 \mu \text{mol/L})$ women = $0,6 - 1,1 \text{ mg/dL} (53 - 97 \mu \text{mol/L})$ Abnormal 200 µmol per liter [2.26 mg per deciliter], Doubling value= nephropathy

4.36. Serum potassium

Observable	
Name	Serum potassium
Туре	clinical
Data type	real
Unit	mEq/L
Values/range	Normal: 3.5-5.3 mEq/L Moderate 5.0 < Serum Potassium < 6.0 mEq/liter (5.0-6.0 mmol/L) High: serum potassium value > 6.0 mEq/liter (>6.0 mmol/L).

4.37. Sex

Observable	
Name	Sex
Туре	personal
Data type	text
Unit	
Values/range	female male

4.38. Smoking intensity

Risk Element	
Name	Smoking intensity



Туре	Personal
Data type	text
Unit	
Values/range	heavy: Cigarettes per day > 20 moderate: 1 < cigarettes per day < 20 occasional: cigarettes per day < 1]

4.39. Smoking status

Risk Element	
Name	Smoking status
Туре	personal
Data type	text
Units	
Diagnosis condition	ex-smoker
	current
	never

4.40. Statin administration

Observable	
Name	Statin administration
Туре	clinical
Data type	text
Unit	
Values/range	yes Atorvastatin Simvastatin Rosuvastatin Pravastatin Lovastatin
	no

4.41. Time after myocardial infarction event

Observable	
Name	Time after acute myocardial infarction event
Туре	clinical
Data type	integer



Unit	days
Values/range	diagnosed not diagnosed

4.42. Total cholesterol

Observable	
Name	Total cholesterol (TC)
Туре	Clinically measured
Data type	Real
Unit	mmol/L or mg/dL
Values/range	Normal: <5 mmol/L (less than ~190 mg/dL) Abnronal: >5 mmol/L (more than ~190 mg/dL)

4.43. Triglycerides (TG)

Observable	
Name	Triglycerides serum concentration (TG)
Туре	Clinically measured
Data type	Real
Unit	mmol/L or mg/dL
Values/range	Normal: <1.8 mmol/L (less than~70 mg/dL) Abnormal: >1.8 mmol/L (more than~70 mg/dL)

4.44. Uric acid serum concentration

Observable	
Name	Uric acid serum concentration
Туре	clinical
Data type	real
Unit	mg%
Values/range	Normal: 2.5 – 6.8 mg% Abnormal: >6.8mg%

4.45. Waist circumference

Observable	
Name	waist circumference



Туре	personal
Data type	integer
Unit	cm
Values/range	Men Normal: < 94 in men decent: 80 to 88 too high: >88 women normal: <80
	decent: 94 to 102 too high: >102

4.46. Waist to height ratio

Observable	
Name	waist to height ratio
Туре	personal
Data type	real
Unit	
Values/range	Normal: 0.30- 0.49
	Abnormal: <0.30 or >0.50

4.47. Waist to hip ratio

Observable	
Name	waist to hip ratio
Туре	personal
Data type	real
Unit	
Values/range	Normal: male: <0.95 female: <0.8
	Abnormal: male: >0.96 female: >0.81



5. Evidence Sources

5.1. PMID = 08025994

Evidence source	08025994
Evidence source PMID	Post WS, Larson MG, Levy D. Impact of left ventricular structure on the incidence of hypertension. The Framingham Heart Study. Circulation. 1994 Jul;90(1):179-85. doi: 10.1161/01.CIR.90.1.179
Evidence source type	observational
OCEBM Level	1

5.2. **PMID = 09552903**

Evidence source PMID	09552903
Evidence source	Prescott E, Hippe M, Schnohr P, Hein HO, Vestbo J. Smoking and risk of myocardial infarction in women and men: longitudinal population study. BMJ. 1998;316(7137):1043-7.
Evidence source type	Longitudinal population study
OCEBM Level	1-2

5.3. **PMID** = 10069784

Evidence source PMID	10069784
Evidence source	Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation. 1999 Mar 9;99(9):1165-72.
Evidence source type	Cohort study
OCEBM Level	3

5.4. **PMID** = 10770144

Evidence source PMID	10770144
Evidence source	Nieto FJ, Young TB, Lind BK, Shahar E, Samet JM, Redline S, D'Agostino RB, Newman AB, Lebowitz MD; Pickering TG; for the Sleep Heart Health Study. Association of Sleep-Disordered Breathing, Sleep Apnea, and Hypertension in a Large Community-Based Study. <i>JAMA</i> . 2000;283(14):1829-1836. doi:10.1001/jama.283.14.1829
Evidence source type	Cross-sectional analyses of a community-based multicenter study
OCEBM Level	



5.5. **PMID = 10972692**

Evidence source PMID	10972692
Evidence source	Halimi JM, Giraudeau B, Vol S, Cacès E, Nivet H, Lebranchu Y, Tichet J. Effects of current smoking and smoking discontinuation on renal function and proteinuria in the general population. Kidney Int. 2000 Sep;58(3):1285-92.
Evidence source type	observational
OCEBM Level	1-2

5.6. **PMID** = 11282794

Evidence source PMID	11282794
Evidence source	Hooi JD, Kester AD, Stoffers HE, Overdijk MM, van Ree JW, Knottnerus JA., Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol. 2001 Apr 1;153(7):666-72.
Evidence source type	
OCEBM Level	

5.7. **PMID** = 11352882

Evidence source PMID	11352882
Evidence source	Sundström J, Lind L, Arnlöv J, Zethelius B, Andrén B, Lithell HO. Echocardiographic and electrocardiographic diagnoses of left ventricular hypertrophy predict mortality independently of each other in a population of elderly men. Circulation. 2001 May 15;103(19):2346-51.
Evidence source type	Comparative Study
OCEBM Level	3

5.8. **PMID** = 11390335

Evidence source PMID	11390335
Evidence source	Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S, Selby JV. Glycemic control and heart failure among adult patients with diabetes. Circulation. 2001 Jun 5;103(22):2668-73.
Evidence source type	cohort
OCEBM Level	3

5.9. **PMID** = 11468199

Evidence source PMID	11468199
Evidence source:	Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and



	Paternal History of Myocardial Infarction and Risk of Cardiovascular Disease in Men and Women. Circulation. 2001;104:393-398
Evidence source type:	Population study
OCEBM Level	

5.10. PMID = 12151467

Evidence source PMID	12151467
Evidence source:	Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347(5):305-13.
Evidence source type:	observational
OCEBM Level	1-2

5.11. PMID = 12695299

Evidence source PMID	12695299
Evidence source:	Albert CM, Chae CU, Grodstein F, Rose LM, Rexrode KM, Ruskin JN, Stampfer MJ, Manson JE. Prospective Study of Sudden Cardiac Death Among Women in the United States. Circulation. 2003;107:2096-2101
Evidence source type:	Prospective cohort study
OCEBM Level	3

5.12. PMID = 12843775

Evidence source PMID	12843775
Evidence source:	Stengel B, Tarver–Carr ME, Powe NR, Eberhardt MS, Brancati FL, Lifestyle Factors, Obesity and the Risk of Chronic Kidney Disease; Epidemiology 14 2003.
Evidence source type:	Cohort study
OCEBM Level	3

5.13. PMID = 14732743

Evidence source PMID	14732743
Evidence source:	O'Hare AM, Glidden DV, Fox CS, Hsu CY, High prevalence of peripheral arterial disease in persons with renal insufficiency: results from the National Health and Nutrition Examination Survey 1999-2000 Circulation. 2004 Jan 27;109(3):320-3. Epub 2004 Jan 19.
Evidence source type:	Cross-sectional national study
OCEBM Level	



5.14. PMID = 15385656

Evidence source PMID	15385656
Evidence source	Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004 Sep 23;351(13):1296-305.
Evidence source type	Longitudinal, retrospective epidemiologic study
OCEBM Level	

5.15. PMID = 15562125

Evidence source PMID	15562125
Evidence source	Wang TJ, Parise H, Levy D, D'Agostino RB Sr, Wolf PA, Vasan RS, Benjamin EJ. Obesity and the risk of new-onset atrial fibrillation. JAMA. 2004 Nov 24;292(20):2471-7.
Evidence source type	observational
OCEBM Level	1-2

5.16. **PMID** = 16039877

Evidence source PMID	16039877
Evidence source	Curkendall SM, DeLuise C, Jones JK, Lanes S, Stang MR, Goehring E Jr, She D. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006 Jan;16(1):63-70.
Evidence source type	cohort
OCEBM Level	3

5.17. PMID = 16157837

Evidence source PMID	16157837
Evidence source:	Selvin E, Coresh J, Golden SH, Brancati FL, Folsom AR, Steffes MW. Glycemic control and coronary heart disease risk in persons with and without diabetes: the atherosclerosis risk in communities study. Arch Intern Med. 2005 Sep 12;165(16):1910-6.
Evidence source type:	cohort
OCEBM Level	3

5.18. PMID = 16310551

Evidence source PMID	16310551
----------------------	----------



Evidence source	Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011 Jan;54(1):32-43. doi: 10.1007/s00125-010-1854-1. Epub 2010 Jul 30.
Evidence source type	Multinational, randomized, double-blind placebo-controlled trial
OCEBM Level	1

5.19. PMID = 16697315

Evidence source PMID	16697315
Evidence source:	Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM. Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol. 2006 May 16;47(10):1987-96.
Evidence source type:	systematic review and meta-analysis
OCEBM Level	1

5.20. PMID = 16738019

Evidence source PMID	16738019
Evidence source:	Tonelli M, Wiebe N, Culleton B, House A, Rabbat C, Fok M, McAlister F, Garg AX. Chronic kidney disease and mortality risk: a systematic review. J Am Soc Nephrol. 2006 Jul;17(7):2034-47.
Evidence source type:	systematic review
OCEBM Level	1

5.21. PMID = 17082208

Evidence source PMID	17082208
Evidence source:	Nicholson A, Kuper H, Hemingway H. Depression as an aetiologic and prognostic factor in coronary heart disease: a meta-analysis of 6362 events among 146 538 participants in 54 observational studies.
Evidence source type:	Meta-analysis
OCEBM Level	1-2

5.22. **PMID** = 17327354

Evidence source PMID	17327354
Evidence source	Jeon CY, Lokken RP, Hu FB, van Dam RM. Physical activity of moderate intensity and risk of type 2 diabetes: a systematic review. Diabetes Care. 2007;30(3):744- 52.



Evidence source type	systematic review
OCEBM Level	1

5.23. PMID = 17541263

Evidence source PMID	17541263
Evidence source:	Jones-Burton C, Seliger SL, Scherer RW, Mishra SI, Vessal G, Brown J, Weir MR, Fink JC. Cigarette smoking and incident chronic kidney disease: a systematic review. Am J Nephrol. 2007;27(4):342-51
Evidence source type:	Systematic review
OCEBM Level	1

5.24. PMID = 18261929

Evidence source PMID	18261929
Evidence source:	Gu Q, Burt VL, Paulose-Ram R, Yoon S, Gillum RF. High blood pressure and cardiovascular disease mortality risk among U.S. adults: the third National Health and Nutrition Examination Survey mortality follow-up study. Ann Epidemiol. 2008 Apr;18(4):302-9.
Evidence source type:	follow-up
OCEBM Level	3

5.25. **PMID** = 18490538

Evidence source PMID	18490538
Evidence source	Messerli FH, Bangalore S, Julius S. Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension. Circulation. 2008 May 20;117(20):2706-15;
Evidence source type	
OCEBM Level	

5.26. **PMID** = 1866765

Evidence source PMID	1866765
Evidence source	Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke. 1991 Aug;22(8):983-8.
Evidence source type	longitudinal study
OCEBM Level	1-2



5.27. PMID = 18755344

Evidence source PMID	18755344
Evidence source	Groenveld HF, Januzzi JL, Damman K, van Wijngaarden J, Hillege HL, van Veldhuisen DJ, van der Meer P. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol. 2008 Sep 2;52(10):818-27. doi: 10.1016/j.jacc.2008.04.061.
Evidence source type	systematic review and meta-analysis
OCEBM Level	1

5.28. PMID = 19046219

Evidence source PMID	19046219
Evidence source	Elley CR, Kenealy T, Robinson E, Drury PL. Glycated haemoglobin and cardiovascular outcomes in people with Type 2 diabetes: a large prospective cohort study. Diabet Med. 2008 Nov;25(11):1295-301.
Evidence source type	cohort
OCEBM Level	3

5.29. PMID = 19320986

Evidence source PMID	19320986
Evidence source	Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009 Mar 25;9:88. doi: 10.1186/1471-2458-9-88.
Evidence source type	Systematic review and meta-analysis
OCEBM Level	1

5.30. PMID = 19368979

Evidence source PMID	19368979
Evidence source:	Nishiyama K, Morimoto T, Furukawa Y, Nakagawa Y, Ehara N, Taniguchi R, Ozasa N, Saito N, Hoshino K, Touma M, Tamura T, Haruna Y, Shizuta S, Doi T, Fukushima M, Kita T, Kimura T. Chronic obstructive pulmonary disease—An independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. International Journal of Cardiology 2010;143:178–183
Evidence source type:	Cohort study
OCEBM Level	3



5.31. PMID = 19705980

Evidence source PMID	19705980
Evidence source	Cameron AJ, Dunstan DW, Owen N, Zimmet PZ, Barr EL, Tonkin AM, Magliano DJ, Murray SG, Welborn TA, Shaw JE. Health and mortality consequences of abdominal obesity: evidence from the AusDiab study. Med J Aust. 2009 Aug 17;191(4):202-8
Evidence source type	prospective, national, population based study
OCEBM Level	3

5.32. PMID = 19903920

Evidence source PMID	19903920
Evidence source	Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray KK, Thompson A, Wood AM, Lewington S, Sattar N, Packard CJ, Collins R, Thompson SG, Danesh J. Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009 Nov 11;302(18):1993-2000.
Evidence source type	meta-analysis
OCEBM Level	1

5.33. PMID = 19933936

Evidence source PMID	19933936
Evidence source	Velagaleti RS, Massaro J, Vasan RS, Robins SJ, Kannel WB, Levy D. Relations of Lipid Concentrations to Heart Failure Incidence The Framingham Heart Study. Circulation. 2009;120:2345-2351. doi: 10.1161/CIRCULATIONAHA.109.830984
Evidence source type	Cohort study
OCEBM Level	3

5.34. PMID = 20167359

Evidence source PMID	20167359
Evidence source	Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ,Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM,Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-42.
Evidence source type	meta-analysis
OCEBM Level	1



5.35. PMID = 20191515

Evidence source PMID	20191515
Evidence source	Kim SY, Guevara JP, Kim KM, Choi HK, Heitjan DF, Albert DA. Hyperuricemia and coronary heart disease: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2010 Feb;62(2):170-80
Evidence source type	systematic review and meta-analysis
OCEBM Level	1

5.36. PMID = 20299666

Evidence source PMID	20299666
Evidence source:	Strazzullo P, D'Elia L, Cairella G, Garbagnati F, Cappuccio FP, Scalfi L. Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke. 2010 May;41(5):e418-26.
Evidence source type:	Systematic review and meta-analysis
OCEBM Level	1

5.37. **PMID** = 20668832

Evidence source PMID	20668832
Evidence source:	Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, Fassett R, Ansquer JC, Dixon P, Davis TM, Pardy C, Colman P, Keech A. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011 Jan;54(1):32-43. doi: 10.1007/s00125-010-1854-1.
Evidence source type:	randomized trial
OCEBM Level	2

5.38. PMID = 20824805

Evidence source PMID	20824805
Evidence source:	Grayson PC, Kim SY, LaValley M, Choi HK. Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken). 2011 Jan;63(1):102-10.
Evidence source type:	systematic review and meta-analysis
OCEBM Level	1

5.39. PMID = 21852664

Evidence source PMID	21852664



Evidence source:	Thomas G, Sehgal AR, Kashyap SR, Srinivas TR, Kirwan JP, Navaneethan SD. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol. 2011 Oct;6(10):2364-73.
Evidence source type:	systematic review and meta-analysis
OCEBM Level	2-3

5.40. PMID = 22020036

Evidence source PMID	22020036
Evidence source:	Dong JY, Zhang YH, Tong J, Qin LQ. Depression and Risk of Stroke A Meta- Analysis of Prospective Studies. Stroke. 2012;43:32-37
Evidence source type:	A meta-analysis of prospective studies
OCEBM Level	1-2

5.41. PMID = 22113526

Evidence source PMID	22113526
Evidence source	Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int. 2012 Mar;81(5):442-8.
Evidence source type	Systematic review and meta-analysis
OCEBM Level	1

5.42. PMID = 22139711

Evidence source PMID	22139711
Evidence source	Chintan S Desai, Hongyan Ning and Donald M Lloyd-Jones. Competing cardiovascular outcomes associated with electrocardiographic leftventricular hypertrophy: the AtherosclerosisRisk in Communities Study. Heart 2012 98: 330-334.doi: 10.1136/heartjnl-2011-300819
Evidence source type	multicenter cohort follow up study
OCEBM Level	3

5.43. PMID = 22342847

Evidence source PMID	22342847
Evidence source	Jain N, Kotla S, Little BB, Weideman RA, Brilakis ES, Reilly RF, Banerjee S. Predictors of hyperkalemia and death in patients with cardiac and renal disease.Am J Cardiol. 2012 May 15;109(10):1510-3. doi: 10.1016/j.amjcard.2012.01.367. Epub 2012 Feb 18
Evidence source type	Comparative Study
OCEBM Level	



5.44. PMID = 22470299

Evidence source PMID	22470299
Evidence source	Li J, Siegrist J. Physical activity and risk of cardiovascular diseasea meta- analysis of prospective cohort studies., Int. J. Environ. Res. Public Health 2012, 9, 391-407
Evidence source type	meta-analysis
OCEBM Level	1

5.45. PMID = 22508734

Evidence source	22508734
Evidence source PMID	Fink HA, Ishani A, Taylor BC, Greer NL, MacDonald R, Rossini D, Sadiq S, Lankireddy S, Kane RL, Wilt TJ. Screening for, monitoring, and treatment of chronic kidney disease stages 1 to 3: a systematic review for the U.S. Preventive Services Task Force and for an American College of Physicians Clinical Practice Guideline. Ann Intern Med. 2012 Apr 17;156(8):570-81. doi: 10.7326/0003-4819-156-8-201204170-00004
Evidence source type	systematic review and meta-analysis
OCEBM Level	1

5.46. **PMID = 22828826**

Evidence source PMID	22828826
Evidence source:	Loke YK, Brown JW, Kwok CS, Niruban A, Myint PK. Association of obstructive sleep apnea with risk of serious cardiovascular events: a systematic review and meta-analysis. Circ Cardiovasc Qual Outcomes. 2012 Sep 1;5(5):720-8. doi: 10.1161/CIRCOUTCOMES.111.964783
Evidence source type:	systematic review and meta-analysis
OCEBM Level	1

5.47. PMID = 22988888

Evidence source PMID	22988888
Evidence source:	Wang X, Bi Y, Zhang Q, Pan F. Obstructive sleep apnoea and the risk of type 2 diabetes: A meta-analysis of prospective cohort studies. Respirology 2013 Jan;18:140–146. doi: 10.1111/j.1440-843.2012.02267.x
Evidence source type:	Meta-analysis
OCEBM Level	1



5.48. PMID = 23144362

Evidence source PMID	23144362
Evidence source	Kodama S, Horikawa C, Fujihara K, Heianza Y, Hirasawa R, Yachi Y, Sugawara A, Tanaka S, Shimano H, Iida KT, Saito K, Sone H. Comparisons of the strength of associations with future type 2 diabetes risk among anthropometric obesity indicators, including waist-to-height ratio: a meta-analysis. Am J Epidemiol. 2012 Dec 1;176(11):959-69. doi: 10.1093/aje/kws172. Epub 2012 Nov 9.
Evidence source type	meta-analysis
OCEBM Level	1

5.49. PMID = 23271790

Evidence source PMID	23271790
Evidence source:	Ho JE, Lyass A, Lee DS, Vasan RS, Kannel WB, Larson MG, Levy D. Predictors of New-Onset Heart Failure Differences in Preserved Versus Reduced Ejection Fraction. Circ Heart Fail 2013;6:279-286. doi: 10.1161/CIRCHEARTFAILURE.112.972828
Evidence source type:	Cohort study
OCEBM Level	3

5.50. PMID = 23322741

Evidence source PMID	23322741
Evidence source:	James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013 Feb;6(1):37-43
Evidence source type:	systematic review and meta-analysis
OCEBM Level	1

5.51. PMID = 23349764

Evidence source PMID	23349764
Evidence source:	Ma Y, Yang Y, Wang F, Zhang P, Shi C, Zou Y, Qin H. Obesity and risk of colorectal cancer: a systematic review of prospective studies. PLoS One. 2013;8(1):e53916.
Evidence source type:	Systematic review of prospective studies
OCEBM Level	1



5.52. PMID = 23322741

Evidence source PMID	23322741
Evidence source:	James MT, Samuel SM, Manning MA, Tonelli M, Ghali WA, Faris P, Knudtson ML, Pannu N, Hemmelgarn BR. Contrast-induced acute kidney injury and risk of adverse clinical outcomes after coronary angiography: a systematic review and meta-analysis. Circ Cardiovasc Interv. 2013;6(1):37-43.
Evidence source type:	systematic review and meta-analysis
OCEBM Level	1

5.53. PMID = 23358488

Evidence source PMID	23358488
Evidence source	Makani H, Bangalore S, Desouza KA, Shah A, Messerli FH. Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ. 2013 Jan 28;346:f360.
Evidence source type	Meta-analysis of randomised trials
OCEBM Level	1

5.54. PMID = 23697611

Evidence source PMID	23697611
Evidence source:	Chen Y, Liu L, Wang X, Wang J, Yan Z, Cheng J, Gong G, Li G. Body mass index and risk of gastric cancer: a meta-analysis of a population with more than ten million from 24 prospective studies. Cancer Epidemiol Observables Prev. 2013 Aug;22(8):1395-408.
Evidence source type:	Meta-analysis
OCEBM Level	1

5.55. **PMID = 23915883**

Evidence source PMID	23915883
Evidence source:	Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, Norman PE, Sampson UKA, Williams LJ, Mensah GA, Criqui MH. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013; 382: 1329–40. doi:10.1016/S0140-6736(13)61249-0
Evidence source type:	systematic review and analysis
OCEBM Level	1



5.56. PMID = 23922053

Evidence source PMID	23922053
Evidence source	Lu L, Mackay DF, Pell JP. Meta-analysis of the association between cigarette smoking and peripheral arterial disease, Heart. 2014;100(5):414-23
Evidence source type	Meta-analysis
OCEBM Level	1

5.57. **PMID = 23933579**

Evidence source PMID	23933579
Evidence source	Huang H, Huang B, Li Y, Huang Y, Li J, Yao H, Jing X, Chen J, Wang J. Uric acid and risk of heart failure: a systematic review and meta-analysis. Eur J Heart Fail. 2014 Jan;16(1):15-24.
Evidence source type	systematic review and meta-analysis
OCEBM Level	1

5.58. **PMID = 24360912**

Evidence source PMID	24360912
Evidence source	Castillo JJ, Ingham RR, Reagan JL, Furman M, Dalia S, Mitri J. Obesity is associated with increased relative risk of diffuse large B-cell lymphoma: a meta- analysis of observational studies. Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):122-30.
Evidence source type	Meta-analysis
OCEBM Level	1

5.59. **PMID = 24468137**

Evidence source PMID	24468137
Evidence source	Li M, Hou W, Zhang X, Tang Z. Hyperuricemia and risk of stroke: a systematic review and meta-analysis of prospective studies. Atherosclerosis. 2014 Feb;232(2):265-70.
Evidence source type	Systematic review and meta-analysis
OCEBM Level	1

5.60. **PMID** = 24859435

Evidence source PMID	24886432
Evidence source:	Peters SA, Huxley RR, Woodward M. Diabetes as risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-



	analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014 May 25.
Evidence source type:	systematic review and meta-analysis
OCEBM Level	1

5.61. PMID = 24913219

Evidence source PMID	24913219
Evidence source	Heiwe S, Jacobson SH. Exercise Training in Adults With CKD:A Systematic Review and Meta-analysis. Am J Kidney Dis. 2014Jun6.pii:S0272-6386(14)00735-5.doi: 10.1053/j.ajkd.2014.03.020
Evidence source type	Systematic Review and Meta-analysis
OCEBM Level	1

5.62. PMID = 2496858

Evidence source PMID	2496858
Evidence source	Shinton R, Beevers G. Meta-analysis of relation between cigarette smoking and stroke. BMJ. 1989 Mar 25;298(6676):789-94.
Evidence source type	Meta-analysis
OCEBM Level	1